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 Ulcerative Colitis, or TRUC) develop microbiota-dependent inflammatory 
bowel disease (IBD). The innate immune mechanisms responsible for causing 
disease are still to be resolved, yet potentially offer novel insights into the 
pathogenesis of IBD, and how T-bet might influence inflammation in the gut. 
In this thesis it was shown that chronic IBD in TRUC mice was dependent on 




innate lymphoid cells (ILCs). 
Depletion of ILCs or IL-17A neutralization cured disease. Cytokines responsible for 
driving innate IL-17A included IL-23, IL-6 and TL1A. IL-23 and IL-6 played 
functionally important roles in TRUC disease, since neutralisation reduced innate IL-







dendritic cells (DCs), synergised with IL-23 to drive IL-
17A production by ILCs. 
Helicobacter typhlonius (HT) was identified as the key colitigenic bacterium driving 
TRUC disease. Four-five-four ribosomal RNA gene sequencing demonstrated that 
HT was consistently present in the faeces of all TRUC mice, but absent from a 




 mice. Inoculation of pure HT 
cultures was sufficient to reinstate disease into this new colony of healthy mice. 
T-bet impacted on colitis in several ways. In the absence of T-bet, ILCs selectively 
produced IL-17A and were poor producers of interferon-γ. Second, T-bet deficient 
DCs produced excess TNFα in comparison with T-bet sufficient DCs. Finally, T-bet 
was a transcriptional repressor of the Il7ra locus. IL-7R was expressed by ILCs and 
signalling through this receptor was critical for TRUC disease. Selective IL-7R 
blockade attenuated disease. Together these data provide new insights into TRUC 
disease and demonstrate at least some of the mechanisms by which T-bet regulates 
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The mucosal immune system is responsible for policing the epithelial barrier 
surfaces. The importance of this task is apparent when considering the global impact 
of infections affecting the gut, lungs and urogenital tracts. However, inappropriate 
activation of mucosal immunity directed against commensal organisms with which 
we share our barrier surfaces may lead to collateral damage to host tissue. The 
challenge of maintaining this delicate balance is perhaps best demonstrated in the 
gut, where the highest volume of commensal bacteria reside. Although 
gastrointestinal infections are a leading cause of death globally and robust immunity 
against luminal pathogens must be maintained, overly exuberant immune responses 
deployed against commensal organisms is thought to result in collateral damage to 
the gut and the emergence of an increasingly common immune mediated disease, 
termed inflammatory bowel disease (IBD). 
Recognition and response to the microbial communities occupying the 
gastrointestinal tract by the mucosal immune system is now recognised to play a 
central role in both the maintenance and loss of intestinal homeostasis. Insights into 
the molecular mechanisms regulating mucosal immunity at the interface with the 
intestinal microbiota are needed to help understand IBD. Transcription factors are 
proteins that selectively switch genes on or off, enabling specific cells, including 
immune cells, to perform particular functions, including inflammatory responses. 
The transcription factor T-bet is expressed by several immune cells and regulates the 
inflammatory behaviour of these cells. Mice genetically lacking T-bet in the innate 
immune system spontaneously develop microbiota-dependent intestinal 
inflammation that resembles IBD and elucidating the immune mechanisms 
responsible for causing disease in these mice offers the opportunity to gain novel 
insights into IBD pathogenesis. In this thesis specific hypotheses were tested 
regarding possible mechanisms of disease in T-bet deficient mice in order to advance 
our understanding of how T-bet impacts on host-microbe interactions in the gut and 
to shed new light on possible mechanisms of disease in IBD. 
21 
1.1 Inflammatory bowel disease 
IBD describes a group of conditions characterised by chronic inflammation of the 
gastrointestinal (GI) tract. The 2 main forms of the disease are Crohn’s disease (CD) 
and ulcerative colitis (UC). CD can affect any part of the GI tract, but UC is 
restricted to the colon (Baumgart and Sandborn, 2007). Both forms follow a 
relapsing and remitting clinical course and commonly experienced symptoms include 
diarrhoea, rectal bleeding, faecal urgency, tenesmus and abdominal pain (Baumgart 
and Sandborn, 2007). Extra-intestinal manifestations are also recognised affecting 
the joints (Orchard et al., 1998), eyes (Mintz et al., 2004), skin (Lebwohl and 
Lebwohl, 1998), and hepatobiliary system (Raj and Lichtenstein, 1999). In addition 
to causing distressing symptoms IBD is associated with significant complications, 
including venous thromboembolism (Miehsler et al., 2004; Solem et al., 2004), 
anaemia (Goodhand et al., 2011) malnutrition (Mijac et al., 2010; Valentini et al., 
2008) and colorectal cancer (Eaden et al., 2001; Rutter et al., 2006). Approximately 
80% of patients with CD will require intestinal surgery in their lifetime and about 10-
30% of UC patients will ultimately require colectomy (Cosnes et al., 2011). IBD is 
linked to excess mortality (Bewtra et al., 2013). 
In view of this burden of disease it is unsurprising that IBD negatively impacts on the 
quality of life and psychosocial wellbeing of affected patients. Chronic fatigue 
(Jelsness-Jorgensen et al., 2011), anxiety and depressive disorders (Graff et al., 
2009), lost work days (Boonen et al., 2002), unemployment (Bernstein et al., 2001; 
Boonen et al., 2002) and difficulties with interpersonal and sexual relationships 
(Trachter et al., 2002) are reported with increased frequency in IBD patients. In 
Europe and North America the incidence of CD and UC is between 0.7-9.8 and 1.5-
20.3 cases per 100,000 person-years, respectively (Loftus, 2004), and over the last 50 
years the incidence of IBD appears to be increasing (Cosnes et al., 2011). 
The aetiology of IBD is unknown. However, both genetic and environmental factors 
are believed to contribute to disease. Twin studies from Northern Europe show 
concordance rates among monozygotic twins with CD of 35-64%, and in UC 
between 16-19%. In contrast, concordance between dizygotic twins is just 2-5% in 
CD and 0-2% in UC (Halfvarson et al., 2003; Jess et al., 2005; Spehlmann et al., 
2008; Tysk et al., 1988). These data confirm that in most patients neither genetic nor 
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environmental factors by themselves are sufficient to account for IBD, but instead it 
is likely that combinations of these factors contribute to disease development. 
1.1.1 Genetic insights into IBD pathogenesis 
In the last 10 years considerable advances have been made in our understanding of the 
role of genetics in IBD. In the main these advances have been facilitated by the advent 
of genome wide association (GWA) studies, in which the profile of many thousands 
of single nucleotide polymorphisms (SNPs) are compared between groups of disease 
defined cases and disease free controls. The first major GWA study in IBD was 
reported in 2007 in a landmark study by the Wellcome Trust case control consortium 
that compared the distribution of SNPs in 7 common diseases, including Crohn’s 
disease (Wellcome Trust Case Control Consortium, 2007). One advantage of GWA 
studies is that they provide unbiased, non-hypothesis driven profiles of the genetic 
architecture of individuals with specific diseases, with the potential to uncover novel 
biological pathways involved in mediating disease. Currently, polymorphisms at 163 
genetic loci are significantly associated with altered IBD risk, including genes 
encoding proteins involved in immune cell activation, cytokine signalling, microbe 
recognition and intestinal epithelial barrier function (Jostins et al., 2012). Most IBD 
susceptibility genes are shared between CD and UC, and indeed with other immune 
mediated diseases, such as ankylosing spondylitis and psoriasis. IBD genetic 
susceptibility also overlaps with infectious diseases and immunodeficiency 
syndromes (Jostins et al., 2012). Genetic studies have provided some novel insights 
into hitherto unsuspected immune pathways that are now regarded as potentially 
disease relevant pathways in IBD. Examples include NOD2, autophagy pathway 
proteins and components of the IL-23/IL-17 cytokine axis. 
As early as 1996, before the advent of GWA studies, the first Crohn’s disease 
susceptibility locus was identified on chromosome 16 by studying the genes of 
families with multiple affected members (Hugot et al., 1996). Subsequently, two 
independently conducted linkage analysis studies were reported simultaneously as 
back to back articles in Nature identifying that the gene responsible for conferring 
disease susceptibility on chromosome 16 encoded a protein called NOD2. 
Interestingly, NOD2 is an intracellular sensor of bacterial products and like several 
toll-like receptors (TLRs) is involved in the innate immune response. The specific 
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ligand of NOD2 is a bacterial cell wall product called muramyl dipeptide (MDP). In 
one of the initial papers from 2001, one of the susceptibility mutations identified at 
the NOD2 locus was located in sequences encoding a functionally important part of 
the protein termed the leucine-rich repeat domain, which is now recognized as the 
portion of the molecule responsible for ligand interaction (Hugot et al., 2001; Ogura 
et al., 2001). Ogura et al. showed that in contrast to the WT protein, the disease 
variant forms of NOD2 had impaired activation of the pro-inflammatory 
transcription factor NFB in response to stimulation with TLR agonists, indicating 
that NOD2 mutations were loss of function mutations. Additional functional studies 
by van Heel et al. showed that PBMCs from Crohn’s disease patients with the most 
common NOD2 mutations had impaired activation in response to direct stimulation 
with MDP (van Heel et al., 2005). In patients with NOD2 mutations there was 
impaired MDP induced production of IL-8 by PMBCs, but also impaired release of 
other crucial pro-inflammatory cytokines when PBMCs were co-stimulated with 
MDP and other TLR agonists. As well as being the most strongly associated risk 
allele in Crohn’s disease, NOD2 is notably absent from the known list of genes that 
alter susceptibility to UC, indicating that there are indeed differences in the genetic 
architecture of CD and UC. 
In addition to confirming NOD2 as a disease susceptibility locus, GWA studies have 
identified numerous other genes involved in innate immunity. Crohn’s disease is 
associated with SNPs at loci encoding the autophagy pathway components ATG16L1 
and IRGM (Jostins et al., 2012). The role of autophagy in Crohn’s disease has yet to 
be fully resolved, but the identification of these loci as susceptibility alleles 
reinforces the notion that innate immune handling of intestinal bacteria is likely 
important in IBD. There appear to be interactions between autophagy and NOD2. 
Stimulation of NOD2 with MDP has been shown to trigger autophagy in DCs, and 
patients with risk variant NOD2 or ATG16L1 alleles have defective autophagy and 
impaired antigen-presentation to T-cells (Cooney et al., 2010). These data are 
important because they show that risk variant alleles at different loci affecting 
different genes in IBD potentially interact to affect immunological processes in the 
gut. They show that genetic variation in innate immune pathways may subsequently 
impact adaptive immune responses. Like NOD2, polymorphisms at loci encoding 
autophagy components were initially thought to be restricted to Crohn’s disease. 
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However, a recent meta-analysis, which has combined data from most of the large 
IBD GWA studies completed to date, comprising 75,000 cases and controls, has 
shown that although SNPs at the ATG16L1 locus are confined to patients with 
Crohn’s disease, risk variant polymorphisms at the IRGM locus are also shared with 
UC. 
One of the other most notable immunological pathways linked to IBD through GWA 
studies is the IL-23/IL-17 axis, comprising the innate immune cytokine IL-23 and the 
effector cytokine IL-17A. SNPs at a number of components involved in this pathway 
are significantly associated with IBD, including IL12B (one of the IL-23 subunits), 
IL23R (its specific receptor), and the IL23R signalling components STAT3, JAK2 and 
TYK2 that are activated by ligation of the IL-23R with IL-23. In addition, SNPs at loci 
encoding the transcription factor RORC and the chemokine receptor CCR6, which are 
markers associated with Th17 cells, are also significantly associated with IBD, and 
notably, these polymorphisms are shared between UC and CD (Jostins et al., 2012). 
Other genetic insights into immune pathways potentially relevant in IBD have been 
gained from reports of patients with extreme phenotypes of intestinal inflammation, 
or IBD-like syndromes, using genetic linkage analysis and candidate gene 
sequencing. A case series has been described of children born to consanguineous 
parents, who developed severe, early onset intestinal inflammation resembling CD. 
The children had mutations in the genes encoding a subunit of the IL-10 receptor, 
which resulted in impaired receptor signalling (Glocker et al., 2009). IL-10 is 
recognised as an immunomodulatory cytokine, which inhibits the production of 
inflammatory cytokines, such as TNFα. PBMCs from the children with loss of 
function mutations at the IL10R locus produced excess TNFα (Glocker et al., 2009). 
Mutations at the IL10 locus are also associated with IBD in GWAS, corroborating 
the potential relevance of this pathway (Jostins et al., 2012). 
In summary, IBD is now among the most complex genetic diseases known and is 
associated with polymorphisms at more genetic loci than any other disease. Many of 
the genes implicated in IBD are immune related genes, encompassing both innate 
and adaptive immune processes and processes involved in immune handling of 
bacteria are strongly implicated, especially in CD. In addition, cytokine responses 
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typically deemed to be important in adaptive immune responses, such as the IL-
23/IL-17 axis, also appear to play a role. 
1.1.2 Environmental considerations in IBD 
Since there is only partial concordance between monozygotic twins (Tysk et al., 
1988), and IBD incidence appears to be increasing over a relatively short period of 
time (i.e. far too quickly to be accounted for by genetic evolution), it follows that 
non-genetic factors contribute to IBD risk. Environmental factors associated with 
altered IBD risk include smoking, geography, exposure to infections and whether 
individuals have had operations, such as appendectomy or tonsillectomy. In most 
cases the causal relationships between environmental exposure and IBD risk have 
still to be resolved. 
It has long been recognised that UC is negatively associated with smoking. In 1982 
Harries et al. conducted a large questionnaire of IBD and control patient, which 
showed that only 8% of UC patients were current smokers in comparison with 44% 
of healthy controls (Harries et al., 1982). As well as replicating the findings of the 
earlier study, other studies have shown that CD patients are more likely to be 
smokers (Somerville et al., 1984; Tobin et al., 1987). In CD, smoking is also 
associated with an increased risk of disease relapse, particularly in women 
(Sutherland et al., 1990). 
There are data from across Europe comparing IBD risk in patients who have 
previously undergone tonsillectomy or appendectomy. In the main these studies tend 
to show reduced UC risk in patients who have previously had a tonsillectomy or 
appendectomy, whereas these operations tend to confer increased risk of CD 
(Castiglione et al., 2012; Gearry et al., 2010; Hansen et al., 2011; Russel et al., 
1997). There are confounding issues that potentially complicate the interpretation of 
these epidemiological studies. For example, an initial presentation of terminal ileal 
CD could easily be confused clinically with appendicitis. Therefore, increased 
incidence of CD in patients who have had an appendectomy may merely reflect 
patients presenting for the first time with CD were mistakenly diagnosed with 
appendicitis and underwent appendectomy, only to re-present later with CD. 
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Dietary factors have also been linked to IBD development. High sugar consumption 
is associated with increased IBD risk, whereas increased consumption of vegetables 
and whole meal bread may be protective (Hansen et al., 2011; Jakobsen et al., 2013). 
Although there is a vast literature on the potential role of omega-3 fatty acids (fish 
oils) in IBD, particularly CD, meta-analyses evaluating trials of omega-3 
supplementation in CD do not show therapeutic benefit (Turner et al., 2009). 
Another intriguing environmental factor that appears to predispose to IBD 
development is exposure to gastrointestinal infection (Garcia Rodriguez et al., 2006; 
Hansen et al., 2011; Porter et al., 2008), including well documented cases of 
microbiologically proven Salmonella and Campylobacter gastroenteritis (Gradel et 
al., 2009). There is a growing literature concerning the role of pathogenic organisms, 
pathobionts and even commensal bacterial species in the breakdown of intestinal 
homeostasis and the emergence of chronic intestinal inflammation. Indeed, the 
profile and community structure of the intestinal microbiota is now regarded as a key 
environmental variable responsible for influencing host health. 
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1.2 Host microbe interactions at the epithelial barrier surfaces 
Following birth the epithelial barrier surfaces of mammals become permanently 
colonised with prodigious numbers of microorganisms, including an estimated 10
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bacteria colonising the skin and 10
14
 bacteria occupying the GI tract of humans 
(Luckey, 1972). Until recently defining the community composition of the 
microbiota colonising mammalian hosts has been hampered by difficulties in 
cultivating bacteria from certain body habitats. However, following the emergence of 
culture independent molecular techniques it is now possible to accurately determine 
the profile and frequency of microbes occupying particular ecological niches. These 
unbiased approaches rely upon sequencing of conserved regions within the 16S 
rRNA genes of microbes using region specific primers and high-throughput DNA 
sequencing. These techniques have provided crucial new insights into our 
understanding of the microbes occupying our epithelial barrier surfaces. We now 
know that the composition of the microbiota is highly variable, both between 
individuals as well between different body habitats in the same individual 
(Huttenhower et al., 2012; Eckburg et al., 2005). The Human Microbiome Project 
Consortium has recently published detailed data regarding the community 
composition of the microbiota colonising 18 body habitats, including the skin, 
urogenital and GI tracts of 242 healthy adults (Huttenhower et al., 2012). In this 
landmark study the community profile of the major bacterial taxa was distinct and 
characteristic at different anatomical sites. Some niches, such as the saliva, 
harboured a diverse range of operational taxonomic units (OTUs) with little variation 
between study individuals, whereas the skin contained fewer overall species but with 
much greater variation between individuals. This study also highlighted how 
particular phyla tend to favour environmental conditions created by particular body 
habitats. For instance, the posterior fornix of the cervix is almost totally dominated 
by Firmicutes, whereas the anterior nares are mostly composed of Actinobacteria. 
The Human Microbiome Project has largely corroborated data from earlier studies 
with fewer subjects (Costello et al., 2009), and has also established that these 
microbial communities are largely stable over time. 
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As well as harbouring the greatest total number of organisms, the microbiota of the 
distal GI tract is also one of the most diverse in terms of community membership and 
inter-individual variation (Huttenhower et al., 2012; Costello et al., 2009; Eckburg et 
al., 2005). The vast majority of organisms present are bacteria with minor 
contributions from archaea (0.8%), other non-human eukaryotic cells (0.5%) and 
viruses (up to 5.8%) (Arumugam et al., 2011). At the phylum level Bacteroidetes and 
Firmicutes represent >90% of bacteria present in the distal GI tract of humans 
(Eckburg et al., 2005), mice (Ley et al., 2005) and indeed other mammals (Ley et al., 
2008). Collectively in humans over 1,000 bacterial species have been identified in 
this habitat and each individual harbours approximately 160 different bacterial 
species (Qin et al., 2010). Intestinal archaea are much less diverse with one species 
in particular, Methanobrevibacter smithii, dominating (Eckburg et al., 2005; Gill et 
al., 2006). Virus-like particles seem to be a stable but highly individual trait, with 
minimal influence of either family or environment (Reyes et al., 2010). The 
composition of the microbiota occupying the lower GI tract mucosa is also distinct 
from microbiota present in the faecal stream (Eckburg et al., 2005), indicating that 
there is compartmentalisation of the microbial communities colonising the gut. The 
composition of the intestinal microbiota is also recognised to vary according to 
geography and age (Yatsunenko et al., 2012). Although neonates are born germ free 
they are immediately colonised by maternally derived bacteria that they are exposed 
to during birth. Vaginally delivered babies are rapidly colonised at different body 
habitats by taxa present in the mother’s vagina, including Lactobacillus, Prevotella 
and Atopobium, whereas infants delivered by caesarean section are predominantly 
colonised by skin taxa, such as Staphylococcus spp (Dominguez-Bello et al., 2010). 
However, by 3 years of age the composition of the intestinal microbiota largely 
evolves to resemble that of adults (Yatsunenko et al., 2012), demonstrating that the 
environmental conditions of a particular ecological niche strongly influence the 
ultimate success of microbial colonisation. Marked variation in the composition of 
intestinal microbiota in individuals from different geographical and socioeconomic 
backgrounds is well recognised (De Filippo et al., 2010; Yatsunenko et al., 2012). 
Importantly, the organisms with which we share our epithelial barrier surfaces 
seldom cause disease in immunologically competent individuals and instead they 
often confer survival advantage to the host, by performing a variety of beneficial 
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functions (Figure 1). Intestinal bacteria possess enzymes genetically absent from 
mammals enabling their host to utilise novel metabolic pathways. These bacteria 
salvage nutrients for the host by degrading otherwise indigestible complex dietary 
polysaccharides (Xu et al., 2003), and generating utilisable short chain fatty acids, 
such as butyrate and acetate by fermentation (Mahowald et al., 2009). The 
microbiota also perform protective roles for the host, including detoxification of 
xenobiotics (Swann et al., 2009) and limit colonization by invasive pathogens, such 
as E.coli 0157:H7 (Asahara et al., 2004). 
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Figure 1. The intestinal microbiota confers health benefits to the host.  Ingested xenobiotics are 
metabolised into inert by-products. Biosynthetic functions involve synthesis of 
biomolecules utilisable by the host (e.g. microbial enzymes biosynthesize vitamin K). 
Immune maturation is dependent on the microbiota (see Table 1). Metabolic functions 
include fermentation of indigestible dietary fibres into metabolites utilisable by the host 
(e.g. short-chain fatty acids). Microbes provide protection by competing with pathogens 
for space and nutrients. Adapted from Powell et al., 2013. 
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1.2.1 Host perception of the microbiota 
For the host/microbiota symbiosis to flourish the host must be able to sense and react 
to the microbes to which it is exposed at the barrier surfaces, but must also 
discriminate between pathogens and symbionts. This difficult task is perhaps most 
challenging in the GI tract, since this location houses the greatest number of 
symbionts but is also one of the sites most susceptible to invasion by pathogens, and 
worldwide GI infection remains one of the most important causes of morbidity and 
mortality (Motarjemi and Kaferstein, 1997). The microbiota is sensed by cells of the 
intestinal mucosa, including epithelial cells, macrophages, DCs, endothelial cells, 
myofibroblasts and adipocytes (Cario, 2005). These cells are equipped with a diverse 
repertoire of receptors, termed pattern recognition receptors (PRRs) that recognise 
conserved microbial components termed pathogen associated molecular patterns 
(PAMPs). Typical PAMPs include bacterial cell wall molecules, such as lipoteichoic 
acid, peptidoglycans and lipopolysaccharide (Cario, 2005). The best known PRRs are 
the TLRs. These transmembrane receptors share common structural motifs and at 
least 11 family members have been identified in mammals (Cario, 2005). Another 
structurally distinct family of PRRs is the NOD like family of receptors, which are 
intracellular receptors (Cario, 2005). By controlling the repertoire, cellular 
distribution and tissue localisation of PRRs the host can sense and respond to 
environmentally encountered microbes in different ways in different anatomical 
locations. For instance, TLR expression may be constitutive or induced, and maybe 
differentially expressed on the apical or basolateral surface of the mucosal epithelium 
(Cario, 2005). Therefore, luminal facing TLRs expressed on the apical surface of the 
epithelium directly interface with colonic microbes, whereas those expressed on the 
basolateral aspect occupy a “privileged” compartment that in the healthy state is not 
exposed to luminal microbes. For example, TLR5 is preferentially expressed on the 
basolateral aspect of intestinal epithelial cells (Gewirtz et al., 2001), where it is 
denied access to its specific agonist flagellin, a conserved structural protein forming 
the flagella of numerous bacteria (Hayashi et al., 2001). However, bacterial 
translocation occurring following epithelial damage in acute GI infection with 
flagellated pathogens, such as Salmonella, results in de novo exposure of TLR5 to its 
ligand and induction of a protective pro-inflammatory cytokine response (Gewirtz et 
al., 2001). Homozygous loss of function mutations in the TLR5 gene results in 
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increased susceptibility to Legionnaire’s disease, a severe lung infection caused by 
another flagellated bacteria Legionella pneumophilia (Hawn et al., 2003). 
Despite their role in stimulating anti-pathogen immunity, it is also recognised that 
PRRs interact with gut symbionts to facilitate their mutualistic relationship with the 
host. The critical importance of the cross talk between the innate immune system and 
the gut microbiota for the maintenance of intestinal homeostasis is readily 
demonstrated by experimental perturbation of either of these components. Disrupting 
innate immune recognition of luminal organisms, for example in mice with genetic 
deficiencies in particular PRRs results in disordered intestinal homeostasis and 
altered susceptibility to inflammatory insult. Indeed, genetic deletion of MyD88, the 
adaptor molecule responsible for TLR ligation mediated induction of NFκB, results 
in enhanced susceptibility of mice to DSS-induced colitis (Rakoff-Nahoum et al., 
2004). Myd88
-/-
mice have exaggerated turnover of intestinal epithelial cells and are 
unable to generate protective factors which promote epithelial homeostasis as a 
consequence of their inability to receive signals from the commensal intestinal 
microbiota. Commensal bacteria were responsible for TLR activation since robust 
depletion with potent mixtures of antibiotics also rendered WT mice highly 
susceptible to DSS colitis/mortality. This sensitivity to disease could be rescued by 
treating microbiota-depleted mice with purified TLR agonists LPS and LTA (which 





mice are also highly sensitive to DSS-induced colitis/mortality, which cannot 
be rescued by administration of LPS (in the case of Tlr4
-/-
 mice) or LTA (in the case 
of Tlr2
-/-
 mice) following microbiota depletion (Rakoff-Nahoum et al., 2004). 
Together these data show that signals delivered by the normal intestinal commensal 
microbiota play an important role in intestinal homeostasis.  
Similarly, Mice lacking TL9 have a pro-inflammatory phenotype and adoptive 
transfer of colonic T-cells from Tlr9
-/-
 mice to immunodeficient recipients triggers 
more severe colitis than transfer T-cells from the gut of WT mice (Hofmann et al., 
2014). Mice lacking TLR5 develop spontaneous colitis (Vijay-Kumar et al., 2007). 
Taken together these data demonstrate that the role of immune recognition of luminal 
commensal bacteria is a highly complex process. 
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Studies of germ-free mice have also provided useful insights into the importance of 
the intestinal microbiota in immune homeostasis. Mice reared in sterile conditions 
devoid of exposure to environmental microbes have numerous immunological, 
physiological and anatomical differences from conventionally reared animals (Table 
1). These changes include grossly enlarged caeca, poor development of gut 
associated lymphoid tissue, fewer mononuclear cells infiltrating the lamina propria 
and reduced TLR expression (Thompson and Trexler, 1971; Wang et al., 2010). 
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1.2.2 Host immunity is modulated by the microbiota and impacts on host 
health 
The intestinal microbiota profoundly impacts on key aspects of host immunity. 
Unlike conventionally colonised mice, there are few T cells present in the intestinal 
lamina propria and intraepithelial compartment of germ free mice (Okada et al., 
1994). T-cell dependent delayed type hypersensitivity reactions are also impaired in 
germ free animals (Carter et al., 1979; Collins and Carter, 1980). The differentiation 
of effector CD4
+
 T-cell lineages has also been shown to be modulated by the 
community composition of the intestinal microbiota. It was recently recognised that 
the capacity of a single strain of mice to generate Th17 responses was dependent on 
which commercial vendor supplied the mice. C57/B6 mice supplied by Jackson 
laboratories, the largest vendor of research mice in the United States, were poor 
generators of IL-17 responses, whereas mice acquired from Taconic Farms and a 
number of other vendors readily produced IL-17 (Ivanov et al., 2008). These data 
indicate that in addition to host genetics, environmental factors also play a central 
role dictating host capacity to mount effector T-cell responses. Crucially, the 
intestinal microbiota was identified as the key environmental variable responsible for 
influencing Th17 differentiation, since Th17 responses could be restored in Jackson 
mice if they were co-housed with Taconic Farms mice or if they were gavaged with 
the caecal contents harvested from Taconic Farms mice (Ivanov et al., 2008). 
Similarly, a potent cocktail of 4 different antibiotics that has been shown to 
dramatically reduce the microbial load present in the intestine also resulted in 
diminished Th17 differentiation (Ivanov et al., 2008). For the first time, these studies 
demonstrated that the microbial communities interfacing with the host immune 
system helps to shape T-cell lineage commitment. 16S rRNA gene sequencing 
identified differences in the intestinal microbiota communities between Jackson and 
Taconic Farms mice, including the identification of an unculturable bacterium from 
the Arthomitus genus termed segmented filamentous bacteria (SFB) that was present 
in Taconic farms, but not Jackson mice (Ivanov et al., 2009). Crucially, 
monoassociation of re-derived germ free mice from Jackson with SFB but not other 
intestinal bacteria resulted in successful acquisition of Th17 responses (Ivanov et al., 
2009). In addition to driving Th17 responses, it has also been demonstrated that SFB 
may be important in driving Th1 immunity (Gaboriau-Routhiau et al., 2009). SFB 
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colonises the terminal ileum where it tightly adheres to the ileal mucosa and 
penetrates into epithelial cells (Ivanov et al., 2009). The close contact formed 
between long filaments from SFB and ileal epithelial cells and PPs, a key inductive 
site of effector T-cells, may be important in their capacity to modulate T-cell 
immunity. Analysis of the gene expression profile of the ileum following 
colonisation of germ free mice with SFB demonstrated upregulation of many genes 
involved in host immunity, such as the antimicrobial peptide RegIII and acute phase 
proteins, such as serum amyloid A, which has been shown to promote Th17 
differentiation in vitro (Ivanov et al., 2009). 
Modulation of host immunity by the intestinal microbiota is also functionally 
relevant in host health. Germ free mice are more susceptible to infections, such as 
Listeria monocytogenes (Inagaki et al., 1996), Nocardia asteroids (Beaman et al., 
1980) and Cryptosporidium parvum (Sacco et al., 1998). Paradoxically, germ free 
mice are less susceptible to T-cell mediated immune diseases, including IBD (Sellon 
et al., 1998), autoimmune arthritis (Wu et al., 2010) and experimental allergic 
encephalomyelitis (EAE), a model of multiple sclerosis (Lee et al., 2011). 
Furthermore, in the case of arthritis and EAE it has been shown that monoassociation 
of germ free mice with SFB was sufficient to successfully reinstate Th17 responses 
and restore disease susceptibility (Lee et al., 2011; Wu et al., 2010). In the GI tract 
the Th17 response is also important in host resistance to certain pathogens, including 
Citrobacter rodentium (Symonds et al., 2009), Shigella flexneri (Sellge et al., 2010) 
and Salmonella typhimurium (Raffatellu et al., 2008). SFB permissive Th17 
responses are functionally important in host resistance to infection, since Jackson 
mice lacking SFB and unable to mount robust Th17 responses are highly sensitive to 
Citrobacter rodentium infection (Ivanov et al., 2009). Crucially, inoculation with 
SFB restored robust Th17 immunity in Jackson mice and bolstered their resistance to 
infection (Ivanov et al., 2009). SFB do not colonise the GI tract of humans (Sczesnak 
et al., 2011), therefore, a role for particular intestinal bacterial species in stimulating 
effector T-cell differentiation has yet to be established in humans. 
The intestinal microbiota also influences the generation of regulatory T-cells (T-regs). 
Monoassociation of germ free mice with the human commensal Bacteroides fragilis 
promotes the accumulation of IL-10 producing Foxp3
+
 T-regs in the intestine (Round 
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and Mazmanian, 2010). A key molecule involved in this process is the capsular 
polysaccharide A (PSA) since mutant strains of Bacteroides fragilis lacking PSA have 
impaired T-reg induction (Round and Mazmanian, 2010). PSA mediated T-reg 
induction is functionally relevant. Administration of purified PSA has been shown to 
augment the number and suppressive capacity of T-regs and to attenuate experimental 
IBD induced by either Helicobacter hepaticus (Mazmanian et al., 2008) or TNBS 
(Round and Mazmanian, 2010). Metagenomic sequencing of the intestinal microbiota 
of healthy human subjects has demonstrated considerable variation in the prevalence 
and frequency of Bacteroides fragilis (Huttenhower., et al. 2012) and studies evaluating 
T-reg phenotype in patients with and without Bacteroides fragilis are eagerly awaited. 
1.2.3 The microbiota and inflammatory bowel disease 
The intestinal microbiota is now under scrutiny as a potentially important contributor 
to IBD pathogenesis, and evidence supporting a role for the intestinal microbiota in 
IBD is shown in Table 2. Patients with IBD have circulating antibodies and T-cells 
specificities directed against normal constituents of their intestinal microbiota 
(Duchmann et al., 1999; Helphingstine et al., 1979; Mow et al., 2004). Manipulation 
of the intestinal microflora may be clinically beneficial in IBD. Under some 
circumstances, antibiotics have proven efficacy in CD, including the treatment of 
perianal disease (Bernstein et al., 1980; Dejaco et al., 2003) and in the prevention of 
disease recurrence following ileocaecal resection (Rutgeerts et al., 1995). Antibiotics 
are the first line therapy for postoperative UC patients who develop pouchitis (Shen 
et al., 2001). Similarly, probiotics, defined as microbes that are beneficial to health 
have been shown to maintain remission in UC in some studies (Ishikawa et al., 2003; 
Kruis et al., 1997) and are therapeutic in pouchitis (Gionchetti et al., 2000). Probiotic 
bacteria appear to alter the balance between inflammatory and regulatory pathways 
in the intestine. For instance, the probiotic mixture VSL#3 induces production of the 
regulatory cytokine IL-10 by DCs and at the same time reduces the expression of 
pro-inflammatory cytokines, such as IL-12, and co-stimulatory molecules, including 
CD80 (Hart et al., 2004). In some circumstances, such as patients with extensive 
small intestinal CD, surgical diversion of the faecal stream away from inflamed 
intestinal segments, thereby reducing exposure to luminal microbes, is recognised to 
promote mucosal healing (Harper et al., 1985). 
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Table 2. Evidence implicating the intestinal microbiota as an important environmental 





The intestinal microbiota also profoundly impact mouse models of intestinal 
inflammation. Il10
-/-
 mice which spontaneously develop colitis when colonised by a 
conventional intestinal microflora are protected from disease when they are housed 
under germ free conditions (Sellon et al., 1998). Indeed, the penetrance of 
typhlocolitis in these mice seems to vary according to the cleanliness of the animal 
facility and some bacteria appear to be particularly effective at triggering disease, 
such as Helicobacter hepaticus (Kullberg et al., 1998) and Enterococcus faecalis 
(Kim et al., 2005b).  
Viral infections have also been implicated in IBD development. Mice with a targeted 
mutation in the CD associated autophagy gene Atg16l1 exhibit marked abnormalities 
of Paneth cells and the intestinal epithelium, including impaired assembly and 
secretion of antimicrobial peptides and increased expression of pro-inflammatory 
cytokines, analogous to the mucosal phenotype observed in CD patients with 
homozygous mutations in ATG16L1 (Cadwell et al., 2008). However, these 
abnormalities only manifest in mice colonised with a conventional bacterial 
microflora and concomitant infection with murine norovirus (MNV), which is 
endemic to many animal houses (Cadwell et al., 2010). In WT mice, MNV infection 
fails to induce abnormalities in either Paneth cells or epithelial cells, demonstrating 
that interaction between MNV and a specific genetic susceptibility was required to 
initiate this CD-like mucosal phenotype. MNV infected Atg16l1 hypomorphic mice 
were more sensitive to DSS-induced colitis, which resulted in histological features 
resembling some aspects of CD, including full thickness ileal inflammation with 
leukocytes infiltrating the muscularis layers and mesenteric fat (Cadwell et al., 
2010). Furthermore, antibiotic therapy targeting the normal bacterial flora of Atg16l1 
hypomorphic mice, or blockade of the inflammatory cytokines TNFα or IFNγ also 
attenuated disease, indicating a key role for the interaction between host immunity 
and intestinal bacteria in disease manifestation (Cadwell et al., 2010). Intriguingly, 
MNV is related to norovirus species that cause acute gastrointestinal inflammation in 
humans. 
Studies have also been undertaken evaluating the community composition of the 
intestinal microbiota of IBD patients in comparison with non-IBD control subjects 
using metagenomic sequencing. Several studies have identified quantitative and 
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qualitative differences in community membership of the intestinal microbiota. A 
frequently observed difference between IBD patients and healthy control subjects is 
reduced intestinal community diversity, in both CD and UC patients (Frank et al., 
2007; Kang et al., 2010; Manichanh et al., 2006; Ott et al., 2004). A relative 
depletion of members of the Firmicutes and Bacteroidetes phyla and expansion of 
Proteobacteria and Actinobacteria has also been reported in IBD patients (Frank et 
al., 2007). Reduced biodiversity of the intestinal microbiota and relative expansion 
of Proteobacteria and Actinobacteria has also recently been observed in IBD 
affected twins in comparison with their healthy siblings (Lepage et al., 2011). It is 
not certain whether changes in the composition of intestinal microbiota are causal or 
secondary to inflammation or diarrhoea itself. Reduced intestinal bacterial 
biodiversity, albeit to a lesser degree, has also been observed in other diarrhoeal 
illnesses, such as infectious gastroenteritis and irritable bowel syndrome (Mai et al., 
2006; Noor et al., 2010). 
Another bacterial component of the intestinal microflora, Faecalibacterium 
prausnitzii, may play an important anti-inflammatory role in the intestine. F. 
prausnitzii is under-represented in patients with active IBD (Sokol et al., 2008; Sokol 
et al., 2009), and reduced F. prausnitzii frequency is associated with an increased 
rate of CD recurrence following surgical resection of an inflamed intestinal segment 
(Sokol et al., 2008). F. prausnitzii was also observed to attenuate TNBS induced 
colitis (Sokol et al., 2008). Although the mechanisms responsible for the anti-
inflammatory properties of F. prausnitzii are still to be resolved, it appears that 
soluble factors contribute at least in part. Supernatants from F. prausnitzii cultures 
significantly inhibited IL-1 induced colonic epithelial production of the 
inflammatory cytokine IL-8. In contrast to other bacteria, F. prausnitzii was a weak 
inducer of IFNγ and IL-12, and instead promoted production of the anti-
inflammatory cytokine IL-10 (Sokol et al., 2008), as has been observed with anti-
inflammatory probiotic bacterial mixtures such as VSL#3 that are therapeutic in IBD 
(Hart et al., 2004). 
Compelling data for a pathogenic role for specific bacterial species in human IBD is 
lacking. In the early 1980s Mycobacterium avium paratuberculosis (MAP) was 
proposed as a possible aetiological agent in CD (Chiodini et al., 1984) and PCR 
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based technologies initially indicated the presence of this organism in a significant 
number of intestinal resection specimens from CD, but not UC or non-IBD patients 
(Sanderson et al., 1992). However, other studies have failed to corroborate these 
findings (Rowbotham et al., 1995). Notably, a large meta-analysis of anti-
mycobacterial therapy in CD failed to show efficacy (Borgaonkar et al., 2000). A 
subsequent comprehensive prospective study was undertaken in which 213 CD 
patients were randomised to receive 2 continuous years of anti-mycobacterial therapy 
(clarithromycin, rifabutin and clofazimine) or placebo, which also failed to show any 
long term benefit (Selby et al., 2007). Therefore, a key role for mycobacterial species 
in driving IBD seems unlikely. 
Other bacterial species have also been implicated in IBD pathogenesis. Escherichia 
coli are enriched in the intestinal mucus layer of CD patients (Martin et al., 2004). 
Moreover, these E. coli adhere to and invade intestinal epithelial cells (Boudeau et 
al., 1999). Adherent and invasive E. coli (AIEC) attach to specialised 
membranous/microfold epithelial cells (M cells) that overly Peyer’s patches (PPs) 
through expression of the virulence factors type 1 pili and long polar fimbriae (LPF) 
(Chassaing et al., 2011). Once translocated beyond the ileal epithelium AIEC survive 
and replicate inside macrophages by evading intracellular killing mechanisms 
(Glasser et al., 2001), thereby facilitating their prolonged access to this key intestinal 
lymphoid structure that plays such an important role in shaping host intestinal 
immunity. There have been reports of disordered microbial loading in the intestinal 
mucus layer in UC. As well as harbouring much higher concentrations of bacteria in 
the mucus layer than healthy controls the mucus layer of UC patients may also 
contain potentially pathogenic species (Swidsinski et al., 2002). For instance, culture 
supernatants harvested from Fusobacterium varum that were isolated from the 
colonic mucus layer of UC patients induced colonic ulceration and histological 
lesions resembling UC when rectally administered to mice (Ohkusa et al., 2003). 
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1.3 Immunology of inflammatory bowel disease 
The immunology of IBD is complex, with cross-talk between multiple adaptive and 
innate immune mechanisms interacting with stromal cells, epithelial cells, 
endothelial cells and contents of the gastrointestinal lumen, including bacteria and 
food antigens. A key aspect of diagnosing IBD is histological assessment of mucosal 
biopsies, which became commonplace following the widespread introduction of 
fibreoptic colonoscopy and is now routinely performed in clinical practice. In UC 
there is marked infiltration of the colonic lamina propria with lymphocytes and 
plasma cells, and usually focal infiltration of neutrophils, which may infiltrate crypts 
causing their architectural distortion or destruction (Morson, 1972). There is goblet 
cell depletion and reactive epithelial hyperplasia. Inflammation is usually confined to 
the mucosa, however, when there is marked destruction of the mucosa, the 
submucosa may become inflamed. In CD, changes are often patchy and 
discontinuous, commonly involves the submucosa and beyond (may be full 
thickness), and tend to cause proportionally fewer crypt abscesses. The infiltrate is 
mostly lymphocytes with fewer neutrophils, which are found at highest frequency 
aggregated at ulcers. There also tends to be more oedema and lymphangiectasia in 
CD in comparison with UC (Morson, 1972; Williams, 1964). The other histological 
hallmark of Crohn’s disease is the formation of epithelioid granuloma. However, 
granuloma are only present in about one third of CD patients (Heresbach et al., 
2005). As well as its role in the diagnosis of IBD, histological assessment of IBD 
confirms involvement of immune cells in disease. The role of different immune cells 
in IBD has been intensely studied for many years. For context the role of adaptive 
immunity will be considered in outline only, since the key objective of this thesis is 
to provide insights into disease relevant innate intestinal immune pathways. Innate 
immune cells, including a relatively newly described population of innate lymphoid 
cells will be described in greater depth. 
1.3.1 Adaptive immunity and IBD 
It has long been recognised that IBD is characterised by increased numbers of 
activated lymphocytes present in mucosal lesions (Fiocchi et al., 1979, 1981). T-cell 
clones generated from intestinal cLP T-cells isolated from IBD patients are activated, 
43 
as measured by proliferative responses, by normal constituents of their gut flora 
(Duchmann et al., 1996; Duchmann et al., 1999), indicating that aberrant T-cell 
activation in IBD is directed against their commensal flora. Initial studies looking at 
the phenotype of T-cells from IBD patients suggested that CD2/CD28 or CD3/CD38 
stimulation was associated with increased IFNγ production in CD and IL-5 
production in UC, with the implication that CD is likely a Th1 disease and UC an 
atypical Th2 disease (Breese et al., 1993; Fuss et al., 1996). Consistent with this, 
macrophage-derived IL-12, which induces the polarization of naïve T cells towards a 
Th1 phenotype, is highly up-regulated in inflamed CD but not in UC mucosa 
(Monteleone et al., 1997). IL-12 signals through STAT4, and in CD but not in UC 
there is abundant phospho-STAT4 in mucosal T cells (Monteleone et al., 1997). 
However, the paradigm of CD as a Th1 disease and UC as an atypical Th2 disease 
has also been challenged with the recognition that mucosal Th17 responses may play 
an important role in IBD pathogenesis. It is well established that disease 
susceptibility genes encoding multiple components of the Th17 pathway are shared 
between CD and UC (Jostins et al., 2012). It is also interesting that susceptibility loci 
associated with the Th1 response are also shared between CD and UC, including 
IFNG, STAT1, STAT4 and IL18RAP, whereas polymorphisms in canonical Th2 
genes, including GATA3, IL4, IL5 and IL13 are not associated with UC nor CD 
(Jostins et al., 2012). Other studies looking at differences in T cell-derived cytokines 
between UC and CD have shown less clear cut distinctions. Th17 cells and Th1/Th17 
cells, which release both IFN and IL-17A, are increased in the gut of CD and UC 
patients in comparison with controls, and IL-17A is overexpressed in both CD and 
UC mucosa (Fujino et al., 2003; Rovedatti et al., 2009). Transcriptomics is an 
unbiased way to look for differences in the transcription profile of immune genes in 
the intestine of patients with CD, UC and healthy controls. Although a number of 
studies have appeared, and indeed differences have been identified, these are 
frequently associated with epithelial renewal and basic biochemical processes than 
with a particular type of immune response (Noble et al., 2008; Noble et al., 2010; 
Schulze et al., 2008), although dysregulated gene expression of the Th17 
components IL23R, STAT3 and JAK2 was observed in CD (Noble et al., 2010). 
Treatments targeting T-cells have also shown efficacy in IBD. Cyclosporine, a 
calcineurin inhibitor that prevents NFAT activation in T-cells, which results in 
44 
impaired pro-inflammatory cytokine synthesis (Breese et al., 1993) and increased 
apoptosis (Ying et al., 2003), is efficacious, particularly in acute, severe forms of UC 
that is unresponsive to steroids (Lichtiger et al., 1994). Steroids, which are also 
commonly used to treat IBD, inhibit antigen-induced T-cell cytokine production 
(Powell et al., 2001). However, despite early promise, visilizumab, an anti-CD3 mAb 
that specifically targets T-cells and is thought to drive T cell tolerance failed to show 
efficacy in UC and was associated with significant systemic cytokine release limiting 
its use (Sandborn et al., 2010). 
T-cells have been shown to play a prominent role in mouse models of IBD. Adoptive 
transfer of naive T-cells into lymphopaenic mice lacking endogenous lymphocytes 
induces severe pan-colitis (Powrie et al., 1994), and is frequently used by many 
research groups to investigate mechanisms of disease. 
1.3.2 Innate immunity and IBD 
Innate immune mechanisms are thought to play an important role in IBD. Mouse 
models of IBD have been described in mice lacking adaptive immunity, including 
disease induced by Helicobacter hepaticus, DSS and agonistic anti-CD40 mAbs 
(Buonocore et al., 2010; Kim et al., 2006; Li et al., 1998; Uhlig et al., 2006). Innate 
lineages with important roles in IBD include dendritic cells, macrophages, 
granulocytes and a new population of cells called innate lymphoid cells, which will 
be discussed in detail. 
1.3.2.1 Innate lymphoid cells 
The term innate lymphoid cell (ILC) is collectively used to define functionally 
heterogeneous cells with shared lymphoid cell characteristics, but lacking adaptive 
immune receptors. These cells include natural killer (NK) cells and innate 
populations of cells that express GATA-3, RORγt or T-bet. ILCs lack common 
lineage markers, such as CD3, CD19, CD11c, CD11b, CD14 and CD16. However, 
all ILC populations appear to express IL-7R and CD90 (also known as Thy-1). 
Currently, there is no standardised classification or agreed nomenclature for these 
populations. Mucosal ILCs can be subdivided into 3 main subsets comprising NK 
receptor expressing intestinal RORγt+ cells that produce IL-22; GATA-3+ cells that 
produce Th2 cytokines; and intestinal RORγt+ cells that lack NK receptors and 
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produce combinations of IL-17, IL-22 and IFNγ. In addition to these mucosal 
dwelling cells an additional subset of related cells termed lymphoid tissue inducer 
(LTi) cells are also recognised, that are involved in secondary lymphoid 
organogenesis. Conventional NK cells involved in systemic immune responses and 
tumour immunity will not be considered in depth in this thesis. In view of the 
confusion regarding a standardised classification for ILCs there has been a recent 
attempt to more formally adopt consistent nomenclature to the different ILC subsets 
(Spits et al., 2013). Group 1 ILCs are defined by their capacity to produce IFNγ, and 
are subdivided into “conventional” NK cells and ILCs that lack phenotypic traits of 
NK cells, but possess NK receptors, such as NKp46. These cells express the 
transcription factor T-bet. Group 2 ILCs are defined by their capacity to produce Th2 
cytokines and express GATA-3. Group 3 ILCs produce Th17 cytokines, but are yet 









) populations. This proposed nomenclature is illustrated in Figure 2. 
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Figure 2. Proposed nomenclature for ILCs.  Group 1 ILCs comprise conventional NK cells as 
well as interferon-γ producing ILCs. Group 2 ILCs produce Th2 like cytokines. Group 3 
ILCs are further subdivided into 3 subsets, including LTi cells, RORγt+ ILCs that lack 
NK cell cytotoxicity receptors (NCR), such as NKp46, and RORγt+ ILCs that express 




























Lymphoid Tissue inducer cells 
Lymphoid Tissue inducer (LTi) cells are the prototypical RORγt+ ILC lineage. They 









populating neonatal LNs, but then progressively decline with time as thymic T-cell 
production begins and lymphocyte migration to the LNs occurs (Kelly and Scollay, 
1992). LTis account for 50% of the cells present in the LN at day 1 of life, declining 




 T-cells begin to dominate (Kelly and Scollay, 
1992). In the peripheral blood these cells peak during embryonic development (day 




 LTi cells 
express the gut homing receptor α47 that binds to its adhesion molecule target 
MAdCAM-1 that as well as being expressed in PPs, is also transiently expressed by 
the high endothelial venules of all LN for up to 24 hours after birth (Mebius et al., 
1997). Secondary lymphoid organogenesis is initiated following interaction between 
lymphotoxin- (LT) provided by LTis, and LT receptor expressed by stromal cells 
(Fu and Chaplin, 1999; Mebius et al., 1997). 
LTi development is dependent on the transcription factor RORγt (Eberl et al., 2004). 
In humans, RORγt+ IL7R+ ILCs that lack other lineage markers, including CD4, are 
also found in the lymph nodes of the 8 week old foetus prior to the arrival of T-cells 
(Cupedo et al., 2009). Interest in ILCs as potential effector cells in autoimmune 
diseases, including IBD have been galvanised following studies showing that both 
human (Cupedo et al., 2009) and murine (Takatori et al., 2009) RORγt+ LTi cells are 
a potent source of IL-17 and IL-22. Furthermore, conditional RORt lineage tracing 
studies have shown that in adult mice the majority of RORγt+ ILCs reside in the 
intestine (Sawa et al., 2010). 
Intestinal RORγt+ innate lymphoid cells 
NK cells are found in the spleen, liver, other secondary lymphoid tissue and indeed 
circulating in peripheral blood. However, some NK cell populations occupying the 
small and large intestine appear to be distinct lineage. Conventional NK cells express 
the Th1 type transcription factors, such as T-bet and eomesodermin (Gordon et al., 
2012; Townsend et al., 2004). They are a rich innate source of IFNγ, possess 
cytotoxic functions and are involved in host defence against viruses, neoplastic 
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change and cell senescence (Vivier et al., 2008). In the gut, cells expressing the NK 
marker NKp46 can be subdivided into 3 populations according to their expression of 





resembling conventional NK cells accounted for only about a third of small intestinal 
NKp46 expressing cells. Like conventional NK cells, these cells produced IFNγ and 







 cells, which lacked other NK markers, such as CD94, Ly49A/D and CD49b 





 cells also lacked NK receptors such as TRAIL and FasL (Satoh-
Takayama et al., 2008), that are required to trigger apoptosis in target cells, 
indicating that these cells are not “natural killers” and instead have a functionally 






 cells also expressed the transcription 
factor RORγt which is not found in conventional NK cells (Satoh-Takayama et al., 













 cells have a completely different expression profile and their 
transcriptome resembles that of RORγt+ LTi cells (Reynders et al., 2011). 
Furthermore, lineage tracing studies indicate that RORγt+ LTi like cells differentiate 
into NKp46
+
 RORγt+ intestinal ILCs, but do not give rise to conventional NK cells. 
For example, RORγt lineage tracing (RORγt-EGFP) can be used to track the fate of 





 mice that lack endogenous NK cells and ILCs, resulted in 
differentiation of both NKp46
+
 RORγt+ and NKp46- RORγt+ ILC populations. In 
contrast, adoptively transferred NK cells failed to differentiate into any RORγt+ 
populations, and instead remained NKp46
+
 RORγt- even when followed for 6 months 
post transfer (Vonarbourg et al., 2010). These data strongly suggest that NKp46
+
 
RORγt+ ILCs are indeed a distinct lineage from conventional NK cells. 
Instead of producing IFNγ, NKp46+ RORγt+ ILCs are a rich source of IL-22 (Sanos 
et al., 2009; Satoh-Takayama et al., 2008), which is a key cytokine involved in early 
host immunity to intestinal pathogens, such as Citrobacter rodentium (Zheng et al., 
2008). Induction of IL-22 peaks at just 4 days post inoculation of C. rodentium and is 
dependent on host expression of IL-23 (Sonnenberg et al., 2011; Zheng et al., 2008). 
Susceptibility to C. rodentium infection is increased in Il22
-/-
 mice or following IL-
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22 neutralisation (Sonnenberg et al., 2011; Zheng et al., 2008). IL-22 dependent 
resistance to infection was also observed in Rag2
-/- 
mice, indicating that innate 
immune mechanisms likely accounted for early host immunity to C. rodentium 
(Zheng et al., 2008). Indeed, IL-22 expressing innate immune populations out 
number IL-22 producing T-cells during the first 8 days of C. rodentium infection 




 mice that lack ILCs altogether are incapable 
of IL-22 production and rapidly succumb to C. rodentium infection (Satoh-Takayama 
et al., 2008). However, a recent report has suggested that the dominant innate source 




 RORγt+ ILCs that 
expressed CD4 but not NKp46 (Sonnenberg et al., 2011). In vivo depletion of CD4 
expressing cells severely impaired C. rodentium resistance in Rag1
-/-
 mice 
illustrating an important functional role for IL-22 expressing CD4
+
 ILCs in C. 
rodentium infection (Sonnenberg et al., 2011). 
There are also populations of IL-22 producing NK like cells in human mucosal 
associated lymphoid tissue (MALT), including the tonsils, PPs and appendix (Cella 
et al., 2009). These cells expressed NKp44, CCR6 and produced IL-22 in response to 
stimulation with IL-23 and to a lesser extent IL-6. These cells lacked perforin, 
granzyme B and did not produce IFNγ, consistent with their lineage separation from 





 RORγt+ cells are present in non-inflamed human gut and are reduced in CD 
patients (Takayama et al., 2010). 
In addition to RORγt+ IL-22 producing ILCs that confer protective immunity to 
intestinal pathogens in mice, it is now recognised that an additional population of 
RORγt+ intestinal ILCs exist that mediate intestinal inflammation. Infection with the 
mouse pathogen Helicobacter hepaticus (Hh) induces typhlocolitis and liver disease 
in susceptible mice strains (Fox et al., 1994; Ward et al., 1996). Chronic colitis in Hh 
infected mice is IL-23 dependent and is fully penetrant in 129 SvEv Rag1
-/-
 mice 
lacking adaptive immunity (Hue et al., 2006), highlighting the importance of innate 
immune mechanisms in this model of IBD. It has recently been shown that chronic 
colitis in Hh infected Rag1
-/-
 mice is mediated by intestinal RORγt+ ILCs (Buonocore 
et al., 2010). These cells expressed hallmark ILC markers, including CD90, IL-7R, 
Sca-1, CD44 and CD25, lacked expression of NKp46, CD4 or other lineage markers, 
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and produced IL-17, IL-22 and IFNγ (Buonocore et al., 2010). Chronic colitis in Hh 
infected Rag1
-/-
 mice is ameliorated by depleting CD90 expressing cells or by 
simultaneously blocking IL-17 and IFNγ (Buonocore et al., 2010). This group were 
also able to show that innate immune mediated colitis induced by administration of 
agonistic anti-CD40 mAbs to Rag1
-/-





 double knockout mice were resistant to disease (Buonocore et 
al., 2010). These results indicate that inflammatory ILCs also exist in the intestine 
and that in the appropriate context these cells are potent inducers of intestinal 
inflammation. RORγt+ ILCs were also seen in immunocompetent mice following 
induction of colitis with Hh (Buonocore et al., 2010), indicating that these cells are 
not merely an artefact of mice lacking adaptive immunity, but may indeed play a 
functionally relevant role in IBD. Recent data indicate that IL-1, an inflammatory 
cytokine, which is upregulated in the intestinal LP of IBD patients (Reinecker et al., 
1993), may also drive inflammatory ILC effector function (Coccia et al., 2012). IL-
1 is elevated in ILC mediated models of colitis, such as Hh induced disease (Coccia 
et al., 2012). ILCs are the major intestinal cell population expressing the IL-1 
receptor and IL-1 blockade significantly reduced ILC numbers and attenuated Hh 
induced colitis in lymphopaenic mice (Coccia et al., 2012). 
The Powrie group has also shown that IL-23 responsive ILCs are present in inflamed 
gut of CD patients (Geremia et al., 2011). Transcripts encoding IL-17 and IL-22 
were further enriched in the non T-cell fraction of cLPLs from both UC and CD 
patients in comparison with non-IBD controls and are further upregulated following 
IL-23 stimulation (Geremia et al., 2011). The innate population of IL-17 producing 
cells lacked major lineage markers (CD3, CD19, CD14, CD16, CD56) but did 
express the IL-7R, consistent with an ILC phenotype (Geremia et al., 2011). In 




cells (Geremia et al., 2011), 
consistent with the likelihood that these cells are the NK like mucosal cells observed 
by other groups that have been shown to co-express CD56 and NKp44 (Cella et al., 




 innate lymphoid cells 
ILCs that express Th2 cytokines have been termed nuocytes (Neill et al., 2010), 
innate helper 2 cells (Price et al., 2010), natural helper cells (Chang et al., 2011) and 
ILC2 cells (Spits and Cupedo, 2011). Like Th2 CD4
+
 cells, these cells express the 
Th2 lineage defining transcription factor GATA-3 (Hoyler et al., 2012; Mjosberg et 
al., 2012) and produce IL-5 and IL-13, but not IFNγ or IL-22 (Hoyler et al., 2012). 
Like other ILC populations, GATA-3
+
 ILCs are dependent on IL7R signalling and 
are increased in the absence of adaptive immunity (Hoyler et al., 2012). However, 
ILC2 development was independent of RORγt and AhR (Hoyler et al., 2012). In the 
first 2 months after birth GATA-3
+
 ILCs express the gut homing integrin α47 and 
are found in 10-20 fold higher numbers in the small and large intestine in comparison 
with other mucosal tissues such as the lung (Hoyler et al., 2012). The migration of 
GATA-3
+
 ILC2 cells to the intestine is CCR9 dependent (Hoyler et al., 2012). In 
mice, GATA-3
+
 ILCs contribute to intestinal helminth expulsion in an IL-13 
dependent manner (Hoyler et al., 2012). GATA-3
+
 ILCs are present in human 
mucosal tissue (Mjosberg et al., 2012). These cells respond to typical “Th2” signals, 
such as IL-33 and TSLP to induce IL-4, IL-5 and IL-13. Effector function of human 
GATA-3
+
 ILCs can be subdued by silencing GATA-3 with small, hairpin RNA 
sequences (Mjosberg et al., 2012), highlighting the importance of this transcription 
factor in the maintenance of effector function of these cells. 
ILC development and maintenance 






progenitors found in the foetal liver are 
thought to give rise ILCs, since adoptive transfer of these progenitors to irradiated 














precursors resemble common lymphoid precursors that reside in the bone 
marrow, which seed all lymphoid lineages in adult mice (Mebius et al., 2001). The 
transcriptional and molecular control of ILC development has been scrutinized in 
recent years and various transcription factors have been identified which play an 
indispensable role in the development of mature ILCs, including RORC, RORα, Id2 
(inhibitor of DNA binding 2), Ahr (aryl hydrocarbon receptor) and Tox (thymocyte 
selection associated high-mobility group box protein). Eberl et al generated 
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RORtGFP/GFP reporter mice that have a fluorescent protein and stop codon inserted 
immediately downstream of the start codon of exon 1t, which is the splice variant of 
the Rorc gene that generates the mature RORt protein. The RORtGFP/+ heterozygote 
can be used to track the fate and tissue distribution of RORt expressing cells and the 









 LTis are one of the earliest cells found in 
embryonic LN and PP anlagens and that RORt is exclusively expressed by ILCs in 
the mouse embryo, it was also shown that RORt is indispensable for ILC generation 
and LN and PP formation (Eberl et al., 2004). 
All ILC subsets described to date, including RORγt+ and GATA-3+ ILCs express the 
helix-loop-helix (HLH) transcription factor Id2 (Hoyler et al., 2012). Id2
-/- 
mice have 






 LTi cells and also lack LNs and 
PPs. Id2 is a transcriptional inhibitor that forms heterodimers with another family of 
transcription factors called E proteins that play a key role in the development and 
differentiation of different immune cell lineages. Id2 binds and sequesters E2A that 
otherwise inhibits ILCs and NK cell development (Boos et al., 2007). ILCs can be 





knockout mice, consistent with the notion that Id2 acts by functionally silencing E2A 
mediated suppression of NK and ILC ontogeny (Boos et al., 2007). Unlike RORt-/- 
mice, Id2
-/-
 mice also lack NK cells and some myeloid lineages, such as CD11b
+
 
cells, consistent with the requirement for Id2 in the development of other immune 
lineages (Yokota et al., 1999). Another transcription factor, Tox, has also been 
shown to be critical for the development of numerous lymphoid lineages, including 
CD4
+
 T-cells, NK cells and LTis, however, some RORt+ NKp46+ cells were 
reported to be present in the small intestine of Tox
-/-
 mice, indicating that some ILC 
populations may develop independently of Tox (Aliahmad et al., 2012). There is 
impaired lymphoid organogenesis, including absent or severely hypoplastic LN and 
PPs in Tox
-/-











 precursors in the bone marrow (Hoyler et al., 2012), and also from common 
lymphoid progenitor cells (Wong et al., 2012), which are even earlier progenitors. 
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Notably, cytokines that promote the differentiation of other innate lymphoid 
lineages, such IL-7 and IL-15 (NK cells), or IL-1, IL-2, IL-7 and IL-23 (RORγt+ 







into other ILC subsets indicating that these cells are committed precursors (Hoyler et 
al., 2012). GATA-3 is also required for maintenance of ILC2 cells, since conditional 
deletion of Gata3 in Id2 expressing cells using the cre-lox recombinase system 
effectively depletes all mature IL-13 producing intestinal ILCs (Hoyler et al., 2012). 
ILC2 cells are also dependent on the transcription factor RORα, since staggerer mice 
(Rora
st/st
) that have a spontaneous deletion of RORa are unable to generate intestinal 
ILC2 cells rendering them highly susceptible to helminth infection (Wong et al., 
2012). Mouse and human ILCs express the aryl hydrocarbon receptor (Ahr) 
transcription factor (Cella et al., 2009; Takatori et al., 2009), an intracellular sensor 
that detects xenobiotics and endogenous ligands including tryptophan metabolites, 
flavinoids and arachidonic acid. Ahr is expressed by Th17 cells, and Th17 
differentiation has been shown to be augmented by natural Ahr agonists and blocked 
by Ahr antagonists (Quintana et al., 2008), underlining the phenotypic similarities 
between some ILC populations and the CD4
+





ILCs are absent and other ILC populations diminished in Ahr
-/-
 and consequently 
these mice have impaired IL-23 induced IL-22 production and are highly susceptible 
to C. rodentium infection (Lee et al., 2012). Ahr may exert some of its biological 
activities in ILCs through the regulation of Notch signalling. Transcripts encoding 





 cells in comparison with Ahr
low
 cells. Furthermore, Notch1 and Notch2 
could also be induced by Ahr agonists, or in cell lines where Ach was constitutively 
activated (Lee et al., 2012). Additional support for the role of Notch in ILCs was 
demonstrated by the reduction in ILCs observed in RBP-Jκ mice that lack the 
transcription factor RBP-Jκ which is the transcriptionally active component of Notch 
signalling (Lee et al., 2012). 
Organised lymphoid tissue is not required for intestinal ILC development, since the 
formation of secondary lymphoid structures is dependent on LT provided by LTi 
cells interacting with the LT receptor expressed by mesenchymal cells. However, 
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IL-22 producing intestinal ILCs developed unhindered in mice lacking the LT 
receptor (Satoh-Takayama et al.). 
Innate lymphoid cells and the intestinal microbiota 
Although a role for ILCs is emerging in host resistance to intestinal infections, there 
are conflicting data regarding the role of the normal intestinal microbiota and 
mucosal ILCs. In one study, using RORγt lineage tracing mice, the number of 
intestinal RORγt+ ILC populations was comparable in germ free, conventionally 
colonised and antibiotic treated mice, as well as in mice lacking the microbial 
sensing molecules Nod1, Nod2 or Myd88 (Sawa et al., 2010). These data have been 
corroborated in other studies (Reynders et al., 2011; Sonnenberg et al., 2012) and are 
in keeping with the identification of RORγt+ ILCs in the intestine of germ-free 
embryo (Reynders et al., 2011). However, other groups have reported that the 
intestinal microbiota does impact ILC development and/or phenotype. For instance it 







 ILC numbers were severely diminished in 
germ free mice (Satoh-Takayama et al., 2008). Evidence supporting impaired ILC 
development in the absence of gut commensals has also been provided by other 
groups (Sanos et al., 2009; Vonarbourg et al., 2010). It has also been suggested that 
IL-22 producing ILCs can influence the profile, distribution and containment of the 
intestinal microbiota (Sonnenberg et al., 2012). In this study depletion of ILCs 
resulted in systemic dissemination of microbes that could be rescued by replenishing 
IL-22 (Sonnenberg et al., 2012). It is intuitive that IL-22 producing ILCs are likely to 
play a role in intestinal barrier function since IL-22 induces the production of many 
antimicrobial peptides by intestinal epithelial cells, including RegIII, RegIIIγ, 
haptoglobin, SAA3, S100A8, S100A9 and lactotransferrin (Zheng et al., 2008). The 
role of the microbiota in inducing and propagating ILCs is in need of further study. 
Cytokine requirements for innate lymphoid cells 
Valuable insights have been gained regarding the cytokine requirements for ILCs in 
various cytokine and cytokine receptor knockout mice. ILCs are virtually absent in 
Rag2
-/-
 mice additionally lacking the common γ chain cytokine receptor (Rag2-/- 
Il2rg
-/-
), a key subunit for the signalling of numerous cytokines, including IL-2, IL-4, 
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IL-7, IL-9, IL-15 and IL-21 (Luci et al., 2009; Satoh-Takayama et al., 2008; Takatori 




mice lacking the IL2R chain, which is 
required for IL-2 and IL-15 signalling, have increased numbers of ILCs, indicating 
that these cytokine are dispensable for ILC development (Satoh-Takayama et al., 






 ILC ontogeny is 
unaffected in Il15
-/-
 mice, whereas there is a complete failure of conventional NK cell 
development (Satoh-Takayama et al., 2008). Crucially, intestinal RORγt+ ILCs are 




 mice (Vonarbourg et al., 2010), indicating 
that among the common γ chain cytokine receptor family members IL-7 signalling 
plays a central role in ILC development and/or maintenance. 
Cytokines such as IL-6, IL-12 and IL-23 appear to be less important for the 
development or maintenance of ILCs. In one study, using fate mapping with RORγt 
lineage tracing mice, there was a minor reduction in the number of RORγt+ ILCs in 
the small intestine of Il6
-/-
 mice (Satoh-Takayama et al., 2008), whereas another 
study found only a negligible reduction in intestinal ILCs in Il6
-/-
 mice (Sanos et al., 
2009). RORγt+ ILCs develop normally in Il12rb1-/- mice unable to respond to IL-12 
or IL-23 (Satoh-Takayama et al., 2008), indicating that these cytokines are 
dispensable for ILC development. 
1.3.2.2 Intestinal dendritic cells 
The term dendritic cell (DC) was first used to describe a population of adherent cells 
present in lymphoid tissues in 1973 (Steinman and Cohn, 1973). They were 
described as large cells of varying shape, including elongated bipolar cells and 
elaborate, stellate and dendritic cells with striking differences from macrophages 
(Steinman and Cohn, 1973). Ralph Steinman was awarded the Nobel Prize for 
Physiology in 2011 for these observations. DCs are specialised antigen presenting 
cells (APCs) that play a key role orchestrating the immune response. DCs initially 
occupy non-lymphoid tissues of the body, such as the intestinal lamina propria in an 
immature state surveying antigens before migrating from their native location to 
secondary lymphoid structures, typically draining LNs, where they then present 
antigen (Ag) to CD4
+
 T-cells (Steinman, 1991). In keeping with their role as 
sentinels intestinal DCs have been observed to project their dendrites between 
intestinal epithelial cells and directly sample fluorescent labelled bacteria present in 
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the gut lumen (Chieppa et al., 2006; Rescigno et al., 2001). DCs express proteins 
involved in tight junction formation, such as claudin-1, occludin, -catenin and E-
cadherin enabling them to form close contacts with epithelial cells and penetrate their 
dendrites between epithelial cell tight junctions without losing the integrity of the 
brush border barrier (Rescigno et al., 2001). Intra-vital studies using mice engineered 
to express fluorescent proteins under control of either the CD11c or MHC class II 
promoters (classical DC markers) have elegantly visualised DCs directly sampling 
luminal bacteria in vivo in real time (Chieppa et al., 2006). Transepithelial dendrite 
protrusions are enhanced by exposing the epithelium to microbes or their products 
(Chieppa et al., 2006; Rescigno et al., 2001) and can be decreased by reducing the 
microbial load in the lumen with antibiotics (Chieppa et al., 2006), indicating that the 







 hosts reconstituted with either CD11c-EGFP or MHCII-
EGFP bone marrow cells convincingly demonstrated that DC epithelial extension 
were responsive to Toll-like receptor (TLR) agonists and were dependent on 
signalling through the TLR adaptor molecule MyD88 (Chieppa et al., 2006). 
In the steady state, tissue dwelling DC, such as those occupying the cLP, express low 
levels of co-stimulatory molecules and instead these cells are predominantly 
pinocytic, in keeping with their role sampling antigens in their immediate 
surroundings (Cruickshank et al., 2005; Krajina et al., 2003). However, once DCs 
have captured and processed Ag they migrate to LNs where they present Ag-derived 
peptides in the context of MHC to CD4
+
 T-cells (Banchereau and Steinman, 1998). 
DCs express surface co-stimulatory molecules, such as CD40, CD80, CD83 and 
CD86 that help to prime T-cell activation (Banchereau and Steinman, 1998). During 
the presentation of Ag, DCs produce cytokines that play a key role shaping the 
differentiation of particular functional T-cell lineages, including IL-12 which is 
required for Th1 differentiation (Macatonia et al., 1995) and IL-23 which is required 
for the differentiation and/or maintenance of Th17 cells (Aggarwal et al., 2003). 
DCs are distributed throughout the small and large intestine lamina propria, PPs, 
isolated lymphoid follicles (ILFs) and mLN, and some of these lymphoid tissues are 
key inductive sites of T-cell activation (Rescigno and Di Sabatino, 2009). Intestinal 
DCs have been subdivided in different subsets that are phenotypically and 
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functionally distinct. Colonic CD11c
high









cells (Denning et al., 
2007). Cx3cr1-GFP lineage tracing mice have been used to demonstrate that CD11b 
expressing DCs can be further subdivided into 3 separate groups based on their 
expression of the chemokine receptor CX3CR1 (Varol et al., 2009). This important 
study also provided crucial insights into the origins of the different intestinal lamina 
propria DC subsets. CD11c-DTR mice have the human diphtheria toxin receptor 
(DTR) cloned upstream of the CD11c promoter, which results in selective expression 
of the DTR in cell lineages that express CD11c, of which DCs are the prototypical 





 DCs resulting in their selective depletion in vivo. By using this 
system and then reconstituting DC depleted mice with specific cellular precursors it 
was possible to identify which precursors were responsible for seeding the different 





 DCs are derived from circulating Ly6C
high





 DCs were derived from macrophage-dendritic 
cell precursors (MDPs) in a Flt3L dependent manner (Varol et al., 2009). This study 




intestinal DCs are functionally distinct, 
particularly in the context of intestinal inflammation. Reconstitution of DC depleted 





were found to have increased susceptibility to DSS induced colitis (Varol et al., 
2009). However, reconstitution with tnfa
-/-
 monocytes was only associated with mild 




 DCs that they seed possess 
colitogenic properties that is at least partially dependent on the pro-inflammatory 
cytokine TNFα. CD11b+ CX3CR1
+
 DCs have also been shown to potently promote 
the differentiation of Th17 cells (Denning et al., 2007). 
It should also be remembered that DCs are part of a larger family of myeloid cells 
that together with monocytes and macrophages comprise the mononuclear phagocyte 
system. There is considerable overlap in the expression of some cell surface markers 
common to these different cell types, including CX3CR1, and accordingly the 
depletion/re-engraftment type experiments described above should be interpreted in 
this light. Indeed, CX3CR1 is broadly expressed by other cells of the mononuclear 
phagocyte system, including DCs (Varol et al., 2009), monocytes (Geissman et al., 
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2003) and macrophages (Yona et al., 2013). Other myeloid markers are also shared 
between these related cells. For instance, F4/80, which is often considered a 
macrophage marker, is also expressed by some DCs (Hume 2008). Likewise, CD11c 
often considered a “pure” DC marker, is also expressed by macrophages (Hume 
2008).  Therefore, definitions of DCs or macrophages by particular cell surface 
markers alone can be confusing or even misleading in some experimental systems.         




 DCs there is evidence linking CD103
+
 DCs to the 
promotion of intestinal FoxP3
+
 T-reg differentiation and the imprinting of gut 
homing properties to circulating lymphocytes. Naive CD4
+
 T-cells differentiate into 
Foxp3
+
 T-regs in the gut following oral administration of their antigen (Coombes et 
al., 2007), a process that has long been recognised to promote immunological 
tolerance. Ag-specific FoxP3
+
 T-reg differentiation from naive precursor cells was 
increased 30-40 fold if these cells were primed with CD103
+
 mLN DCs rather than 
CD103
- 







 T-regs isolated directly from the spleen could also be supported 
and sustained far more effectively by CD103
+
 DCs (Coombes et al., 2007). The 
production of inflammatory cytokines, such as TNFα, IL-6, IL-12p40 and IL-23p19 
was also diminished in CD103
+
 DCs (Coombes et al., 2007). CD103
+
 DCs, but not 
CD103
-
 DCs from the mLN potently induced the gut homing molecules α47 and 
CCR9 in responder T-cells that they prime with antigen (Johansson-Lindbom et al., 
2005). A similar observation was made in DCs isolated from human mLNs, with 
enhanced induction of CCR9 observed in responding T-cells interacting with 
CD103
+
 DCs, however, α47 induction on T-cells was comparable with CD103+ and 
CD103
-
 DCs (Jaensson et al., 2008). 
DCs have been implicated in the pathogenesis of IBD. Recently an attempt has been 
made to try to link disease susceptibility genes identified in a meta-analysis of the 
major GWA studies in IBD to specific cells types, and interestingly the greatest 
number of hits was found in DCs (Jostins et al., 2012). In experimental colitis there 
are increased numbers of DCs in the cLP and mLN, and there is marked upregulation 
of co-stimulatory molecules and pro-inflammatory cytokines by these cells 
(Cruickshank et al., 2005; Krajina et al., 2003). Activation of DCs and other myeloid 
cells with agonistic anti-CD40 antibodies has been shown to trigger colitis in mice 
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lacking T and B cells (Uhlig et al., 2006). Depletion of DCs in DSS colitis using 
CD11c-DTR mice also protected from disease in both WT and Rag1
-/-
 mice indicating 
that this property was independent of T-cells (Abe et al., 2007). Studies in human 
IBD have also shown increased activation of intestinal DCs in inflamed mucosa. In 
contrast to non-inflammatory controls or non-inflamed intestinal segments from the 
same patient, lamina propria DCs from inflamed gut segments have increased 
expression of activation markers, such as CD40, and increased expression of pro-
inflammatory cytokines, such as IL-12 and IL-6, which in the case of IL-6 also 
positively correlated with disease activity (Hart et al., 2005; Ng et al., 2011). DCs 
also express pattern recognition receptors, such as TLRs and in IBD patients there is 
significantly increased expression of TLR2 and TLR4 in lamina propria DCs (Hart et 
al., 2005). Recently, insights into how IBD susceptibility genes identified in GWA 
studies might impact on DC function in a disease relevant manner have been provided 
by analysing the phenotype of DCs from patients with polymorphisms in NOD2. 
MDP, the bacterial derived ligand for NOD2, triggers autophagosome formation and 
upregulation of autophagy in DCs in a NOD2 dependent manner (Cooney et al., 
2010). MDP induced DC autophagy was dependent on recognised autophagy 
components, including ATG5, ATG7 and ATG16L1 and resulted in increased 
expression of MHC class II on the surface of DCs, linking NOD2 dependent 
autophagy to Ag presentation in DCs (Cooney et al., 2010). Crucially, DCs from 
individuals harbouring NOD2 variants associated with CD had markedly impaired 
MDP induced autophagy and failed to upregulate MHC class II (Cooney et al., 2010), 
consistent with the likelihood that disease associated NOD2 polymorphisms are 
linked to loss of autophagy/Ag presentation function in DCs. 
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1.4 Transcriptional regulation of the mucosal immune system 
Mucosal immune responses are tightly regulated since the host must rapidly deploy 
aggressive, inflammatory responses in the event of pathogen exposure, yet at the 
same time exercise restraint against non-pathogenic agents by utilising regulatory 
mechanisms. The inflammatory and regulatory properties of mucosal immune cells 
are governed by cell-specific transcriptional programmes, which in turn are 
controlled by transcription factors that dictate which immune response genes are 
switched on or off at any given moment. Among the most important transcription 
factors involved in controlling T-cell effector function are T-bet (Szabo et al., 2000), 
RORγt (Ivanov et al., 2006), GATA-3 (Zheng and Flavell, 1997) and FoxP3 (Hori et 
al., 2003). These transcription factors are considered the master regulators 
responsible for controlling the fate and phenotype of Th1, Th17, Th2 and T-reg 
CD4
+
 T-cells, respectively. Other notable transcription factors involved in the 
regulation of host immunity at the barrier surfaces include the signal transducer and 
activator of transcription (STAT) family of proteins and NFκB. The STATs, 
including STAT1, STAT3, STAT4 and STAT6 have important role in T-cell 
differentiation, but are also critically involved in innate immune cells, including 
macrophages, NK cells and DCs (Stark and Darnell, 2012). 
1.4.1 T-bet 
T-bet (T-box expressed in T-cells) is a 62kDa 530 amino acid protein encoded by the 
Tbx21 gene on chromosome 11 in mice (Szabo et al., 2000). When it was first cloned 
in 2000 it was shown to be present in Th1 cells where it bound at the promoters of 
the Il2 and Ifng loci. It was rapidly induced in naive T-cells within 24 hours under 
Th1 polarising conditions, but not under Th2 conditions (Szabo et al., 2000). T-bet 
was a potent transactivator of the Ifng gene and retroviral transduction of T-bet into 
primary CD4
+
 T-cell upregulated IFNγ production (Szabo et al., 2000). T-bet even 
redirected committed effector Th2 cells towards the Th1 lineage. Retroviral 
transduction of T-bet into in vitro differentiated Th2 cells resulted in suppression of 
IL-4 and IL-5 and the emergence of IFNγ production (Szabo et al., 2000). These 
experiments identified T-bet as the key transcription factor responsible for directing 
the transcriptional control of Th1 cells. 
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T-bet plays a critical role in regulating systemic, mucosal and organ specific immune 
responses, such that changes in T-bet expression profoundly influence the balance 
between the development of autoimmunity or susceptibility to infection (Table 3). T-
bet deficient mice are resistant to experimental models of autoimmunity, such as 
diabetes (Esensten et al., 2009), EAE (Bettelli et al., 2004), lupus (Peng et al., 2002) 
and colitis (Neurath et al., 2002), yet on the other hand have heightened 
susceptibility to infections including Mycobacteria (Sullivan et al., 2005), 
Salmonella (Ravindran et al., 2005), Leishmania (Cobb et al., 2009), trypanosome 
(Rosas et al., 2006) and viruses (Matsui et al., 2005; Svensson et al., 2005). 
Accordingly, T-bet must be rigorously regulated in a dynamic fashion to maintain the 
capacity to resist infection, without exposing the host to increased risk of 
autoimmunity, particularly at mucosal surfaces often in contact with commensal and 
pathogenic microorganisms. 
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Table 3. T-bet impacts disease phenotype of multiple inflammatory, infectious and neoplastic 
diseases of the mucosae.  References cited in the table are linked to the original paper 
(Powell et al., 2010). 
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T-bet expression is almost exclusively restricted to the immune system, and to date 
its expression has been detected in CD4
+
 T-cells (Szabo et al., 2000), CD8
+
 T-cells 
(Szabo et al., 2000), B-cells (Szabo et al., 2000), monocytes (Lighvani et al., 2001), 
DCs (Lighvani et al., 2001; Lugo-Villarino et al., 2003), NK cells (Szabo et al., 
2000) and ILCs (Buonocore et al., 2010). Although most work so far has 
concentrated on the role of T-bet in T-cells, its role in the innate immune system, as 
well as in coordinating the complex interplay between innate and adaptive immune 
components, may yet prove to be even more significant. The multi-layered effects of 
T-bet on different cell types, particularly in the mucosal surfaces, are depicted in 
Figure 3. 
Transcriptional targets of T-bet include cytokines, cytokine receptors, other 
transcription factors, and genes encoding proteins involved in cell metabolism, 
trafficking and cellular differentiation (Jenner et al., 2009). Like other immune 
transcription factors, such as STAT4 and STAT6 (Wei et al., 2010), T-bet tunes 
epigenetic modifications at loci encoding key immune proteins. It interacts with 
histone modifying enzymes such as H3K9 methyltransferase and H3K27 
demethylase to alter the transcriptional activity of target loci, such as Ifng and Cxcr3 





Figure 3. T-bet mediated regulation of mucosal immunity.  1 Loss of T-bet in DCs results in 
over-expression of TNFα, resulting in colonic epithelial apoptosis and colitis. T-bet 
expression in DCs is also required to recruit mast cells to gut. 2 Th1 cells provide 
resistance to intracellular organisms (e.g. mycobacteria)and are T-bet dependent. 3 In the 
absence of T-bet, Th17 cells preferentially expand. Th17 cells trigger neutrophil 
accumulation and are implicated in immunity to extracellular bacteria and IBD 
pathogenesis. 4 T-bet is implicated in Treg development (responsible for limiting Th1 
responses). 5 In the absence of T-bet, Th2 cells expand and produce IL-4, IL-13, (Ig class 
switching to IgE and activation of mast cells), and IL-5 (expansion and activation of 
eosinophils). Eosinophilic inflammation is implicated in immunity to helminths and in 
the pathogenesis of asthma/rhinitis. 6 T-bet is inducible in B cells, leading to impairment 
of IgE class switching. Cross linking of IgE on mast cells activates mast cells. 7 Absence 
of T-bet leads to overexpression of IL-13 by mucosal NKT cells. Ag, antigen; ECP, 
eosinophil cationic protein; IFN, interferon; MBP, major basic protein; MPO, 
myeloperoxidase. Adapted from Powell et al., 2010. 
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1.4.1.1 The role of T-bet in CD4+ T-cells 
The mechanisms whereby T-bet directs Th1 polarisation are multifactorial and 
include direct transactivation of Th1 promoting genes, interaction with other 
transcription factors, epigenetic modification and repression of Th2 and Th17 
differentiation. In Th1 cells alone T-bet binds at the promoter of more than 800 
protein encoding genes (Jenner et al., 2009). T-bet transactivates the Ifng gene 
through binding to multiple proximal and distal cis-acting enhancer elements (Cho et 
al., 2003; Lee et al., 2004). Transactivation of other Th1 related genes, such Tnfa and 
Il18rap ensures that a coordinated and concerted Th1 response ensues (Jenner et al., 
2009). Interactions between T-bet and other transcription factors may also contribute 
to Th1 lineage specification. T-bet interacts with STAT4 at multiple Ifng distal 
enhancer sites and recruits RelA to the Ifng locus to facilitate efficient transcription 
of the Ifng gene (Balasubramani et al., 2010). 
T-bet also impacts on the differentiation and effector function of Th2, Th17 and T-
reg lineages in functionally meaningful ways at the mucosal barrier. Th2 T-cells 
produce cytokines such as IL-4, IL-5 and IL-13 and play an important role driving 
allergic inflammatory disease, such as asthma and hay fever (Corrigan and Kay, 
1992; Kay, 1991). T-bet mediated negative regulation of GATA-3 has also been 
proposed as a potential mechanism responsible for T-bet instigated Th1 
differentiation and limitation of Th2 differentiation (Usui et al., 2006). Consistent 
with this notion, GATA-3 levels are increased in Tbx21
-/-
 T-cells and forced 
expression of T-bet in Th2 cells suppresses GATA-3 expression (Usui et al., 2006). 
Although, GATA-3 is an important transcriptional regulator of Th2 differentiation, 
the interaction between T-bet and GATA-3 is a key event in determining the fate of 
T-cell lineage commitment. T-bet physically interacts with GATA-3, preventing it 
from binding to its transcriptional targets and repressing Th2 differentiation (Hwang 
et al., 2005). In addition to direct physical contact between these transcription 
factors, T-bet and GATA-3 also bind to a shared profile of target genes that are 
differentially expressed in Th1 and Th2 cells (Jenner et al., 2009). Accordingly, T-
bet and GATA-3 interactions influence allergic inflammatory responses at mucosal 
surfaces. Notably, mice lacking T-bet spontaneously develop airway changes 
resembling human asthma with an eosinophil and T-cell rich inflammatory infiltrate, 
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overexpression of Th2 cytokines, increased peribronchial collagen deposition 
suggestive of airway remodelling, and bronchial hyper-responsiveness, (Finotto et 
al., 2002). Restoration of T-bet in T-cells reverses these changes (Park et al., 2009). 
T-bet expression is reduced in T-cells from the airways (Finotto et al., 2002) and 
blood (Ko et al., 2007) of patients with asthma. Polymorphisms at the TBX21 locus 
are associated with an increased risk of asthma and airway hyper-responsiveness 
(Munthe-Kaas et al., 2008; Raby et al., 2006) and influence the response to inhaled 
corticosteroid therapy, the mainstay of asthma treatment (Tantisira et al., 2004). 
In addition to their impaired Th1 differentiation, Tbx21
-/-
 T-cells preferentially 
differentiate into Th17 cells (Durrant et al., 2009; Harrington et al., 2005; Park et al., 
2005). T-bet inhibits Th17 development by inhibiting IL-23R expression (Harrington 
et al., 2005) and physically limiting another transcription factor, Runx1, from trans-
activating the Th17 master transcription factor RORt (Lazarevic et al., 2011). A 
complex interplay between T-bet and Th17 cells exists in disease models. Even 
though spontaneous asthma in Tbx21
-/-





 cells also preferentially convert to Th17 cells, 
highlighting the importance of T-bet in limiting Th17 ontogeny (Fujiwara et al., 
2007). Antigen-specific T-bet deficient T-cells preferentially differentiate into Th17 
cells instead of Th1 cells and induce severe autoimmune disease (Villarino et al., 
2010). However, in EAE T-bet appears to be required for disease not only in Th1 
cells, but also in encephalitogenic Th17 cells (Yang et al., 2009). It is not certain 
whether T-bet confers pathogenic properties to Th17 cells, or whether these in vivo 
observations speak to issues regarding T-cell plasticity, since Th17 cells have been 
shown to differentiate into Th1 cells in vivo (Bending et al., 2009; Lee et al., 2009). 
One possibility is that T-bet is required for Th17 cells to differentiate into pathogenic 
Th1 cells. 
T-bet is also upregulated in regulatory T cells (Tregs) in models of inflammation and 
infection, and its expression was required to suppress inflammation (Koch et al., 
2009). Similar to Th1 cells, T-bet in Tregs was induced by Th1 conditions and 
required intact STAT1 and IFN-R. One of the proposed mechanisms whereby T-bet 
is required for Tregs to exert control of inflammatory reactions is through 
transcriptional control of CXCR3. This chemokine receptor is a transcriptional target 
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of T-bet in both mice (Lord et al., 2005) and humans (Jenner et al., 2009), and its 
expression may facilitate Treg migration to sites of inflammation. 
1.4.1.2 T-bet is expressed by cells of the innate immune system 
T-bet expression has been detected in several innate immune cell types, including 
monocytes (Lighvani et al., 2001), DCs (Lighvani et al., 2001; Lugo-Villarino et al., 
2003), NK cells (Soderquest et al., 2011; Szabo et al., 2000; Townsend et al., 2004) 
and ILCs (Buonocore et al., 2010). 
1.4.1.3 The role of T-bet in NK cells 
When T-bet was first identified it was observed that in addition to being expressed in 
Th1 cells, T-bet was also expressed by the NK cell line YT cells (Szabo et al., 2000). 
Subsequent work has shown that T-bet plays an important role in the homeostasis and 
maturation of NK cells. In Tbx21
-/-
 mice there are significantly fewer NK cells in the 
spleen, liver and peripheral blood (Townsend et al., 2004). In addition to their 
numerical deficit, NK cells in T-bet deficient hosts exhibit maturation delay and 
evidence of hyperactivation. Recent data from our laboratory has shown that unlike 




 population of 





 stage (Soderquest et al., 2011). This defect was previously shown to be 
specific to the haemopoeitic system, since reconstitution of sub-lethally irradiated WT 
mice reconstituted with Tbx21
-/-
 bone marrow cells also exhibited defective terminal 
maturation of NK cells, whereas reconstitution of irradiated Tbx21
-/-
 mice with WT 
bone marrow cells rescued this maturation arrest (Townsend et al., 2004). This T-bet 
dependent maturation defect is dependent on monocytes, which are able to facilitate 








 NK cells 
(Soderquest et al., 2011). T-bet expression is induced in NK cells by IL-12 and IL-15. 
Although by themselves, IFNγ and IL-18 do not induce significant T-bet expression in 
NK cells, both of these cytokines potentiate IL-12 induced T-bet expression 
(Townsend et al., 2004). T-bet deficient NK cells also appear to have defective 
effector function with reduced killing of YAC-1 target cells (Townsend et al., 2004). 
Tbx21
-/-
 mice have markedly reduced absolute numbers of invariant NK T-cells 




 T-cells these cells have defective 
interferon-γ production and instead overproduce Th2 cytokines (Kim et al., 2009). 
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1.4.1.4 The role of T-bet in dendritic cells 
T-bet is inducible in myeloid populations, including DCs, monocytes and monocytic 
cell lines by exposure to IFN (Lighvani et al., 2001; Lugo-Villarino et al., 2003). T-
bet protein expression has also been demonstrated in DCs (S-100
+
 cells) in human 
colon in the steady state, indicating a potential role for this transcription factor in gut 
DCs (Garrett et al., 2007). The functional role of T-bet in DCs has been addressed in 
animal studies utilising T-bet deficient mice. In one study it was shown that 
immunomagnetically sorted CD11c
+
 DCs from Tbx21
-/-
 mice were poor inducers of 
Th1 effector responses in comparison with WT DCs (Lugo-Villarino et al., 2003). 
Conversely, primary CD11c
+
 DCs transduced with T-bet were more effective at 
promoting Th1 responses and cytotoxic CD8
+
 T-cell responses and were able to slow 
tumour growth (Qu et al., 2010), indicating that T-bet is required for DCs to initiate 
optimal inflammatory responses. Similarly, Tbx21
-/-
 mice which are resistant to 
autoimmune arthritis have fully restored disease susceptibility when T-bet sufficient 
DCs are adoptively transferred (Wang et al., 2006). In this study T-bet deficient DCs 
were inferior at priming specific antigen-specific T-cell proliferation and effector 
cytokine responses (both IFN and IL-4). T-bet expression in DCs also influences T-
cell polarization in the airways. Sensitized mice receiving antigen pulsed DCs 
intranasally are unable to redirect pro-allergic Th2 airways responses towards Th1 
responses in the absence of T-bet (Heckman et al., 2008). 





develop spontaneous colitis, which is characterised by increased expression of TNFα 
(Garrett et al., 2007). The central role played by DCs in TRUC disease was 
demonstrated by reconstituting lethally irradiated TRUC mice with CD11c DTR tg 
DCs. Following engraftment of CD11c DTR DCs in the colon of TRUC mice 
diphtheria toxin was administered to chimeric mouse groups (TRUC grafted with 
TRUC bone marrow and TRUC grafted with CD11c DTR tg bone marrow). 
Diphtheria toxin mediated deletion of colonic DCs attenuated disease in TRUC mice, 
highlighting a key role of DCs in this model of IBD (Garrett et al., 2009). One of the 
key transcriptional targets of T-bet in DCs is the gene encoding the inflammatory 
cytokine TNFα. There are T-bet consensus sites upstream from the transcriptional 
start of the Tnfa locus (Garrett et al., 2007), and chromatin immunoprecipitation 
(ChiP) studies confirm that T-bet binds at the TNFα promoter (Garrett et al., 2007). 
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In contrast to its role in T-cells, T-bet appears to be a transcriptional repressor of 
TNFα in myeloid lineages. Transfection of T-bet into the RAW cell line results in 
suppression of Tnfa promoter activity in a luciferase assay (Garrett et al., 2007). 
These data are consistent with the observed overproduction of TNFα in DCs 
genetically deficient of T-bet. Further evidence that T-bet was a transcriptional 
repressor of the Tnfa locus in DCs was shown by generating TRUC mice that over-
expressed T-bet under control of the CD11c promoter. Ectopic over-expression of T-
bet in DCs resulted in repression of TNFα and reduced colitis (Garrett et al., 2009). 
T-bet expression in DCs also impacts other innate lineages and has been implicated 
in the homeostatic homing of mast cells to the small intestine (Alcaide et al., 2007). 
Tbx21
-/-
 mice have reduced numbers of intestinal mast cells and their progenitors. 
Mast cells from T-bet null hosts have diminished binding to VCAM-1 and 
MAdCAM-1, whose expression on small intestinal vascular endothelium is 
responsible for mast cell recruitment. Although T-bet expression has not been 
detected in mast cells at any stage during ontogeny, adoptive transfer of T-bet 
sufficient DCs restores normal mast cell homing to the small intestine, implying that 
T-bet indirectly influences mast cell trafficking to the gut through its actions in DCs. 
1.4.1.5 T-bet and intestinal inflammation 
T-bet has been shown to play an important role in preclinical models of 
gastrointestinal inflammation that are reliant on Th1 T-cells. Experimental colitis 
secondary to adoptive transfer of naive T-cells, TNBS administration and the 
spontaneous colitis developing in Il10
-/-
 mice, are all associated with increased 
expression of T-bet in lamina propria T-cells (Neurath et al., 2002). In the naive T-
cell transfer model of colitis, recipients of Tbx21
-/-
 T-cells do not develop disease, 
whereas recipients of T-cells overexpressing T-bet develop accelerated disease 
(Neurath et al., 2002). In contrast, Th2 mediated murine models of inflammatory 
bowel disease (IBD), such as oxazolone induced colitis and the TCR-α-/-µ-/- 
spontaneous colitis model are not associated with increased T-bet expression in 
lamina propria T-cells and Tbx21
-/-
 mice develop more severe oxazolone disease in 
association with increased expression of Th2 cytokines (Neurath et al., 2002).  
In humans, elevated expression of T-bet has also been confirmed in lamina propria 
T-cells from patients with intestinal inflammation, most notably in Crohn’s disease 
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(Matsuoka et al., 2004; Monteleone et al., 2005; Neurath et al., 2002) and coeliac 
disease (Monteleone et al., 2004), where Th1 cells have been implicated as effector 
cells (Fuss et al., 1996; Nilsen et al., 1998; Nilsen et al., 1995; Parronchi et al., 
1997). Increased expression of T-bet has also been observed in peripheral blood T-
cells, B-cells and monocytes of untreated patients with coeliac disease (Frisullo et 
al., 2009). Following implementation of gluten avoidance and disease remission, T-
bet levels fell, implying that dynamic changes in T-bet expression may be a useful 
biomarker to track disease activity in coeliac disease. 
In Crohn’s disease T-cell stimulation through the T-cell receptor with anti-CD3 
antibodies induces T-bet expression in lamina propria T-cells (Matsuoka et al., 2004; 
Monteleone et al., 2005). In the case of coeliac disease, where the offending antigen is 
known, stimulation of duodenal T-cells with specific peptide antigen also induces T-bet 
expression (Fina et al., 2008). In these human Th1 associated diseases, blockade of IL-
21 (Fina et al., 2008; Monteleone et al., 2005), or interferon-γ (Monteleone et al., 2004) 
reduces the expression of T-bet in T-cells, whilst antagonism of the anti-inflammatory 
cytokine TGF-β induces T-bet expression (Di Sabatino et al., 2008), suggesting that 
other inflammatory and regulatory pathways converge with T-bet mediated pathways to 
influence the prevailing inflammatory response. Anti-inflammatory therapies, such as 
steroids, which are effective in the management of severe exacerbations of IBD, also 
inhibit T-bet expression in T-cells (Liberman et al., 2007). The activated glucocorticoid 
receptor physically interacts with T-bet in the nucleus preventing it from transactivating 
proinflammatory genes (Liberman et al., 2007). Inhibition of T-cell activation with Ca
2+
 
channel blocking drugs also reduces T-bet expression, with attendant reduction in T-cell 
interferon-γ production (Di Sabatino et al., 2009). 
Clearly, transcription factor programming of cellular behaviour is complex. A number 
of genes identified as T-bet binding targets by ChIP studies are at loci at which SNPs 
are significantly associated with IBD or coeliac disease in GWA studies. For instance, 
SNPs at loci encoding tumour necrosis factor superfamily 4, chemokine receptor 5 
and IL-18RAP (Barrett et al., 2008; Dubois et al., 2010) are also genes specifically 
bound by T-bet in ChIP experiments (Gocke et al., 2007; Jenner et al., 2009). 
71 
1.4.1.6 T-bet deficiency in the innate immune system results in spontaneous 
IBD 
Loss of T-bet confined to the innate immune compartment in mice lacking an 
adaptive immune system (Rag2
-/-
 mice), results in spontaneous colitis resembling 





 Ulcerative Colitis) mice develop a predominantly distal colitis. 
Histological appearances resemble human UC with predominantly superficial 
colonic inflammation, crypt abscess formation and infiltration of the colonic lamina 
propria with neutrophils and mononuclear cells (Garrett et al., 2007). 
The inflammatory process is characterised by overproduction of TNFα in the lamina 




 myeloid cell populations, 
including dendritic cells. Selective depletion of CD11c
+
 cells (Garrett et al., 2009), 
or TNFα blockade prevents disease (Garrett et al., 2007), and TRUC mice lacking 
the p55 component of the TNFα receptor (triple knockout Tbx21-/-, Rag2-/-, Tnf1/p55-
/-
 mice) (Garrett et al., 2007) are resistant to disease. 
In TRUC mice deregulated TNFα was shown to cause increased epithelial 
permeability and was shown to be directly toxic to colonic epithelial cells, in which it 
triggered apoptosis (Garrett et al., 2007). Importantly, early treatment with TNFα 
neutralizing antibodies was capable of reversing early disease in TRUC mice, 
however, if anti-TNFα mAbs were administered beyond 12 weeks of age they failed 
to control disease (Garrett et al., 2007; Garrett et al., 2009). As well as showing the 
importance of TNFα in TRUC disease, these data also indicate that alternative innate 
immune mechanisms are responsible for driving chronic disease. 
Interestingly, Tregs were shown to suppress colitis in TRUC mice (Garrett et al., 






 Tregs migrated to the colon 
of TRUC mice and fully inhibited colitis development. Tregs were observed in close 
proximity to DCs in the colon of TRUC consistent with the possibility that Tregs 
suppress colitis by controlling the inflammatory potential of DCs. 
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1.4.1.7 The TRUC model of IBD is dependent on the intestinal microbiota 
Several lines of evidence indicate that the TRUC model of IBD is dependent on the 
colonic microflora. Colitis could be communicated to WT mice co-housed or cross-
fostered with TRUC mice, leading to the hypothesis that host deficiency of Tbx21 
somehow encouraged the establishment and expansion of a colitigenic community of 
intestinal microbes that could subsequently be transmitted to other mice (Garrett et 
al., 2007). Treatment of TRUC mice with a combination of broad-spectrum 
antibiotics (vancomycin, metronidazole, neomycin and ampicillin), a mixture that 
has been shown to substantially deplete intestinal bacteria (Fagarasan et al., 2002), 
resulted in 100,000 fold depletion of culturable anaerobes and induced remission of 
disease (Garrett et al., 2007). Monotherapy with metronidazole or gentamicin also 
cured disease (Garrett et al., 2010). Probiotic supplementation in TRUC mice with a 
Bifidobacterium lactis containing bacterial mixture also reduced colitis (Veiga et al., 
2010), further demonstrating how manipulation of the intestinal microbiota can alter 
the severity of colitis in genetically susceptible animals. Probiotic bacteria reduced 
the pH of the caecum of TRUC mice, prompted expansion of short-chain fatty acid 
producing bacteria and increased levels of butyric acid, acetic acid and proprionic 
acid in the caecum. 




 double knockout mice re-derived 
under germ free conditions failed to develop colitis, which demonstrated conclusively 
that environmental bacteria are absolutely required for disease penetrance in this model 
(Garrett et al., 2010). The authors reported the first comprehensive comparison of the 
intestinal microbiota between TRUC and Rag2
-/-
 mice using culture independent 
sequencing 16S rRNA genes. In TRUC mice there was a relative expansion in the 
proportion of Bacteroidetes and a reduction in the proportion of Firmicutes (Garrett et 
al., 2010). The authors also performed extensive cultures of the faeces of TRUC and 
Rag2
-/-
 mice and noted that the bacteria Klebsiella pneumoniae and Proteus mirablis 
were present in all TRUC mice, and that these bacteria were additionally observed to 
be sensitive to both metronidazole and gentamicin. However, inoculation of GF mice 
with these bacteria by themselves, or in combination, was unable to recapitulate 
disease, demonstrating that exposure to additional as yet unrecognised environmental 
stimulus was necessary to trigger colitis in T-bet deficient hosts. 
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1.4.1.8 TRUC mice develop inflammation associated colorectal cancer 
In addition to sharing a number of important clinical features with UC, TRUC mice 
developed colonic epithelial dysplasia and adenocarcinoma due to long-standing 
uncontrolled colonic inflammation (Garrett et al., 2009). Carcinogenesis in the 
TRUC model recapitulates many phenotypic and molecular features of 
carcinogenesis in UC. By 3 months of age, half the colony has dysplasia, rising to 
96% by six months of age. By that time, 42% have frank adenocarcinoma. Similar to 
carcinogenesis in UC, carcinoma in the TRUC mouse arises from mucosa with the 
longest-standing inflammation (the rectum), is typically flat and arises from areas of 
dysplasia. The TRUC epithelium is rich in reactive oxygen species and DNA 
adducts, the levels of which correlate with duration of colonic inflammation. The 
molecular pathogenesis of CRC in TRUC mice more closely resembles UC-
associated CRC than sporadic CRC, with early loss of function of p53, early 
increased epithelial COX-2 expression and later APC mutations, leading to abnormal 
-catenin localisation. Furthermore, unlike the cytokine signature observed in early 
TRUC colitis, that is dominated by TNFα expression, the inflammatory 
microenvironment associated with dysplasia and adenocarcinoma is also 
characterized by increased expression of other proinflammatory cytokines, such as 
IL-6, similar to the situation observed in UC associated CRC (Danese and 
Mantovani, 2010; Garrett et al., 2009). 
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Hypothesis and Aims 
The key aims of this thesis are: 
1 To identify the unknown innate immune mechanisms responsible for driving 
chronic intestinal inflammation in TRUC mice 
2 To identify the microbial drivers of intestinal inflammation in TRUC mice 
3 To define how T-bet might impact on relevant host-microbe interactions in gut 
 
The hypotheses tested in this thesis are: 
1 Innate lymphoid cells are emerging as key mediators of mucosal inflammation. 
This thesis will test the hypothesis that ILCs are responsible for mediating 
chronic IBD in TRUC mice. 
2 Cytokines such as the IL-23/IL-17 axis, IL-6 and TL1A are strongly suspected 
to play a key role in IBD pathogenesis. Although these molecules are 
conventionally thought to drive adaptive mucosal responses, this thesis will test 
the hypothesis that these molecules are involved in driving innate immune 
mediated colitis. 
3 Intestinal inflammation in TRUC mice is dependent on the intestinal microbiota. 
This thesis will test the hypothesis that a particular intestinal bacterial species 
will be responsible for driving the innate immune mechanisms responsible for 




Material and Methods 
2.1 Animal husbandry 
BALB/c Tbx21
-/-
 (Jackson labs), Rag2
-/-










(TRnUC) mice was generated and remotely maintained at geographically distinct 
isolators from the TRUC colony that was descendant from the original described TRUC 






 mice were generated internally 
and housed remotely. Mice were housed in Specified Pathogen-Free (SPF) conditions. 
All mice were handled according to both local (KCL) and national standards, and all 
experimental protocols were reviewed and approved by our local ethics review 
committee. All animal experiments were conducted in accredited facilities in 
accordance with the UK Animals (Scientific Procedures) Act 1986 (Home Office 
license number PPL 70/6792). 
2.2 Genotyping 
Genomic DNA was isolated by overnight digestion at 56°C of ear or tail samples in 
200μl of lysis buffer (5 mM EDTA, 100 mM Tris-HCl pH 8.5, 0.2% SDS, 200 mM 
NaCl, 1mg/ml Proteinase K). Digested samples were diluted 1:4 in nuclease-free 
water. PCR reaction comprises 12.5μl 2x Mango Mix (Bioline Ltd., London, UK), 
10μl nuclease-free water, 1 μl each of PCR primers (diluted in nuclease-free water to 
25μM), 0.5μl genomic DNA. PCR products were mixed with Gel loading dye 
(Biolabs) and 10 μl loaded on a 1 % agarose gel premixed with GelRed Nucleic Acid 
Gel Stain (Biotium) to visualise DNA bands following UV illumination (Unipro 
Gold). 
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2.3 Tissue harvest and preparation 
Mice were euthanized by inhalation of a rising concentration of carbon dioxide gas or 
by cervical dislocation, and then dissected in a laminar flow cabinet using aseptic 
technique. Spleen and mLN were excised and placed in ice-cold complete cell culture 
medium. Colon was excised and prepared by gentle expulsion of colonic contents, 
followed by flushing with ice-cold sterile PBS. Mechanical disruption of spleen and 
mLN through nylon mesh was performed to prepare a single cell suspension suitable 
for further manipulation. Cell suspensions isolated from spleen (but not mLN) were 
subjected to red blood cell lysis by resuspension for 2 minutes in ACK lysis buffer 
(0.15M NH4Cl, 1mM KHCO3, 0.1mM Na2EDTA, pH 7.2-7.4). All cell washing and 
resuspension was performed with complete culture medium (see below) unless 
otherwise stated and trypan-blue staining was used to assess cell viability and count 
live cells. 
2.4 Isolation of colonic lamina propria leukocytes 
Colons were cut longitudinally, faecal material removed and washed with PBS. 
Colons were then cut in to 5 mm segments and the epithelium removed by incubating 




 (Invitrogen) supplemented with 10% FCS foetal calf 
serum gold (FCS) (PAA Laboratories), 10mM HEPES (Fisher Scientific), 100IU/mL 
penicillin and 100μg/mL, streptomycin (Invitrogen) and EDTA (5mM). Epithelial 
removal step was performed for 20 minutes at 37
o
C with constant agitation in a 
shaking water bath. Cells from the epithelial layer (present in the supernatant) were 
discarded and the remaining epithelia-free colon fragments were captured using 
nylon mesh. Tissue was mechanically disrupted using GentleMACs (Miltenyi) using 
program C (45 second disruption) in 10mL of digestion buffer which comprised 
complete medium (see below) supplemented with 25μg/mL collagenase D (Roche), 
10μg/mL DNAse I (Roche) and 1.5mg/mL dispase (Roche). Following mechanical 
disruption in the GentleMACs the crude tissue/cell mixture was incubated in 
digestion buffer for 45 minutes in a shaking water bath (37
o
C). 40mL of complete 
medium was added to the unfractionated crude cell mixture which was pelleted by 
centrifugation for 5 minutes at 652g. This process of resuspending cells in medium 
or PBS followed by 5 minutes centrifugation at 652g is subsequently referred to as 
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cell “washing”. Cells were resuspended in 40% Percol (GE Healthcare) and layered 
on 80% Percol. Centrifugation was performed for 20 minutes at 805g without brakes 
at 20
o
C. The cLPL enriched population was harvested from the interface between the 
40% and 80% Percol using a Pasteur pipette. Cells were washed in complete medium 
and stored on ice pending downstream analysis.  





/ml) and cLP cells (1x10
5
/mL) 
were cultured in complete medium: RPMI-1640 medium (PAA Laboratories), 
supplemented with 10% FCS (PAA Laboratories), 50μM 2-mercaptoethanol (Gibco), 
2µM L-glutamine (Sigma), 1mM sodium pyruvate (Sigma), 10mM HEPES (Fisher 
Scientific), non-essential amino acids (Sigma), 50IU/mL penicillin and 50μg/mL 
streptomycin (Sigma), (subsequently referred to as complete medium). Cells were 
cultured in medium alone or in the presence of recombinant murine cytokines, 
including IL-23 (20ng/mL), TNFα (20ng/mL), IL-6 (50ng/mL) and TL1A (50ng/mL 
or 100ng/mL) (R&D systems). Supernatants were harvested and cytokines 
concentrations measured by ELISA. 
2.6 Immunomagnetic cell isolation 
Enrichment of CD11c
+
 cells from the cLP was achieved by positive selection using 
immunomagnetic cell purification. Unfractionated cLPLs were washed in PBS and 
resuspended in MACs buffer (PBS, 5mM EDTA, 1% FCS). Cells were incubated 
with anti-CD11c microbeads for 20 minutes at 4
o
C. Excess beads were removed by 
centrifugation according to the manufacturer’s instructions and microbead-labelled 
cells were resuspended in MACS buffer before being and passed through MACS LS 
columns mounted on a quadroMACS magnet. Positively selected cells were eluted 
and washed in complete medium and stored at 4
o
C pending downstream analysis/use. 
All reagents and equipment supplied by Miltenyi Biotec Gmbh, Bergisch Gladbach, 
Germany. In some instances anti-PE beads were used following cell labelling with 
PE-conjugated mAbs (e.g. anti-F4/80 and CD11b). 
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2.7 Ex vivo organ culture 
3mm punch biopsies (Miltex) were used to acquire full thickness colonic biopsies. 3 
biopsies were cultured in 300-500μL of complete medium for 48 hours. Cytokine 
concentrations in culture supernatants were measured by ELISA (R&D systems or 
eBiosceince). 
2.8 Inhibition of STAT3 phosphorylation 
STAT3 phosphorylation was inhibited in vitro using the soluble small molecule S3I-
201(Merck, UK) at doses of 20μg/ml and 100μg/ml in explant culture and at 
100μg/ml in splenocyte and mLN culture. S3I-201 was dissolved in 0.1% DMSO. 
Control wells were incubated in the presence of 0.1% DMSO alone. Changes in 
cytokine production in culture supernatants were measured by ELISA. 
2.9 ELISA 
Cytokine concentrations were measured in culture supernatants by ELISA. Samples 
were measured in duplicate and standard curves created with serial dilutions of 
standards provided according to the manufacturer’s instructions. Cytokine 
concentrations in samples were calculated by interpolation from the standard curve in 
the linear phase of the curve using standards (recombinant cytokine) of known 
concentration provided by the supplier. ELISA kits were purchased from R&D 
systems unless otherwise stated for the following cytokines; IL-17A, interferon-, IL-
22, TNFα and IL-6 (eBioscience).  
2.10 Flow cytometry 
Flow cytometry was performed on unfractionated splenocytes, mLN or cLPL cells. 
In experiments where cells were stimulated prior to performing flow cytometry, 
1x10
6
 cells were plated in 48 well tissue culture plates in 1ml of complete medium. 
Cells were stimulated with 50ng/ml phorbol 12-myristate 13-acetate (PMA; Sigma) 
and 1μg/ml ionomycin (Sigma), or IL-23 (10-20ng/ml), IL-6 (50ng/mL), TL1A (20-
100ng/ml) or TNFα (20ng/mL) for 4 hours, adding 2μM monensin (Sigma) for the 
final 2 hours to inhibit intracellular protein exportation. To analyse intracellular 
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TNFα production by cLP DCs, unfractionated cLPLs were cultured in the presence 
of monensin for 4 hours at 37
0
C. A control population of cLPLs was incubated on ice 
without monensin to serve as negative controls and to facilitate the definition of flow 
cytometry gates showing TNFα producing cells. After stimulation (and control 
incubation) cells were washed once in PBS and resuspended in 200µL of PBS 
containing ant-CD16/CD32 to block non-specific binding via fc receptors. Cells were 
washed in PBS and then resuspended in 200µL of PBS containing appropriate 
surface staining monoclonal antibodies together with cell viability stain 
(LIVE/DEAD® fixable Aqua dead cell stain kit, Life Technologies) for 20 minutes 
at room temperature covered in foil. This viability stain is an exclusion dye and is 
compatible with subsequent cell fixation. Antibody clones and fluorochromes used 
are listed in Table 4. After surface/viability staining cells were fixed by resuspending 
in 400 µL of 2% paraformaldehyde for 20 minutes at room temperature. After 
fixation surface cells were washed in permeabilisation buffer (eBioscience) by 
adding 1mL of permeabilisation buffer directly to the paraformaldehyde suspended 
cells. After washing cells were resuspended in 200 µL of appropriate intracellular 
staining monoclonal antibodies in 1x permeabilisation buffer for 30 minutes at 4
0
C. 
Cell were washed in PBS and resuspended in 400 µL of PBS and stored at 4
o
C in the 
dark pending acquisition. Cells were acquired within 24 hours of staining. 
Samples were acquired using identically configured BD LSR II and BD LSR 
Fortessa (BD Biosciences) flow cytometers (20 parameter SORP instrument, 355 nm 
(nUV), 405 nm (violet), 488nm (blue), 561nm (Yellow-green), 633 nm (red)), 
allowing simultaneous use of all lasers. Sample data were recorded in FCS 3.0 data 
format using BD FACSDiva 6.0 software (BD Biosciences). Sample analysis was 
performed using FlowJo software (Treestar Inc., Ashland, OR, USA). 
2.11 Flow cytometry compensation calculation 
Calculating fluorescence compensation was first achieved using the automated 
compensation calculator programme in BD FACSDiva. Compensation set up was 
achieved using anti-mouse or anti-rat compensation beads (BD
TM
 CompBeads, BD 
Biosciences) labelled with a single fluorochrome conjugated monoclonal antibody. 
Compensation beads were coupled to the same fluorochrome conjugated antibodies 
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as those used for the specific stains used to label cells in the same experiment. 
Compensation beads were labelled with the appropriate fluorochrome conjugated 
monoclonal antibody for 15 minutes at room temperature. In early experiments 
unstained cells were used in the compensation set up to define the absence of 
staining. In later experiments negatively stained compensation beads were used. 
Automatically calculated spectral overlap values were manually inspected and the 
emission spectra of each single stained control analysed for spill over in to other 
fluorochrome channels. Where necessary compensation was manually corrected/fine 
tuned by adjusting automated compensation values.   
2.12 Flow cytometry gating strategies 
Positively stained cell populations were defined by comparing cell populations 
stained with an appropriate specific antibody with analogous cell populations stained 
with species/isotype matched fluorochrome conjugated control antibodies. For 
intracellular cytokine staining in experiments employing stimulation (e.g. PMA and 
ionomycin), the main control used to define positive staining was an analogous 
population of unstimulated cells that were treated with monensin alone. In these 
experiments cell populations were stimulated with PMA and ionomycin for 4 hours 
and monensin (2μM, Sigma) added for the final 2 hours of stimulation. In the 
unstimulated cells monensin alone was added for the final 2 hours of the incubation. 
In flow cytometry experiments the “monensin only” population of cells was used to 
identify the “negative” population of cells based on the assumption that without 
stimulation the cells would not produce any cytokine. In some experiments it was 
clear that a significant minority of cells stained positive for intracellular cytokine 
even in the absence of exogenous in vitro stimulation (e.g. Figure 6). In these cases 
an additional isotype control arm to the experiment was used. In isotype control 
experiments cell surface labelling antibodies were used in the same manner as in the 
stimulated cells stained with specific anti-cytokine monoclonal antibody, however, 
an isotype matched control antibody conjugated with a matched fluorochrome was 
used instead. Using this strategy cytokine negative populations were defined.   
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2.13 Flow cytometry cell sorting of ILCs 
In some experiments ILCs from TRUC and Rag2
-/-
 mice were purified from mLN by 
FACs. mLNs were used as a rich source of ILCs since target cells can be rapidly and 
easily isolated. Unfractionated mLN cells were harvested and a single cell 
suspension generated by mechanically disrupting cells through nylon mesh in 
complete medium. Unfractionated mLN cells were then labelled with 10µL of anti-
CD90 (PE) and 10µL of anti-NKp46 (APC) for 15 minutes at room temperature 
together with the viability stain (AmCyan) in a volume of 300µL of PBS. Cells were 
washed in PBS and resuspended in 500µL of PBS. Cells were sorted on a  
FACSAria™ II Cell Sorter (BD Biosciences). Cells were initially gated on the 
lymphocyte gate identified by forward and side scatter. Live cells were identified by 
gating on the unstained population of cells using the viability stain. Subsequently, 
NKp46
- 
(to exclude NK cells), CD90
+ 
cells (ILCs) were identified and collected into 




Table 4. Monoclonal antibodies and fluorochromes used in flow cytometry experiments
Antigen Clone Fluorochrome Provider 
CD45 30-F11 Pacific blue/AX700 eBioscience 
CD4 RM4.5 PECy7 eBioscience 
CD11b M1/70 FITC/Pacific Blue eBioscience 
CD11c N418 PE/APC Cy7 eBioscience 
CD103 2E7 PE eBioscience 
F4/80 BMP PE/PECy7 eBioscience 
CD90.2 30H12 PE/FITC/Pacific Blue eBioscience 
NKp46 29A1.4 APC/FITC eBioscience 
CD127 A7R34 PE/Pacific Blue eBioscience 
RORγt AFKJS-9 PE eBioscience 
CCR6 140706 PE R&D systems 
Sca-1 D7 AX700 Invitrogen 
Gr-1 RB6-8C5 APC eBioscience 
IL-6R D7715A7 PE/APC BioLegend 
DR3 Polyclonal Biotin R&D systems 
T-bet eBio4B10 PE/APC eBioscience 
α-IFNγ XMG1.2 FITC/Pacific Blue/PE eBioscience 
IL-17A eBio17B7 PE/FITC eBioscience 
TNFα MP6-XT22 PE eBioscience 
IL-22 IH8PWSR PE eBioscience 
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2.14 RNA extraction 
RNA extraction was performed using Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions, within a dedicated RNA work area. Equipment and 
surfaces were cleaned with RNaseZap solution (Ambion Inc., Austin, TX, USA) to 
reduce potential nuclease contamination. Cells were pelleted and resuspended in 1ml 
Trizol. Samples were either processed immediately or stored at -80°C prior to 
extraction. Whole colon segments (0.5-1cm) were harvested immediately after 
culling experimental animals and snap frozen in liquid nitrogen and then stored at -
80
o
C pending RNA extraction. Frozen colon segments were then homogenised using 
a Tissue lyzer II (Qiagen) with a Stainless Steel Beads (5 mm) (Qiagen) set to 25Hz/s 
for 5 minutes in 1mL Trizol reagent (Invitrogen). Cells or tissue homogenates were 
then immersed in 200μl chloroform (Sigma Aldrich), with the sample then mixed 
thoroughly and incubated at room temperature for 2 minutes. This was then 
centrifuged at 12,000g for 15 minutes at 4°C to allow phase separation. The upper 
colourless (aqueous) phase was carefully transferred to a fresh tube without 
disturbing the interphase, and 500μl of ice-cold isopropanol was then added. After 
vortex-mixing, the sample was centrifuged for 15 minutes at 4°C, at which point a 
pellet was observed. The supernatant was carefully removed; the pellet was then 
washed with 1ml 75% ethanol and centrifuged for a further 5 minutes at 7500g. The 
supernatant was then removed and the pellet allowed to air dry prior to resuspension 
in an appropriate volume of nuclease-free water. Samples were then assessed for 
quality, contamination and RNA concentration by analysis with a NanoDrop 
spectrophotometer. RNA was then stored at -80°C pending further analysis. 
2.15 cDNA synthesis and quantitative PCR 
cDNA was generated with the cDNA synthesis kit (Bioline) according to the 
manufacturer’s instructions. Quantitative PCR was used to quantify mRNA 
transcripts using TaqMan gene expression assays (Applied Biosystems, Warrington, 
UK). Gene expression was normalized to the expression of β-actin to generate ΔCT 
values and relative abundance quantified using the 2
-ΔCT
 method. The following 
Taqman qPCR primer sets were used according to the manufacturer’s instructions; 
IL-17A (Mn00439619), IL-22 Mn00444241), IL-21 (Mn00517640), IFN- 
84 
(Mn01168134), TNF (Mn00443258), IL-4 (Mn99999154), TL1A (Mn00770031), 
IL23p19 (Mn00518984), IL12p40 (Mn00434165) and the housekeeping gene β-actin 
(4352341E). 
2.16 Histology and colitis scores 
Five to ten millimetre segments of distal (within 0.5cm of the anal verge) and in 
some experiments proximal colon were fixed in 10% paraformaldehyde, and 
embedded in paraffin blocks. 5μm sections were stained with haematoxylin and 
eosin. Colon histology preparation was performed by the Pathology Core at QMUL. 
Colitis scores comprising epithelial hyperplasia (0-3), epithelial injury (0-3), 
polymorphonuclear infiltrate (0-3) and mononuclear infiltrate (0-3) were reported in 
a blinded fashion (TTM) as described previously (Garrett et al., 2007). In most of the 
experiments reported in this thesis using TRUC mice the distal colitis score was used 
as one of the main experimental outcome readouts, since this is the area of the colon 
that appears to be preferentially affected from the macroscopic appearance of the 
colon (see Figure 4C). In the IL-6 blockade experiment the proximal colon was also 
scored histologically. This was the final in vivo blockade experiment performed 
during this thesis, hence proximal colon histology segments were not taken for 
analysis in the other in vivo experiments. The recognition that colitis is more severe 
in the distal colon in comparison with the proximal colon in this experiment did 
result in conducting an experiment to formally show the colitis scores in the distal 
and proximal colon of TRUC mice (Figure 5C).          
2.17 Immunofluorescence 
Fluorescent immunohistochemistry was performed in collaboration with Dr. Ellen 
Marks as follows. Tissue samples were snap frozen in Jung tissue freezing medium 
(Leica Microsystems). 7 µm cryostat sections were fixed in acetone and then blocked 
with 20% normal horse serum (PAA Laboratories). Sections were incubated with 
FITC-conjugated anti-CD90.2 (eBioscience). Nuclei were counterstained with 
1µg/mL DAPI (Invitrogen). Images were acquired with an Olympus BX51 
microscope using Micro-Manager software (Vale Laboratory, University of 
California San Francisco). 
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2.18 Tbx21-/- x Rag2-/- Ulcerative Colitis (TRUC) model of colitis 
The TRUC mice studied in this thesis were a kind gift from Professor Laurie 
Glimcher and were descendant from the originally described TRUC colony from 
Harvard University (Garrett et al., 2007). In view of the transmissibility of TRUC 
colitis, TRUC mice were housed in a separate isolator. TRUC mice develop 
spontaneous colitis and were vigilantly observed for adverse signs, including 
wasting, piloerection, intractable rectal prolapse or severe rectal bleeding. Animals 
developing these features or other adverse events were humanely culled on welfare 
grounds. 
2.19 Anti-CD40 model of inflammatory bowel disease and systemic 
autoimmunity 
One hundred and twenty-five µg of agonistic anti-CD40 mAb (clone FGK4.5) or rat 
IgG2a isotype control mAb (clone 2A3) (both from BioXCell, West Lebanon, US) 







mice. Mice were weighed at baseline and inspected on a 
daily basis for signs of disease including diarrhoea, rectal bleeding, clinical features 
of peritonism, hunched appearance and piloerection. Mice were sacrificed and 
examined between days 7-8 days post injection of anti-CD40. Following sacrifice 
organs were harvested and weighed, including colon, mLN, spleen and liver. 
2.20 In vivo treatment of mice 
Antibody treatments comprised: 500μg anti-TNFα (clone XT3.11, days 0, 3, 6, 9, 12, 
15, 18, 21), 150μg anti-IL23p19 (G23-8, eBioscience, days 0, 4, 8, 13, 16), 450μg of 
anti-IL-17A (17F3, days 0, 4, 8, 11, 15, 18 and 21), 1mg anti-CD90.2 mAb (30H12, 
days 0, 7, 14, 21 and 28), 1mg anti-IL7R (A7R37, days 0, 3, 6, 9, 12, 15, 18, 21), 
750µg anti-IL-6 (MP5-20F3, days 0, 4, 9, 14, 18, 23 and 27), 1mg anti-CD4 (clone 
GK1.5, days 0, 7, 14, 21 and 28) and 500µg anti-TL1A (a kind gift from Professor 
Aymen Al-Shamkhani, Southampton, days 0, 4, 8 and 14). Control isotype clones 
used were MOPC-21 (mouse IgG1), HRPN (rat IgG1), 2A3 (rat IgG2a), LTF-2 (rat 
IgG2b). Monoclonal antibodies were purchased from Bio X Cell (West Lebanon, 
US) unless otherwise stated and were administered i.p in sterile PBS. With regards to 
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the mAb doses and administration intervals used in the protocols for in vivo 
blockade/depletion, these were largely based on previously published protocols, such 
as CD90 depletion (Buonocore et al., 2010), CD4 depletion (Sonnenberg et al., 
2011), IL-17A neutralization (Buonocore et al., 2010), IL-23p19 neutralization 
(Hagemann et al., 2008, Cornelissen et al., 2013), IL-6 neutralization (Starnes et al., 
1990) and IL-7R blockade (Seki et al., 2007). TL1A neutralization was empirically 
based on advice from the supplier (Professor Al-Shamkani). Additional 
considerations included the amount of antibody purchased and the number of 
available age matched mice for treatment. In most cases experimental design 
permitted the use of antibody quantities at least equal to, or in most cases in excess of 
the amount used in previously published studies. The TL1A neutralizing antibody 
was potentially used in a suboptimal dosing regimen (for less time than other anti-
cytokine treatments) in view of the limited supply of antibody. Accordingly, results 
from this experiment should be interpreted with this in mind.      
2.21 454 pyrosequencing analysis of intestinal microbiota 16S rRNA 
genes 
Bacterial 16S rRNA genes were kindly sequenced by Dr Alan Walker and Professor 
Julian Parkhill (Sanger Institute, Cambridge). DNA was extracted from frozen faecal 
pellets using the FastDNA® SPIN Kit. 16S rRNA gene PCR-amplicons were 
generated for Lib-L 454 Titanium sequencing using barcoded primers targeting the 
V3-V5 regions of the 16S rRNA gene. The primers and barcode sequences used are 
given in Table 4. PCR products were generated using AccuPrime™ Taq DNA 
Polymerase High Fidelity (Invitrogen). PCR cycling conditions were as follows: 
94ºC for 2mins followed by 20 cycles of 94ºC for 30secs, 53ºC for 30secs and 68ºC 
for 2mins. PCR products were then quantified using a Qubit® 2.0 Fluorometer 
(Invitrogen). Raw sequences were passed through the PyroTagger pipeline (Kunin et 
al., 2010), which filters poor quality reads, clusters sequences into OTUs at 97% 
similarity and assigns taxonomic classifications to each OTU based on the 
GreenGenes (DeSantis et al., 2006) and SILVA (Pruesse et al., 2007) databases, and 
trimmed to a length of ~400 bases. Further taxonomic classifications for each OTU 
were obtained by using the mothur software package (Schloss et al., 2009) to classify 
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the sequences according to the RDP (Cole et al., 2009) and SILVA (Pruesse et al., 
2007) databases.  
2.22 Helicobacter PCR 
Bacterial DNA was extracted from faeces using the QIAamp DNA stool minikit 
(Qiagen). Helicobacter typhlonius specific PCR was performed using primer pairs 
that have been shown to amplify a 122bp sequence of the 16S rRNA gene in H. 
typhlonius, but not other Helicobacter spp. (Feng et al., 2005). (5’-AGG GAC TCT 
TAA ATA TGC TCC TAG AGT-3’, and 5’ ATT CAT CGT GTT TGA ATG CGT 
CAA-3’). The PCR conditions used were as follows: 95oC for 30 seconds, 55oC for 
30 seconds and 72
o
C for 30 seconds for 35 cycles. Helicobacter genus generic PCR 
was performed with the primer pair (5’-TAT GAC GGG TAT CCG GC-3 and 5’-
ATT CCA CCT ACC TCT CCC A-3’) (Beckwith et al., 1997). The 374bp PCR 
product generated by genus generic primers was recovered from acrylamide gel for 
subsequent DNA sequencing, which was performed by an outside vendor (Charles 
River Laboratories UK). 
2.23 Bacterial growth conditions 
Helicobacter typhlonius (CCUG 48335 T) was acquired from the culture collection 
of the University of Gothenburg. HT was grown and maintained either on blood agar 
plates (Oxoid, UK) containing 5% defibrinated horse blood (TCS Bioscience, 
Buckingham, UK) or in brain heart infusion broth supplemented with 1% yeast 
extract and 5% horse serum by Dr Ahmed Hashim at QMUL. Cultures were 
incubated in an anaerobic atmosphere consisting of 80% N2, 10% H2 and 10% CO2 
(Don Whitley Scientific, Shipley, UK). 1-5 x10
7 
organisms were gavaged into 
selected mice as described in the text. Transfer of TRUC microbiota was achieved by 
homogenizing freshly harvested faecal pellets from adult TRUC mice in PBS. Solid 
matter was removed by low speed centrifugation and the resulting microbial 
suspension used for oral gavage. Each gavage recipients received PBS suspension 
corresponding to approximately 50% of an individual faecal pellet.    
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2.24 Statistical analysis 
Statistical analyses were performed using GraphPad Prism version 5 (GraphPad 
Software Inc., La Jolla, CA, USA). Non-parametric data were analysed using the 
Mann-Whitney U test and normally distributed data using the student T-test. Some 
samples were also analysed using paired T-tests where appropriate. Statistical 
significance was assumed if the p value was <0.05. Where appropriate non-
parametric data was also expressed as medians and interquartile ranges (IQR). 
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Table 5. Barcodes used for each 454-sequenced mouse faecal sample.  Faecal samples were 
acquired from 4x TRUC mice and 8x TRnUC mice. Bases in italics are the 454 Lib-L ‘B’ 
adaptor. Bases in bold are the 454 Lib-L ‘A’ adaptor.  
 
 


















Results: Defining the cellular and molecular determinants 
of chronic intestinal inflammation in TRUC mice 
TRUC mice develop a spontaneous colitis that resembles aspects of human UC 
demonstrating that T-bet plays an important role in the maintenance of intestinal 
homeostasis, and that in the absence of T-bet innate immunity is sufficiently 
dysregulated such that spontaneous disease manifests. Despite the early work 
identifying an important role for TNFα in this model, the innate immune mechanisms 
responsible for maintaining chronic disease in TRUC mice are unknown. By 
investigating the innate immune mechanisms operating in chronic IBD in TRUC 
mice this thesis set out to provide new insights into how T-bet controls innate 
immunity in the gut. 
One of the key immune mechanisms operating in early TRUC disease is deregulated 
colonic TNFα production by CD11c+ cells and accordingly early stages of TRUC 
colitis can be reversed by blocking TNFα (Garrett et al., 2007). However, beyond 12 
weeks of age the therapeutic benefit of anti-TNFα mAbs is lost (Garrett et al., 2009), 
indicating that alternative immune mechanisms are responsible for driving chronic 
disease. Therefore, to determine which other immune mechanisms were potentially 
involved in the evolution of chronic TRUC IBD, the intestinal and systemic immune 
response of TRUC mice aged >12 weeks old was investigated. 
3.1 TRUC mice developed severe distal colitis resembling aspects of 
human UC 
TRUC mice developed spontaneous colitis with rectal prolapse, distal colonic 
thickening and mesenteric lymphadenopathy (Figure 4A-C). In comparison with age 
matched Rag2
-/-
 controls, they developed significantly increased colonic mass 
(Figure 4D) and splenomegaly (Figure 4E). Histologically, the colonic lesion was 
characterised by goblet cell depletion, crypt abscess formation and infiltration of the 
lamina propria with granulocytes and mononuclear cells (Figure 5A). Marked 
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epithelial hyperplasia was also a prominent feature of chronic TRUC IBD. 
Histological colitis scores, based on epithelial hyperplasia (0-3), mucosal injury (0-
3), polymorphonuclear infiltration (0-3) and mononuclear cell infiltration (0-3) were 
significantly higher in TRUC mice in comparison with Rag2
-/-
 controls (Figure 5B). 
Histological lesions were also noted to be more severe in the distal colon, with 
variable and less severe extension into the proximal colon (Figure 5C), as is the case 








Figure 4. The TRUC model of IBD.   A TRUC mice developed rectal prolapse. B Abdominal 
dissection demonstrated distal colonic thickening, splenomegaly and mesenteric 
lymphadenopathy.  C The colon of TRUC mice was also markedly thickened, particularly 
distally, in comparison with Rag2
-/- 
mice. D Colon and E spleen mass in 12 week old 
TRUC (n=15) and Rag2
-/- 







Figure 5. Histological features of the colon in TRUC mice.  A Histological appearance of the 
distal colon (distal margin taken from within 0.5cm of the anal verge) of age matched (12 
week old) TRUC and Rag2
-/- 
mice (H&E stained micrograph). Magnification is the same 
for both panels (approximately x40).   B Colitis histology scores from the distal colon in 
TRUC (n=25) and Rag2
-/- 
mice (n=15) mice. *P<0.001. C Histology scores from the 
distal and proximal colon of 12-16 week old TRUC mice (n=15). *P<0.001. In Figure B 
each dot represents an individual mouse. In Figure C each pair of connected dots are from 







3.2 Colonic CD45+ immune cells from TRUC mice produced IL-
17A and IL-22 
To gain insights in to the potential immune mechanisms operating in chronic TRUC 
disease, cytokine production by colonic immune cells was investigated in mice >12 
weeks old. Lamina propria leukocytes (LPLs) were isolated from the colon of TRUC 
mice by collagenase digestion and enrichment using density gradient centrifugation. 
Following purification, unfractionated cLPLs were stimulated with PMA and 
ionomycin to trigger cytokine production. In this experiment 2 additional controls 
were used. The first control (which was employed throughout the this thesis) used 
unstimulated cells treated with monensin alone. However, since there was sometimes 
a small amount of cytokine detectable in unstimulated cells treated with monensin 
alone it was also considered appropriate to use an additional control population of 
cells to appropriately define the negative and positive staining cell populations. This 
control was termed the isotype control. Cells were stimulated with PMA and 
ionomycin in the presence of monensin (added for the final 2 hours of the stimulation 
as in all other experiments). However, instead of adding the cytokine-specific 
intracellular mAb, an isotype-matched control mAb labelled with the same 
fluorochrome was added instead. In these experiments identical surface staining 
antibodies were used, thereby allowing isotype staining to be identified in specific 
cell populations.        
Immune cell (CD45
+
) expression of different cytokines potentially involved in 
mediating intestinal inflammation, including IFNγ, IL-4, IL-17A and IL-22 was then 
determined by intracellular flow cytometry. Following cell stimulation, cLPL were 
stained with a live/dead stain to identify viable cells and also with a surface antibody 
stain directed against CD45 to identify immune cells within the colon (Figure 6A). A 
control isotype matched antibody labelled with the same fluorochrome as the specific 
anti-CD45 mAb was used to define CD45
+
 population within the colon. At the time 
of surface staining the unfractionated cells were also labelled with a viability 
exclusion dye that is compatible with cell fixation. Accordingly, unstained, live cells 
were defined and gated on for downstream analysis of intracellular cytokine. In 
comparison with unstimulated cells treated with monensin alone stimulation with 




 immune cells, particularly in the case of IL-17A and IL-22. Although 
few colonic CD45
+
 cells expressed IFNγ or IL-4 even following activation with 
PMA and ionomycin, there were many cells expressing IL-17A and IL-22 (Figure 6C 






























TRUC mice.A Gating strategy employed to define CD45
+
 cells by comparing specific anti-
CD45 mAb staining with a matched fluorochrome conjugated isotype (bottom panel).  Live 
cells were defined by the absence of LIVE/DEAD
®
 fixable Aqua dead cell stain.  B Gating 
strategy to define the proportion of cells (% of CD45
+
 cells) positive for intracellular cytokine. 
Unstimulated cells treated with monensin alone (+M) were compared to cells stimulated with 
PMA and ionomycin with monensin (P&I +M). The positive cytokine gate was defined in 
stimulated cells stained with the same surface stain (CD45 and viability stain), but using an 
isotype control intracellular staining mAb. C Representative intracellular cytokine staining. D 
Statistical analysis (paired t-test) comparing the proportion of cytokine expressing cells in 
unstimulated /monensin alone cells compared to cells stimulated with P&I +M. Paired samples 
are from the same donor. Four biological replicates (individual mice) are shown. Adapted 
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Cytokine expression by CD45
+
 immune cells was also measured in other tissues 
from TRUC mice, including the spleen and mesenteric lymph nodes (mLNs). 
Unfractionated splenocytes, mLN cells and cLPLs were stimulation with PMA and 
ionomycin and intracellular cytokine expression determined by flow cytometry. 
Although marked IL-17A expression was observed in both the cLP and mLN of 
TRUC mice, cytokine production by splenocytes was less pronounced (Figure 7), 
indicating that inflammatory cytokine production is enriched at the chief site of 
disease in TRUC mice, that is, in the colon and associated lymphoid tissue. Both 
colonic and mLN cells were a rich source of IL-17A. 
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Figure 7. Cytokine expression by CD45
+
 splenic, mLN and cLP immune cells in TRUC mice.  
Unfractionated splenocytes, mLN cells and cLPLs were stimulated with PMA and 
ionomycin. Intracellular expression of IFNγ and IL-17A was determined in live, CD45+
 
cells in the tissues/organs specified (gating strategy as shown in Figure 6A). These flow 
cytometry plots are representative of >5 different experiments. 
 








3.3 IL-17A production was increased in colon explant cultures from 
TRUC mice 
Colon explant culture can be used to investigate cytokine production in disease 
relevant tissues. In these experiments full thickness colon was sampled from 
experimental animals. To standardise the size of colon assessed, 3mm wide biopsies 
were acquired from the distal colon of TRUC or Rag2
-/- 
mice aged >12 weeks using a 
skin punch biopsy. Cytokines spontaneously secreted into culture supernatants were 
then measured following 48 hours of culture by ELISA. In comparison with Rag2
-/- 
mice, explants from TRUC mice produced significantly more IL-17A and IL-22 





Figure 8. Cytokine production in colon explant culture.  3mm punch biopsies were taken from 
the distal colon of 12-16 week old Rag2
-/-
 and TRUC mice. 3x biopsies were placed in 
500µL of complete medium and incubated for 48 hours. Cytokine production was 
measured in supernatants by ELISA. Cytokine concentrations were interpolated from the 
linear part of the standard curve generated by measuring known standard concentrations 
of recombinant cytokines provided by the ELISA kit.  Each data point represents an 
individual mouse. Lines depict median cytokine concentration. 
 
.   
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3.4 Transcripts encoding IL-17A were increased in the colon of 
TRUC mice 
The expression of transcripts encoding inflammatory cytokines was also investigated 
in the colon of TRUC mice. 5mm segments of distal colon were harvested from 
TRUC and Rag2
-/-
 mice into Trizol solution and stored at -80
o
C. cDNA was then 
synthesized. Cytokine-specific primers and real time PCR were then used to quantify 
relative abundance of cytokine transcripts in colonic tissue. In agreement with flow 
cytometry and organ culture experiments, transcripts encoding Il17a and Il22 were 
significantly increased in the colon of TRUC mice in comparison with Rag2
-/-
 
controls (Figure 9). However, there was no significant difference in the abundance of 
transcripts encoding Ifng or Il4 in TRUC mice in comparison with Rag2
-/-
 mice. 
Indeed, transcripts encoding Ifng were below the limit of detection in TRUC and 
Rag2
-/-
 mice. In keeping with previous reports describing increased production of 
TNFα in TRUC disease (Garrett et al., 2007; Garrett et al., 2009), there was 
significantly increased abundance of transcripts encoding Tnfa in the distal colon of 
TRUC mice in comparison with Rag2
-/-
 controls. 
Since Il17a and Il22 transcripts were significantly increased in TRUC mice, the 
possibility that other “Th17” like cytokines might also be increased in TRUC disease 
was considered. The cytokine IL-21 is also produced by Th17 cells and (Wei et al., 
2007), and therefore the abundance of Il21 transcripts in the colon of TRUC and 
Rag2
-/-
 mice was also measured. Unlike transcripts encoding Il17a or Il22, which 
were elevated in TRUC mice, transcripts encoding Il21 were not detected in the 
colon of most TRUC or Rag2
-/-
 mice (Figure 9). 
102 
 
Figure 9. Quantification of cytokine transcripts in the colon of TRUC mice.  RNA was 
extracted from 0.5cm segments of distal colon (within 0.5cm of anal verge) of Rag2
-/-
 and 
TRUC mice. cDNA was synthesized and cytokine-specific PCR primers used to amplify 
corresponding transcripts. Line depicts median relative abundance of cytokine transcript. 
Each dot represents an individual mouse.     
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3.5 Innate lymphoid cells were the principle source of IL-17A in 
TRUC mice 
Since excessive colonic production of IL-17A, a cytokine strongly implicated in IBD 
pathogenesis, was a prominent feature of chronic TRUC IBD, an attempt to define 
the cellular source of this cytokine was made. Innate sources of IL-17A have been 
reported to include ILCs (Buonocore et al., 2010; Takatori et al., 2009), NK cells 
(Hughes et al., 2009) and even neutrophils (Ferretti et al., 2003). To address this 
question, cells from TRUC mice were stimulated to produce IL-17A and then flow 
cytometry was employed, using antibodies directed against major lineage markers. 
Using flow cytometry it was observed that most of the IL-17A expressing cells 
present in the colon and mLN of TRUC mice were CD90
+ 
(Figure 10), a marker of 
ILCs (Buonocore et al., 2010). The expression of other cell surface innate immune 
cell lineage markers among the IL-17A
+
 cell population was also investigated. There 
was no appreciable expression of NKp46 (NK cells), CD11c (myeloid cell lineages, 
including DCs), F4/80 (macrophages) and Gr-1 (granulocytes) among the IL-17A
+
 
cell population (Figure 11), indicating that other innate immune lineages were not 
responsible for significant IL-17A production in TRUC mice. Given that most of the 
IL-17A producing cells present in TRUC mice expressed CD90, the presence or 
absence of other ILC markers was determined in the IL-17A producing population of 
cells in TRUC disease. IL-17A
+
 cells were observed to have increased expression of 
CCR6, RORγt, Sca-1 and IL-7Rα (Figure 11), consistent with the phenotype of ILCs 
(Buonocore et al., 2010; Sonnenberg et al., 2011). Taken together these data 





, RORγt+ IL-7Rα+ cells, consistent with the phenotype of ILCs, and 
that the other major innate immune lineages present in TRUC mice are not a 
significant source of IL-17A in this model. 
104 
 
Figure 10. Most IL-17A producing cells in the colon and mLN of TRUC mice expressed the 
ILC marker CD90.  Flow cytometry plot showing CD90 and IL-17A expression in 
unfractionated cLPLs and mLN cells following stimulation with PMA and ionomycin. 
These plots are gated on live, CD45
+
 cells (as previously). These data are representative 
of many experiments (>10). Unstimulated cells cultured in the presence of monensin 
alone are denoted by (-) and cells stimulated with PMA and ionomycin in the presence of 
monensin are denoted by (+).  
Gated on live, CD45+ cells 
( - ) (+) 






Figure 11. The phenotype of IL-17A expressing cells in TRUC colitis was consistent with the 
phenotype of ILCs.  Unfractionated cLPLs (left panel) and mLN cells (right panel) were 
stimulated with PMA and ionomycin in the presence of monensin to define IL-17A 
producing cells. Positive staining was identified by comparing staining in unstimulated 
cells treated with monensin alone. Cells were stained for IL-17A and other cell surface 










 population (dotted line histogram) are 
shown. Data are representative of at least 2 individual experiments. Adapted from Powell 
et al., 2012.    
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3.6 Antibody mediated depletion of CD90 expressing cells reduced 
the number of IL-17A producing cells in TRUC mice 
The chief cellular source of increased IL-17A production in TRUC colitis was CD90 
ILCs. ILCs have been shown to play an important role in a number of mucosal 
disease settings (Buonocore et al., 2010; Sonnenberg et al., 2011) and therefore 
experiments were conducted to establish the functional significance of CD90
+
 ILCs 
in TRUC IBD. The surface marker CD90 appears to be consistently expressed by all 
mucosal ILC populations, including the CD4
+
 ILCs that contribute to host immunity 
to Citrobacter rodentium infection (Sonnenberg et al., 2011), CD4
-
 ILCs that 
mediate inflammation in murine models of colitis (Buonocore et al., 2010), and also 
by nuocytes that express Th2 cytokines, such as IL-5 and IL-13 (Chang et al., 2011; 
Neill et al., 2010). 
Therefore, to investigate the functional significance of CD90
+
 ILCs in chronic TRUC 
colitis CD90 expressing cells were depleted in vivo in TRUC mice. In this 
experiment 1mg of depleting anti-CD90 (clone 30H12) or control antibody (rat 
IgG2b, clone LTF-2) was administered i.p. to 12-14 week old TRUC mice, once 
weekly for 4 weeks (Figure 12). This antibody clone has previously been to shown to 
successfully deplete colonic ILCs (Buonocore et al., 2010; Sonnenberg et al., 2011). 
Five mice received the control antibody and 4 mice received the depleting anti-CD90 
antibody. At the end of the experiment (48 hours after the administration of final 
dose of depleting antibody) organs including the colon, spleen and mLN were 
harvested from study animals and analysed. 
The total number of mononuclear cells present in different tissues of anti-CD90 and 
control mAb treated TRUC mice was calculated. Colons were harvested from study 
animals and cLPL isolated by collagenase digestion. Mononuclear cells were also 
harvested from the mLN and spleen following mechanical dissociation of the tissue. 
The total number of mononuclear cells present in each of the organs of study animals 
was then calculated. The number of splenocytes was significantly reduced in anti-
CD90 treated mice (median = 4.7 x x10
6
, inter-quartile range (IQR) 4.3-5.8) in 
comparison with control antibody treated mice (median = 10.1 x10
6
, IQR 9.6-12.7, 
P<0.016). Similarly, the total number of mononuclear cells present in the mLN of 






) in comparison with control mice (median = 1.1 x 10
6
, IQR 1.3-8.9 x10
6
, 
P<0.02). There were also fewer cells present in the cLP of anti-CD90 treated TRUC 
mice (median = 1.05 x10
6
, IQR 0.9-2.7 x10
6
) in comparison with control mice 
(median = 2.2 x10
6
, IQR 1.1-3.9 x10
6






















Figure 12. Protocol for in vivo depletion of CD90 or CD4 expressing cells in TRUC mice.  1mg 
of anti-CD90 (clone 30H12), 1mg anti-CD4 (clone GK1.5) or control antibody (clone 
LTF-2) was administered to 12-14 week old TRUC mice on days 0, 7, 14, 21 and 28. 
Mice were culled and organs harvested on day 30 (48 hours after the final dose of 
antibody). The CD90 depletion protocol was informed by previously published data 
regarding in vivo ILC depletion in the colon (Buonocore et al., 2010). In view of the 
paired anti-CD4 treatment, the GK1.5 was used at the same dose and timing. Previous 
studies have used comparable doses (e.g. 250µg every 3-4 days, Sonnenberg et al., 2011). 
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 expressing cells in the cLP and mLN of TRUC mice 
was also determined by flow cytometry. In this experiment, unfractionated cells were 
first stimulated with PMA and ionomycin to enable identification of IL-17A 
producing cells. Prior to intracellular staining (for IL-17A), cells were also stained 
with an anti-CD90 mAb. Crucially, administration of anti-CD90 resulted in marked 
depletion of CD90
+
 cells in TRUC mice. A representative flow cytometry plot is 
shown in Figure 13A. As well as marked depletion of CD90
high
 cells in both the cLP 
and mLNs of TRUC mice, the majority of IL-17A producing cells were also depleted 
following anti-CD90 administration, consistent with initial data showing that CD90
+
 
cells were the major source of IL-17A in TRUC mice. The absolute number of IL-
17A producing cells in the cLP and mLN was also calculated by multiplying the 
proportion of IL-17A
+
 cells in the cLP and mLN of the study TRUC mice by the 
total number of live mononuclear cells isolated from the tissues of each animal. In 
keeping with CD90
+
 ILCs being the chief source of IL-17A in TRUC colitis, CD90 
depletion resulted in a significant reduction in the absolute number of IL-17A
+
 cells 
both the cLP (P<0.02) and mLN (P<0.016) of TRUC mice (Figure 13B).  
The impact of CD90 cell depletion on colonic expression of transcripts encoding IL-
17A in TRUC mice was also investigated. Il17a mRNA was quantified by qPCR 
following treatment with anti-CD90 or control antibody. Although there was a 
reduction in the median relative abundance of Il17a mRNA in the 5 anti-CD90 
treated TRUC mice in comparison with the 4 control antibody treated animals, this 
did not achieve statistical significance (Figure 13C). 
In addition to using flow cytometry, CD90 expressing cells were also visualised in 
the colon of TRUC mice by immunofluorescence (Figure 14). In anti-CD90 treated 
mice there were very few CD90
+
 cells seen in the colon. In contrast, CD90
+
 cells 




Figure 13. Anti-CD90 treatment depleted CD90 expressing cells.  A Flow cytometry plot of cells 
from the mLN and cLP from TRUC mice following in vivo administration of anti-CD90 
or control (isotype-matched) mAb. Cells were first stimulated with PMA and ionomycin. 
B Absolute number of IL-17A
+
 cells in the cLP and mLN of TRUC mice after treatment 
with anti-CD90 or control isotype (after stimulation of cells with PMA and ionomycin). 
Bars represent mean cell number. Error bars indicate SEM. C qPCR quantifying Il17a 
mRNA in the colon of TRUC mice after treatment with anti-CD90 (n=4) or isotype 
(n=5). Bars indicate mean relative abundance of Il17a transcripts and error bars indicate 
SEM. Mice in this experiment were aged between 12-14 weeks old. Adapted from Powell 




Figure 14. Anti-CD90 treatment depleted CD90 expressing cells.  Immunofluorescence staining 
of colon segments harvested from TRUC mice following in vivo administration of anti-
CD90 or control (isotype-matched) mAb. Sections were stained with anti-CD90-FITC. 
Nuclei were counter stained with DAPI. Magnification is the same in both panels 
(initially approximately x40, and further increased in equal proportion to generate the full 






3.7 Depletion of CD90+ cells significantly abrogated chronic TRUC 
disease 
The impact of antibody-mediated depletion of CD90 expressing cells on TRUC 
disease parameters was also investigated. In these experiments the functional impact 
of CD4 depletion was also simultaneously investigated (the rationale and results for 
this intervention are presented in 3.10). TRUC mice treated with control antibody 
developed severe histological features of colitis, including marked epithelial 
hyperplasia, widespread crypt abscess formation, goblet cell depletion and 
infiltration of the cLP with mononuclear cells and PMNs (Figure 15A). In contrast, 
anti-CD90 treated mice had markedly improved histological appearances. The colitis 
scores in control antibody treated mice gave a median score of 12 (IQR 7-12), while 
anti-CD90 treated mice had a median histology score of 1 (0.25-1.75, P<0.02). 
Although the results of CD4 depletion are presented in section 3.10, it is noteworthy  
that mice treated with anti-CD90 mAbs had significantly less severe colitis than anti-
CD4 treated mice, which did not differ significantly from control antibody treated 
mice (Figure 15A and B).    
Other TRUC disease parameters were also changed by anti-CD90 treatment. 
Splenomegaly is a common feature of chronic TRUC disease (Figure 4E). In anti-
CD90 treated mice there was a significant reduction in spleen size (median = 50mg, 
IQR 50-53.75mg) in comparison with control antibody treated mice (median = 
90mg, IQR 82.5-105mg, P<0.018, Figure 16A). Colon weight was also significantly 
reduced in anti-CD90 treated mice (median = 315mg, IQR 225-337.5mg) in 
comparison with control antibody treated mice (median = 390mg, IQR 350-450mg 
P<0.02, Figure 16B). There was a tendency for anti-CD90 treated mice to exhibit 
improved weight gain in comparison with control mice over the course of the 5 week 
experiment. Mice treated with anti-CD90 had a median weight gain over the 5 week 
experiment of 6.4% (IQR 4-8.5%) in comparison with control antibody treated mice 
that only gained 1.7% (IQR -1.75-9.4%), however, this did not achieve statistical 
significance (P<0.19) (Figure 16C). Taken together these data are consistent with a 
key functional role for CD90
+
 ILCs in TRUC IBD with a statistically significant 
difference seen in major disease parameters in mice treated with an anti-CD90 mAb, 
which was observed to significantly deplete the majority of CD90
+
 cells in the colon 
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of TRUC mice. Notably, mice treated with anti-CD90 also had significantly less 







Figure 15. Anti-CD90 treatment significantly attenuated chronic colitis in TRUC mice, but 
anti-CD4 treatment was ineffective.  A H&E stain showing the histological appearance 
of the distal colon of TRUC mice following treatment with anti-CD90, anti-CD4 or 
control (isotype-matched) mAb. Magnification is the same in both panels (approximately 
x40). Crypt abscess formation was readily visible in control mAb and anti-CD4 treated 
mice as depicted. B Colitis histology scores in the same study animals. The line 
represents the median colitis score. Each dot represents an individual animal. These data 














   
 
Figure 16. Anti-CD90 treatment significantly attenuated other disease parameters in TRUC 
mice, but anti-CD4 treatment was ineffective.  A Change in body weight expressed as 
a % of initial body weight (final body weight/initial body weight x 100),  B Colon mass   
and C spleen mass in TRUC mice treated with either control mAb (n=5), anti-CD90 
(n=4) or anti-CD4 (n=4). These data are all from a single experiment, which was not 







3.8 There was a CD4+ subset of CD90+ ILCs in TRUC mice 
A potentially important cell surface marker that distinguishes between different 





 ILCs have been described in the gut that appear to mediate colitis 




 ILCs may be 
involved in host resistance to intestinal pathogens (Sonnenberg et al., 2011). 
Therefore, the expression of CD4 by intestinal ILCs from TRUC mice was 
investigated. 
Although CD90 expression was clearly seen in CD45
+
 cLPLs from TRUC mice, 
there was very little CD4 expression (Figure 17A). In contrast, in the mLN of TRUC 
mice CD4
+
 cells could be observed (Figure 17A). Notably, the majority of CD4
+
 
cells also expressed CD90 consistent with the likelihood that most CD4
+
 cells 




 double positive ILCs. On the 
other hand the majority of CD90
+
 cells in the mLN of TRUC mice did not express 
CD4. These data indicate that there are (at least) 2 populations of CD90
+
 cells in the 
mLN of TRUC mice characterised by differential expression of CD4. 




 cell populations to produce IL-17A was 
investigated using flow cytometry. In the colon there were very few CD4
+
 cells and 
these cells did not express appreciable IL-17A (Figure 17B). Instead, most IL-17A 
production in the colon of TRUC mice was produced by CD90
+
 cells. IL-17A 
production by CD90 and CD4 expressing cells was also investigated in the mLN of 




cell populations (Figure 
17B). Interestingly, subdivision of mLN CD90
+
 cells into CD4
+














 cell populations expressed IL-17A (Fig 18A). Although both 
single and double positive cells were frequently IL-17A
+
, it was also noted that a 




 double positive cells expressed IL-




 cells P<0.019, Figure 18B). 
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Figure 17. CD4 and CD90 expressing cells in TRUC mice. A CD4 and CD90 expression in the 
cLP and mLN of TRUC mice. B  IL-17A expression in CD4 and CD90 cells in TRUC 
mice. Unfractionated cells were stimulated with PMA and ionomycin in the presence of 
monensin. Positive staining was defined by comparing unstimulated cells incubated with 
monensin alone. Cells were gated on live cells (and additionally with CD45 for cLP). The 
CD4 gate was defined by comparing analogous samples from mice receiving depleting 
anti-CD4 mAb (section 3.9). Data are representative of >4 individual experiments. Mice 











3.9 Depletion of CD4+ cells failed to limit innate IL-17A expressing 
cells in TRUC mice 
To establish the relevance of CD4
+
 cells in TRUC disease, a depleting mAb was 
administered to TRUC mice. This experiment was performed at the same time as the 
depleting CD90 experiment in a parallel protocol using the same set of control 
antibody treated mice as comparison. Utilisation of a common control population of 
isotype antibody treated mice was enabled since the anti-CD90 and anti-CD4 mAbs 
are both rat antibodies of the same immunoglobulin subclass (IgG2b). Therefore, a 
common isotype control mAb clone was used for control mice (clone LTF-2). A 
common administration protocol was also used (Figure 12). One mg of anti-CD4 
(clone GK1.5), or control antibody (clone LTF-2) was administered i.p. to 12-14 
week old TRUC mice once weekly for 4 weeks. This clone has been shown to 
successfully deplete CD4
+
 ILCs (Sonnenberg et al., 2011). At the end of the 
experiment (48 hours after the final administration of antibody) mice were culled and 
organs harvested.  








 single positive 
ILC populations was analysed by flow cytometry following administration of 
depleting anti-CD4 mAb or control antibody. In control mAb treated mice there was 




cells in the mLN that were producers of IL-17A 
(Figure 18C). However, following administration of anti-CD4, the CD4
+
 population 
of cells was almost completely depleted (Figure 18C). However, there was still 
substantial production of IL-17A cells which were CD90
+
 (Figure 18C). These data 
indicate that whilst anti-CD4 mAbs can be used to successfully deplete CD4 














failed to limit innate IL-17A production.  A Flow cytometry plot showing intracellular 








 ILCs in mLN of TRUC mice. 
Statistical analysis of biological replicates is shown in B. Each connected pair of dots are 
from a single mouse. C Flow cytometry plot showing CD90, CD4 and IL-17A expression 
in mLN of TRUC mice following in vivo treatment with an anti-CD4 or control (isotype) 
antibody. Cells were stimulated (in both A and C)  with PMA and ionomycin (in the 
presence of monensin as previously described). Gating strategy has been described 
previously.  
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3.10 Antibody-mediated depletion of CD4 expressing cells in vivo 
failed to attenuate disease in TRUC mice 
The functional significance of CD4
+
cell depletion on TRUC disease parameters was 
investigated. Anti-CD4 treated mice developed severe colitis with pronounced 
epithelial hyperplasia, infiltration of the colon with polymorphonuclear cells and 
mononuclear cells, and crypt abscess formation (Figure 15A). There was no 
significant difference in histology scores in anti-CD4 or control antibody treated 
TRUC mice (Figure 15B). Other disease parameters were also assessed. There were 
no significant differences in body weight changes (Figure 16A), colon weight 





3.11 Chronic TRUC IBD was IL-17A dependent 
In view of the dominant IL-17A response observed in chronic TRUC IBD in organ 
culture, flow cytometry of CD45
+
 immune cells, and by qPCR in TRUC mice, the 
functional significance of this cytokine was investigated. A neutralising anti-IL-17A 
(clone 17F3) or isotype control antibody (mouse IgG1) was administered i.p. every 
3-5 days (7 doses in total) to TRUC mice aged 12 weeks old, when chronic colitis is 
well established (Figure 19). Seven mice received the neutralizing antibody and 8 
mice received the control isotype matched antibody. Organs were harvested 48 hours 
after the final injection of anti-IL-17A or control antibody. 
Administration of anti-IL-17A mAb significantly improved colitis scores (P<0.02) 
(Figure 20A and 20B). Indeed, 71% (5/7) of anti-IL-17A treated mice had complete 
resolution of colitis (colitis score=0). Improvements in histology sub-scores for 
epithelial hyperplasia and epithelial injury were particularly striking, with all 7 mice 
in the anti-IL-17A treated group scoring 0 for epithelial injury and 6/7 mice scoring 0 
for epithelial hyperplasia. In this experiment IL-17A blockade did not significantly 
impact on other clinical features, such as colon weight (Figure 20C) or splenomegaly 
(Figure 20D). 
Consistent with the biological activities of IL-17A, antibody blockade also markedly 






 granulocytes infiltrating the 
colon (Figure 21A and 21B). However, the proportion of cLP F4/80
+
 macrophages 
was comparable in treated and untreated mice. Notably, there was also a small, but 
statistically significant proportional increase in the percentage of CD90
+
 cells in the 
cLP of TRUC mice following IL-17A blockade. It is probable that this apparent 
increase is due to the marked reduction in granulocytes in anti-IL17A treated animals 
resulting in a relative increase in the number of CD90
+
 cells. These data highlight 
one of the drawbacks of only measuring the relative proportion of cells in a tissue 





Figure 19. Experimental protocol followed to evaluate the functional role of Il-17A in chronic 
TRUC disease.  450µg of an anti-IL-17A (clone 17F3) or control isotype antibody (clone 
MOPC-21) was administered i.p. to 12 week old TRUC mice. Organs were harvested 2 
days following administration of the final antibody dose. The anti-IL-17A neutralizing 
protocol was based on previously published data of blocking this cytokine in vivo in 
innate models of colitis (Buonocore et al., 2010). In this previously published study 
375µg of anti-IL-17A was used twice per week, although it was a different clone.      
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Figure 20. IL-17A neutralisation significantly attenuated TRUC colitis.  A Histological 
appearance of the colon (H&E staining) of 12 week old TRUC mice receiving control 
mAb or anti-IL-17A. Magnification is the same in both panels (approximately x40). B 
Colon histology scores in TRUC mice receiving either control (isotype) antibody (n=8) 
or anti-IL-17A (n=7). C Colon mass and D spleen mass in control mAb or anti-IL-17A 
mAb treated TRUC mice. In all cases individual dots represent an individual mouse. In 
graphs lines depict median score or mass. Adapted from Powell et al., 2012. 
Isotype 
Anti - IL17A 
A 
B C D 
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Figure 21. IL-17A neutralisation significantly reduced colonic neutrophil infiltration in TRUC 
mice.  A Representative flow cytometry plot showing the proportion of Gr-1
high 
granulocytes in the colon of TRUC mice treated with either control (isotype) or anti-IL-













 ILCs in the colon of TRUC mice treated with 
either control (isotype) antibody (n=8) or anti-IL-17A (n=7). Each dot represents an 
individual mouse and lines represent median % cells (as defined in y-axis) of CD45+ 





The results presented in the first results chapter shed new light on the TRUC model 
of IBD. For the first time it is demonstrated that IL-17A producing CD90
+
 ILCs play 
an indispensable role in disease manifesting in TRUC mice. These novel data change 
the interpretation of the original papers discussing the TRUC model of IBD, as 
previously it was thought that this disease was entirely mediated by DCs producing 
TNF (Garrett et al., 2007, Garrett et al., 2009). In comparison with Rag2-/- controls, 
IL-17A was increased in colon explant culture in TRUC mice. In agreement with 
these findings Il17a message was significantly increased in the colon of TRUC mice 
in comparison with Rag2
-/-
 controls. Although statistically significant increased 
abundance of Il17a transcripts were detected in the colon of TRUC mice in 
comparison with Rag2
-/-
 controls, it is noteworthy that Il17a mRNA levels were 
undetectable or at very low levels at the limit of detection in some TRUC mice. 
These data highlight the some of the limitations in using real time PCR on small 
(approximately 0.5cm) colon segments where RNA extracted from whole tissue, 
including epithelial cells and stromal cells are processed in the absence of exogenous 
stimulation. An alternative approach, to increase the probability of detecting 
appreciable changes in cytokine abundance, might be to purify cLPLs and stimulate 
them with powerful stimuli, such as with PMA and ionomycin prior to performing 
real time PCR experiments. Using greater cell numbers (e.g. using the entire cLPL 
population isolated) might also improve the sensitivity of quantitative PCR assays. 
For the first time the importance of IL-17A in chronic TRUC disease has been 
demonstrated. In vivo neutralization of IL-17A with a specific mAb was therapeutic 
in TRUC disease. It markedly reduced colitis histology scores and attenuated colonic 
infiltration with Gr-1
high
 granulocytes. These novel data show that IL-17A is 
functionally important in TRUC disease. Unlike other ILC-mediated models of 
colitis, which required simultaneous neutralization of IL-17A and IFN for optimal 
suppression of colitis (Buonocore et al., 2010), disease in TRUC mice could be 
abrogated by monotherapy with anti-IL-17A alone. Indeed, in TRUC mice IFN 
production was limitedconsistent with the T-bet deficient status of TRUC mice, 
since T-bet has been shown to be a key transactivator of the IFN transcription (at 
least in T-cells) (Szabo et al., 2000). These data support the notion that excess IL-
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17A production is pathogenic in the gut under appropriate conditions. These data are 
also consistent with host genetic factors playing a central role in host cytokine 
responses. Interestingly, despite the large number of genetic loci (163 genes) now 
associated with IBD (Jostins et al., 2012), variation at the TBX21 locus has yet to be 
associated with this disease state. However, it has recently been shown that 
polymorphisms at the TBX21 locus are associated with increased risk of ankylosing 
spondylitis, an autoimmune arthropathy (Cortes et al., 2013). Interestingly, 
ankylosing spondylitis is associated with subclinical or overt IBD in many patients 
and like IBD is also linked genetic variation in IL-23/IL17 axis components, such as 
IL23R, IL12B, TYK2 and IL6R (Cortes et al., 2013).     







 RORγt+ IL-7R+ cells which share phenotypic markers with ILC3 cells. 
Notably, there was also, albeit smaller, population of IL-17A producing cells in the 
CD90
-
 population of cells in TRUC mice, most prominently seen in the mLN. 
Although the identity of these cells was not pursued in this thesis possible cellular 
sources include neutrophils (Ferretti et al., 2003)  and NK cells (Hughes et al., 2009).   
ILCs were functionally important in TRUC disease, since depletion with anti-CD90 
monoclonal antibodies cells cured colitis. However, it should be noted that other 
non-ILC cell populations have also been shown to express CD90, including neurones 
(Feng et al., 2000), mesenchymal stem cells (Jones et al., 2002), and some other 
stromal cells (Owens et al., 2013). In many of the experiments performed at the 
beginning of this period of research there were some difficulties isolating cLPLs. A 
major problem encountered was a low yield of viable cells, which was particularly 
challenging in long experiments, which required cell stimulation following cell 
isolation. Defining some cell surface markers, such as CCR6, was technically 
difficult in stimulated cells, particularly cLPLs. Unlike the situation in T and B cell 
replete mice isolating immune cells from the colon of lymphopaenic mice is more 
challenging. For this reason many experiments were performed on mLN or spleen, 
since cells from these tissues can be readily isolated and analysed. Consequently, 
some of the data presented in this thesis should be interpreted bearing in mind which 
tissue is being presented in particular experiments/figures. This is a potentially 
important issue since it was observed that ILC populations appeared to differ in 
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different tissue compartments. For example, in the mLN some ILCs expressed CD4, 
whereas CD4 expressing ILCs were seldom seen in the colon, the primary site of 
disease in TRUC mice. Likewise, simultaneous staining for CD90 in the colon and 
mLN from the same donor mouse often showed CD90 expression to be seemingly 
higher in the colon in comparison with the mLN (Figure 10 and Figure 11). The role 
of the cell surface marker CD90 in ILCs is unknown and differential expression of 
CD90 in these different tissue compartments may reflect heterogeneity in ILCs from 
different tissues. Alternatively, the difference in CD90 expression in ILCs from the 
colon and mLN may reflect differences in the activation status of these cells. Indeed, 
CD90 modulates activation of other lymphoid lineages, such as CD4
+
 T-cells (Bellio 
et al., 1991), and therefore, may also supply co-stimulatory/inhibitory signals to ILCs. 
Accordingly, it is possible that CD90 expression is differentially regulated at different tissue 
locations or disease states. 
Although differential CD4 staining of ILCs in distinct tissue compartments in TRUC 
mice indicates that colonic ILCs and mLN ILCs are not interchangeable, the 
subsequent depletion studies performed in this study provide some useful 




 ILCs in TRUC mice were only seen in the mLNs and not in colon 









 ILCs, depletion of CD4 expressing cells did not significantly impact 
disease outcome. Therefore, unlike the CD4
+
 ILCs, which are responsible for IL-22 
dependent resistance to Citrobacter rodentium infection (Sonnenberg et al., 2011), 
CD4
+
 ILCs do not play a significant role in colitis development in TRUC mice. 
Indeed, even after depletion of CD4+ cells it could be seen that there was still 




 ILCs can compensate for 
the absence of CD4
+
 ILCs and cause disease.   
A number of experimental/technical lessons were also learned during some of these 
early experiments, which may have some bearing on the results reported and may 
also inform refinement and improvement of future experiments. For instance, in 
some flow cytometry experiments the percentage of particular cell types was 
reported rather than absolute cell numbers. Although this approach may be useful in 
most settings a potential disadvantage of this approach is that relative changes in cell 
proportions may occur due to expansion or loss of an “unrecorded” or “unmeasured” 
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population of cells. In contrast, measuring absolute numbers of cells in particular 
tissues offers the advantage of being able to directly compare cell numbers across 
different animals and different experimental conditions. For instance, in depletion 
studies it may be more informative to detail the total number of cytokine producing 
cells in a particular tissue rather than the relative amount between different cells. The 
major reason for reporting relative proportions in this thesis was that whole colons 
were seldom used for flow cytometry experiments alone and instead additional 
pieces of colon were used to set up organ culture, RNA extraction, histology, etc. 
However, recognition of the merit of recording absolute cell numbers was realised 
and implemented in many of the later experiments.  
Another potential problem was the use of the same clone of mAb for staining in flow 
cytometry experiments as the antibody clone employed to deplete cells in vivo. For 
example, the same clone of mAb used to deplete CD90 in vivo was also then used to 
detect the presence of CD90 expressing cells in subsequent flow cytometry 
experiments (in this case clone 30H12). It is possible that the staining mAb would be 
unable to recognise CD90 expressing cells since the epitope bound by the staining 
mAb would already be occupied by the depleting mAb which had previously been 
administered in vivo. However, since mAb binding to its specific Ag is a dynamic 
process the addition of the staining mAb in vast excess during the surface staining 
procedure would likely negate this potential issue. In any case, the number of IL-17
+
 
cells was markedly diminished after in vivo depletion, and since CD90
+
 cells were 
the most prominent source of IL-17A in TRUC mice, these data provide indirect 
support for the assertion that this antibody depleted CD90 expressing cells in vivo. In 
future depleting experiments it may prove useful to use different antibody clones (or 
alternative markers, e.g. Sca-1 or IL-7R, see Figure 11) for surface staining to the 
ones used to deplete cells in vivo. Such an approach might improve confidence that 
lack of detection of a particular cell is really due to its loss/depletion rather than an 
inability to detect it experimentally for technical reasons.         
In conclusion, data presented in this chapter demonstrate that disease in TRUC mice 
is dependent on IL-17A producing CD90
+
 ILCs. These important data build on 
mounting evidence implicating overly exuberant immune activation as an important 
event in the development of chronic intestinal inflammation. Importantly, cytokine 
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producing ILCs have been identified in the gut of patients with Crohn’s disease 
(Geremia et al., 2011) as well as in other preclinical models of IBD (Buonocore et 
al., 2010). Accordingly, ILCs should be added to the list of potentially important 
effector cells that may play an important role in the pathogenesis of IBD. 
Interestingly, ILCs such as those identified in TRUC mice in this thesis, as well as 
those reported by other groups, are linked to a variety of molecules in which genetic 
variation is associated with IBD. These include RORC, IL-23R, IL-12B, CCR6 and 
IL7R (Jostins et al., 2012). This raises the possibility that polymorphisms at these 
IBD associated loci may impact on the phenotype of ILCs in a functionally important 
way. This would raise the intriguing possibility that polymorphisms at genetic loci 
that impact on ILC phenotype have a critical bearing on IBD susceptibility. This 
would lead to a major paradigm shift in current thinking since it has always been 
assumed that increased disease susceptibility conferred by these IBD associated 
polymorphisms likely to result from their impact on the phenotype of mucosal T-
cells rather than innate immune cells. Given the similarity of ILCs to T-cells in terms 
of cellular morphology, shared phenotypic markers, shared master transcriptional 
regulators and common cytokine secreting profiles it is of course possible that 
polymorphisms at genetic loci encoding proteins shared by T-cells and ILCs 
contribute to IBD risk. The relative contributions of ILCs and T-cells as effector cells 
in human IBD remains to be established. Although ILCs are numerically inferior to 
T-cells in the gut of IBD patients (Geremia et al., 2011) it is likely that activation of 
these cells is triggered by different stimuli. T-cells are primarily activated through 
their recombined antigen-specific T-cell receptor, with or without co-stimulation. By 
definition ILCs lack antigen-specific receptors and instead are likely to be stimulated 
by cytokines or other innate signals in the local environment. In view of the 
likelihood that the effector function of ILCs and T-cells are activated by distinct 
triggers implies that either the dynamics or environmental conditions which result in 
activation of these different cell types is likely to be different. It is tempting to 
speculate that ILCs are present at the mucosal barrier surfaces as rapid responders to 
changes in the local tissue cytokine milieu to enable immediate mobilisation of a 
potent effector response, irrespective of the offending pathogen. On the other hand 
T-cells are present to provide response specificity to previously encountered 
pathogenic organisms and build up immunological memory of commonly 
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encountered pathogens. Indeed, IL-22 producing ILCs are crucial in early resistance 
to Citrobacter rodentium infection (Sonnenberg et al., 2011), whereas enduring 
immunity is conferred by IL-22 producing CD4
+
 T-cells (Basu et al., 2012). 
Therefore, mucosal ILCs and T-cells might contribute distinct but complimentary 
arms of the immune responses which operate in a co-ordinated manner to improve 
the effectiveness of host immunity. Unfortunately, it is possible that this system 
might become perturbed/dysregulated and result in chronic, immune mediated 
disease, such as IBD, particularly in individuals with genetic variation in molecules 
which impact on ILC and T-cell phenotype. In the next chapter of this thesis some of 





Results: Defining the proximal molecular signals 
responsible for driving activation of ILCs in TRUC mice 





ILCs in the colon of TRUC mice as functionally important drivers of 
chronic TRUC disease. To further understand the immune mechanisms responsible 
for driving innate immune mediated pathology in TRUC mice, it is also desirable to 
understand and define the proximal molecular signals responsible for driving 
activation of these cells in vivo. ILCs have only recently been identified as important 
mediators of intestinal inflammation and consequently there are relatively few data 
regarding the molecular basis for their activation. 
In this chapter the proximal cytokine signals potentially responsible for driving ILC 
effector function in TRUC mice was investigated, focussing on cytokines that 
stimulate other ILC populations, such as IL-23, as well as cytokines which are 
thought to play an important role driving IL-17 responses in disease settings. 
. IL-23 has been shown to play an important role in the innate immune mediated 
colitis model occurring when 129 SvEv Rag1
-/-
 mice are inoculated with 
Helicobacter hepaticus (Hue et al., 2006) and has been shown to stimulate innate IL-
17A production in other models of colitis (Buonocore et al., 2010). In addition to IL-
23, a number of other molecules may be important for the differentiation and/or 
maintenance of Th17 cells, including IL-1β (Shaw et al., 2012), IL-6 (Hu et al., 
2011) and TL1A (Pappu et al., 2008). Recently, it has already been shown that IL-1β 
triggers activation of intestinal ILCs (Coccia et al., 2012). IL-6 is a pleiotropic 
cytokine that may be important in IBD. Peripheral blood and colonic lamina propria 
leukocytes produce excess IL-6 in IBD (Reinecker et al., 1993; Suzuki et al., 1990), 
often at levels correlating with disease activity (Hyams et al., 1993). A 
polymorphism at the IL6 locus is linked with early-onset CD (Sagiv-Friedgut et al.) 
and polymorphisms at loci encoding IL-6 receptor (IL-6R) signalling components, 
such as STAT3, JAK2 and TYK2 are associated with increased IBD risk (Jostins et al., 
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2012). IL-6 plays a functionally important role in animal models of IBD, although 
the assumption has been made that the therapeutic mechanism of IL-6 blockade was 
attributable to limitation of T-cell mediated pathology (Atreya et al., 2000; Kitamura 
et al., 2004; Mitsuyama et al., 2006; Naito et al., 2004), since IL-6 contributes to 
intestinal Th17 differentiation (Hu et al., 2011). The role of IL-6 in innate immune 
mediated chronic intestinal pathology is unknown. In view of the perceived role of 
IL-6 in driving adaptive IL-17 production, the hypothesis that IL-6 would be a 
functionally important driver of innate IL-17 production in the gut in TRUC mice 
was tested.  
Finally, there has been considerable interest in TL1A, a member of the tumour 
necrosis factor super family (also called TNFSF15) in IBD. SNPs at the locus 
encoding this protein confer an increased risk of IBD (Jostins et al., 2012). TL1A 
expression is increased in inflamed gut in IBD patients (Bamias et al., 2003), and has 
been shown to play an important functional role in animal models of intestinal 
inflammation (Meylan et al., 2011). Crucially, TL1A promotes CD4
+
 T-cell effector 
function (Bamias et al., 2003), including Th17 responses (Pappu et al., 2008). The 
hypothesis that the cytokines IL-23, IL-6 and TL1A might also be important for 











4.1 IL-23 stimulated innate IL-17A production in TRUC disease 
To determine whether IL-23 induced IL-17 production by cells from TRUC mice, 
unfractionated cells from different tissues from TRUC mice were cultured in the 
presence or absence of recombinant IL-23 for 24 hours. The production of IL-17A by 
innate immune cells in these tissue compartments was then measured by ELISA. 
There was significant IL-17A protein induced by recombinant IL-23 in all tissues 
examined, including unfractionated colonic LPLs, mLN cells and splenocytes from 
TRUC mice (Figure 22). Notably, IL-17A production was most pronounced in the 
colon and draining lymph nodes compared to the spleen of TRUC mice. 
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Figure 22.IL-23 stimulated innate IL-17A production in TRUC mice.  Unfractionated cells from 
the cLP (1x 10
5
/mL, n=4 individual mice/biological replicates for each experimental 
condition), mLN (1x 10
5
/mL) (6 individual mice) or spleen (2x10
6
/mL) (5 individual 
mice) were cultured in the presence of IL-23 (20ng/mL) or medium alone for 24 hours. 
IL-17A concentration was measured in culture supernatants by ELISA. Bars denote mean 
and error bars denote SEM of IL-17A production in culture supernatants of biological 
replicates. These data are a composite of 2 different experiments using identical 
experimental conditions. Adapted from Powell et al., 2012. 
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4.2 IL-23 stimulated CD90+ NKp46- ILCs to produce IL-17A 
In the previous chapter it was demonstrated that ILCs were the major source of IL-
17A in TRUC mice, at least when cells were stimulated with PMA and ionomycin. 
Therefore, to determine whether IL-23 was responsible for triggering cytokine 
production by CD90
+
 ILCs in TRUC mice, cells were stimulated with IL-23 
followed by intracellular IL-17A staining. PMA and ionomycin stimulation was used 
as a positive control. Unstimulated cells treated with monensin alone were used as a 
negative control. 
In these experiments unfractionated mLN cells were harvested from TRUC mice, 
since this tissue compartment is readily accessible and was a rich source of IL-17A 
producing ILCs in TRUC mice. Unfractionated mLN cells were cultured with 
medium alone (unstimulated), IL-23 (20ng/mL) or with PMA and ionomycin for 4 
hours (last 2 hours with monensin added). Cells were then fixed (2% 
paraformaldehyde), stained with appropriate cytokine specific antibodies and then 
flow cytometry performed. As expected PMA and ionomycin stimulated marked 




 ILCs from the 
mLN of TRUC mice (Figure 23). However, IL-23 also induced IL-17A and to a 
lesser extent IL-22 by ILCs from TRUC mice. IL-23 had little effect on IFNγ 





Figure 23. IL-23 stimulated IL-17A production by ILCs in TRUC mice – analysis by flow 
cytometry.  Representative flow cytometry plots showing the proportion of cytokine 




 cells) from mLN from TRUC mice 
following stimulation with IL-23 (20ng/mL), PMA and ionomycin (P&I, positive 
control) or unstimulated (Monensin only). Cells were stimulated for 4 hours (last 2 hours 
monensin was added). In the unstimulated condition monensin was added for the final 2 
hours (+M). In this experiment mLN were pooled from 4 individual TRUC mice and 
plated out at 1x10
6
 cells prior to stimulation. These data are representative of >3 
individual experiments.  
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4.3 IL-23 mRNA expression in the colon of TRUC mice 
In view of the ability of IL-23 to stimulate innate IL-17A production, the expression 
of transcripts encoding the different subunits of IL-23 was determined in TRUC and 
Rag2
-/-
 mice. IL-23 is a heterodimer comprised of IL-12p40 (a subunit which it 
shares with IL-12) and the unique subunit IL-23p19, encoded by the Il12a and Il23 
genes respectively. 
Accordingly, the abundance of Il12a and Il23 transcripts was quantified in the colon 
of TRUC and Rag2
-/-
 mice by qPCR. Both transcripts were present in the distal colon 
of TRUC and Rag2
-/-
 mice (Figure 24). However, as well as being at low abundance, 
there was no statistically significant difference in the abundance of these transcripts 
between TRUC and Rag2
-/-
 mice (Figure 24). 
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Figure 24. Transcripts encoding the IL-23 subunits Il12a (IL-12p40) and Il23 (IL-23p19) were 
present in the colon of TRUC mice.  qPCR analysis of transcripts encoding Il12a and 
Il23 in distal colon of TRUC (n=10) and Rag2
-/- 
 
(n=6) mice. Each dot represents an 




4.4 IL23p19 blockade attenuated colitis in TRUC mice 
To determine the functional importance of IL-23 in TRUC disease, in vivo blocking 
experiments were performed with a neutralising antibody that only recognises the IL-
23 specific subunit p19, and therefore blocks IL-23, but not IL-12. This mAb has 
been shown to neutralize IL-23 activity in vivo (Hagemann et al., 2008).  
Anti-IL23p19 (n=4) or control isotype (n=7) antibodies were administered (i.p.) to 
TRUC mice aged 12 weeks old according to the protocol illustrated in Figure 25. 
Most notably, administration of anti-IL-23p19 significantly reduced chronic colitis in 
TRUC mice. The histological appearances of the distal colon of TRUC mice 
demonstrated marked reduction in colitis (Figure 26A) and significantly reduced 
histology scores in comparison with control antibody treated mice (P<0.01, Figure 
26B). Anti-IL-23p19 treatment also significantly reduced colon weight in TRUC 
mice (P<0.05, Figure 26C). However, anti-IL-23p19 treatment had no impact on the 
splenomegaly in TRUC mice (Figure 26D). Together, these data indicate that 
neutralisation of IL-23 attenuates colonic disease in TRUC mice and demonstrate 




Figure 25. Experimental protocol followed to evaluate the functional role of IL23 in chronic 
TRUC disease.  150µg of anti-IL23p19 (clone G23.8) mAb (n=4) or control isotype 
antibody (n=7) was administered i.p. to 12 week old TRUC mice. Organs were harvested 
on day 19 of the experiment. Dosing regimen of anti-IL23p19 treatment was empirically 
based on the affordability of this expensive reagent. There are no data available regarding 
the use of this commercially available mAb in innate models of colitis. However, a 
neutralizing anti-IL23p19 mAb has previously been used in vivo in a mouse model of 
arthritis at 100µg every 6-7 days. In that experiment this dosage of mAb was calculated 
based on data from a functional assay (Cornelissen et al., 2013). Similarly, 100µg of 
G23.8 administered twice weekly has been shown to be biologically active (Hagemann et 
al., 2008).      
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Figure 26. IL-23p19 blockade significantly reduced colitis in TRUC mice.  A Representative 
H&E staining of distal colon specimens from TRUC mice treated with anti-IL23p19 
(n=4) or control antibody (n=7). Magnification is the same in both panels (approximately 
x40). B Colitis histology scores, C colon mass and D spleen mass, following treatment 
with anti-IL23p19 (n=4) or control antibody (n=7). In Figure B the bars represent mean 
colitis score and error bars denote SEM. In Figures C and D each dot represents an 








4.5 IL23p19 blockade reduced innate IL-17A production in TRUC 
mice 
Since IL-23 stimulated innate IL-17A production in TRUC mice and plays a 
functionally important role in TRUC disease, it would be expected that IL-23 
blockade would reduce colonic expression of IL-17A. IL-17A production in explant 
colon cultures was measured in TRUC mice treated with anti-IL-23p19 or control 
mAb. Importantly, in vivo IL-23 blockade significantly reduced spontaneous IL-17A 
production in explant organ culture (P<0.035, Figure 27A). 
Using qPCR, mRNA encoding IL-17A was also quantified in the colon of TRUC 
mice following treatment with anti-IL-23p19 or control mAb. Following treatment, a 
0.5cm segment of distal colon was immediately snap frozen in Trizol reagent, 
pending RNA extraction, cDNA synthesis and qPCR using IL-17A specific PCR 
primers. qPCR demonstrated that Il17a mRNA was reduced in the colon of anti-
IL23p19 treated mice in comparison to control mAb treated mice, although this did 
not achieve statistical significance (P<0.153, Figure 27B). 
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Figure 27. IL-23p19 blockade reduced colonic IL-17A expression in TRUC mice.  A Explant 
organ culture from TRUC mice treated with anti-IL23p19 (n=4) or control antibody 
(n=7). Each dot represents an individual mouse. Line depicts median . B From the same 
mice transcripts encoding Il17a in the distal colon were quantified by qPCR. Bars 
represent mean relative abundance of Il17a mRNA and error bars denote SEM. Blockade 
experiments were performed in a single experiment and not repeated.  Adapted from 


















In view of the prominent IL-17 response observed in TRUC colitis, and the 
perceived role of IL-6 in driving IL-17A responses (at least in the adaptive immune 
system), the role of IL-6 in innate IL-17A responses in the gut of TRUC disease was 
examined. The concentration of IL-6 in the serum of TRUC mice and age matched 
control Rag2
-/-
 mice was measured by ELISA. Serum levels of IL-6 were 
significantly increased in TRUC mice in comparison with Rag2
-/-
 controls 
(P<0.0025, Figure 28A). Notably, IL-6 was undetectable in the serum of Rag2
-/-
 mice 
without intestinal inflammation. In contrast, IL-6 was detectable and significantly 
elevated in all TRUC mice. 
The concentration of IL-6 in culture supernatants following culture of colon explants 
was measured by ELISA. In contrast to the serum, IL-6 was detectable in organ 
culture from TRUC and Rag2
-/-
 mice. However, IL-6 levels were significantly 
increased in explant cultures from TRUC mice in comparison with Rag2
-/-
 controls 




Figure 28. Increased IL-6 in TRUC disease.  A The concentration of IL-6 in the serum of 12 week 
old TRUC (n=6) and Rag2
-/- 
(n=5) mice, measured by ELISA. B Concentration of IL-6 in 
culture supernatants of colon explants from TRUC (n=9) and Rag2
-/- 
(n=4) control mice. 
Each dot represents an individual mouse. Lines depicts median  
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4.7 ILCs from TRUC mice expressed the IL-6R 
IL-6R expression by ILCs from TRUC mice was investigated by flow cytometry. 







). By gating on the ILC population, the relative staining of IL-6R on 
ILCs was determined. In contrast to the lack of specific staining with the control 
isotype antibody, there was marked positive staining using the specific anti-IL-6R 
antibody (Figure 29A). 
IL-6R expression was also analysed in ILCs from the colon of TRUC mice. IL-6R 







). As in the spleen, there was a lack of specific staining with the 
control isotype antibody, but marked positive staining using the specific anti-IL-6R 
antibody (Figure 29B). 
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Figure 29. Splenic and colonic ILCs from TRUC mice expressed IL-6R.  IL-6R (red line) or 
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4.8 IL-6 stimulated innate IL-17A production in TRUC mice 
Since IL-6 it thought to play an important role in shaping adaptive IL-17 responses, 
the role of IL-6 in innate IL-17A responses in TRUC mice was investigated. In the 
previous Chapter it was demonstrated that unfractionated mLN cells are a 
particularly rich source of innate IL-17A production in TRUC mice (Figure 7). 
Therefore, unfractionated mLN cells from TRUC mice were cultured in the presence 
of IL-6 (50ng/mL) or with medium alone. As a positive control cells were also 
stimulated with IL-23 (20ng/mL). As observed previously, IL-23 potently induced 
innate IL-17A production. However, IL-6 also induced significant production of IL-6 
protein (P<0.05, Figure 30A). 
Since ILCs are the major source of IL-17A in TRUC mice, the role of IL-6 in 
triggering IL-17A production by this cells population was investigated by flow 
cytometry. Unfractionated mLN cells were stimulated with IL-6 (50ng/mL) for 4 
hours or with medium alone. As a positive control, cells were also stimulated with 
IL-23 (20ng/mL). Cells were stimulated for a total of 4 hours (the last 2 of which 
monensin was added). Following stimulation, cells were harvested and ILCs were 




 cells (Figure 30B). Crucially, in 
comparison with cells cultured with medium alone, IL-6 induced marked IL-17A 




 ILCs (Figure 31C). As anticipated IL-23, the 
positive control, also induced IL-17A production in ILCs (Figure 30C). Taken 
together these data indicate that IL-6, which is increased in TRUC disease, stimulates 
innate IL-17A production. Furthermore, ILCs which are the major source of IL-17A 
in TRUC mice express the IL-6R and can be stimulated to produce IL-17A by IL-6. 
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Figure 30. IL-6 induced innate IL-17A expression in TRUC mice.  A 1 x 10
5
 unfractionated  
mLN cells from TRUC mice were stimulated with IL-23 (n=3, 20ng/mL) or IL-6 (n=3, 
50ng/mL) or incubated with medium alone (n=5), denoted as (-) for 24 hours. Bars 
represent mean IL-17A concentration in culture supernatants. Error bars denote SEM. B 
Gating strategy for identifying ILCs in the mLN of TRUC mice. C Intracellular IL-17A 
production in ILCs following stimulation with IL-23 (20ng/mL) or IL-6 (50ng/mL) or 
incubated with monensin alone (+M). Cells were stimulated for 4 hours. Monensin was 
added to stimulated cells for the final 2 hours for each condition, including unstimulated 



















+M IL-6 +M IL-23 +M 
150 
4.9 Inhibition of STAT3 phosphorylation attenuated innate IL-17A 
production 
In T-cells, ligation of the IL-6 receptor triggers STAT3 phosphorylation (Stahl et al., 
1994). However, it is unknown whether STAT3 signalling is important in ILC 
biology. The possibility that IL-6 induced STAT3 phosphorylation might be relevant 
in TRUC IBD was explored. STAT3 phosphorylation can be specifically inhibited 
both in vitro and in vivo by the soluble small molecule inhibitor S3I-201 (Zhang et 
al., 2011). Therefore, a series of experiments was conducted with S3I-201 to 
determine whether innate IL-17A production in TRUC mice was dependent on 
STAT3 activation. 
Colon explants from TRUC mice were set up in culture in the presence or absence of 
S3I-201. In contrast to explants incubated with DMSO alone, which produced high 
levels of IL-17A there was a dose-dependent reduction in IL-17A concentration in 
culture supernatants when explants were cultured in the presence of S3I-201 (Figure 
31A). At a S3I-201 concentration of 20µg/mL there was approximately 50% 
inhibition of innate IL-17 production (P<0.05). At a S3I-201 concentration of 
100µg/mL there was approximately 65% inhibition of innate IL-17 production 
(P<0.01). 
The role of STAT3 activation in IL-6 induced IL-17A production was also examined. 
As previously observed IL-6 induced IL-17A production by unfractionated 
splenocytes (2x10
6 
cells/mL) from TRUC mice (Figure 31B). However, IL-6 induced 
IL-17A production was significantly attenuated in the presence of S3I-201 (P<0.005, 
Figure 31B). Taken together these data indicate that innate IL-17A production is at 
least partly dependent on STAT3 phosphorylation and that inhibition of STAT3 
activation reduces IL-6 induced IL-17A production. 
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Figure 31. Innate IL-17A production was attenuated by inhibition of STAT3 phosphorylation.  
A IL-17A concentration in culture supernatants following culture of colon explants from 
TRUC mice (n=8) Explants were incubated in the presence of medium with DMSO 
(0.1%) or with different concentrations of an inhibitor of STAT3 phosphorylation (S3I-
201) at a final concentration of DMSO 0.1%. *P<0.05, **P<0.01 B Unfractionated 
splenocytes (2x10
6
/mL) from TRUC mice (n=8) were stimulated with IL-6 in the 
presence or absence of S3I-201. Bars denote mean cytokine concentration and error bars 
denote SEM.  
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4.10 IL-6 blockade attenuated TRUC disease  
IL-6 has been shown to be functionally important in adaptive immune mediated 
models of IBD, including IBD manifesting in Il10
-/-
 (Atreya et al., 2000) or 
SAMP/Yit mice (Mitsuyama et al., 2006). Blockade of IL-6 signalling reduces the 
severity of colitis induced by adoptively transferred naive CD4
+
 T-cells (Kitamura et 
al., 2004) or TNBS administration (Atreya et al., 2000). Similarly, IL-6 null mice 
have less severe colitis and fewer inflammatory cells infiltrating colonic lamina 
propria following DSS administration (Naito et al., 2004). However, in these 
experiments with adaptive immune mediated models of IBD, the functional 
importance of IL-6 was typically attributed to its role in driving T-cell responses. 
The functional importance of IL-6 in innate immune mediated models of colitis is 
unknown. To determine whether excess IL-6 observed in TRUC mice was 
functionally important in TRUC disease experiments were conducted in which IL-6 
was neutralized in vivo with a blocking monoclonal antibody. 
Anti-mouse IL-6 (clone: MP5-20F3, Bio X Cell) or control isotype rat IgG1 (clone: 
HRPN, Bio X Cell) antibodies were administered (750µg) via intraperitoneal 
injection to age matched, 12 week old TRUC mice on days 0, 4, 9, 14, 18, 23 and 27. 
This clone has previously been shown to neutralize the biological activity of IL-6 in 
vivo (Starnes et al., 1990). Anti-IL-6 was administered to 8 mice and control mAb to 
9 mice. Mice were culled on day 29 and organs harvested. One animal (in the control 
antibody treated group) was withdrawn from the study and humanely culled due to 
progressive weight loss and severe rectal prolapse. 
In comparison with control antibody treatment, administration of anti-IL-6 mAb 
resulted in significant loss of IL-6 bioavailability in the serum of TRUC mice 
(P<0.0002, Figure 32A). Similarly, IL-6 production was significantly reduced in 
explant organ culture of anti-IL-6 treated mice (P<0.015, Figure 32B). 
Crucially, in vivo neutralization of IL-6 significantly attenuated disease in TRUC 
mice. Anti-IL-6 treated mice had significantly reduced colitis histology scores in the 
distal colon (P<0.037, Figure 33A), the site of maximal disease. However, there was 
no significant difference between histology scores in the proximal colon of anti-IL-6 
and control mAb treated mice (Figure 33B). Anti-IL-6 treatment also resulted in a 
153 
significant reduction in splenomegaly in TRUC mice (P<0.007, Figure 33C). There 
was a tendency for colonic weight to be reduced in anti-IL-6 treated TRUC mice in 
comparison with control antibody treated animals, however, this was not statistically 
significant (Figure 33D). There was no significant change in weight gain/loss 
between anti-IL-6 or control mAb treated mice (Figure 33E). 
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Figure 32. Anti-IL-6 reduced the bioavailability of IL-6 in TRUC mice.  A Concentration of IL-6 
in the serum of TRUC mice following treatment with an anti-IL-6 mAb (n=8) or control 
(isotype) antibody (n=8). B Concentration of IL-6 in the explant organ culture of TRUC 
mice following treatment with an anti-IL-6 mAb (n=8) or control (isotype) antibody 
(n=8). IL-6 was measured by ELISA. In both graphs lines show median IL-6 
concentration.    
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Figure 33. Anti-IL-6 attenuated TRUC disease.  A Distal and B proximal colitis histology scores, 
C spleen mass, D colon mass and E changes in body mass in TRUC mice following 
treatment with an anti-IL-6 mAb (n=8) or control (isotype) antibody (n=8). In Figure E 
dots (or squares) represent mean % change in body weight in the treatment groups 
specified. In Figures A-D each dot represents an individual mouse. Lines depicts median 
of the variable defined by the y-axis. Note: this was one of last experiments performed 
during the laboratory phase of this thesis. The acquisition of both distal and proximal 
colon segments for histological assessment was used as an experimental readout for the 
first time. Accordingly, this experimental readout was not available in other in vivo 
blockade/depletion studies.  
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4.11 IL-6 blockade reduced innate IL-17A production in TRUC mice 
Since IL-6 was observed to stimulate IL-17A production by ILCs from TRUC mice 
the hypothesis that IL-6 blockade would reduce innate IL-17A production in TRUC 
mice was tested. In these experiments, spontaneous production of IL-17A was 
measured in cells isolated from different organs of TRUC mice following in vivo 
treatment with anti-IL-6 or control isotype antibody. 
IL-17A concentration was measured in the serum of TRUC mice treated with anti-
IL-6 or control antibody but were undetectable in either group (data not shown). 
Spontaneous IL-17A production was also measured in culture supernatants of 
splenocytes harvested from TRUC mice treated with anti-IL-6 or control antibody. 
Splenocytes were cultured at 2 x10
6
 cells/mL for 24 hours. Anti-IL-6 treated mice 
had a significant reduction in spontaneous IL-17 production by splenocytes (P<0.01, 
Figure 34A). Spontaneous production of IL-17A in colon explant culture was also 
investigated in anti-IL-6 and control antibody treated TRUC mice. The median 
concentration of IL-17A in explant culture supernatants from anti-IL-6 treated mice 
was significantly lower than in control antibody treated mice, (P<0.022, Figure 34B). 
Similarly, there was a tendency for reduced spontaneous production of IL-17A by 
unfractionated mLN cells in anti-IL-6 treated mice in comparison with control 
antibody treated TRUC mice, although this also did not reach statistical significance 
(P<0.083, Figure 34C). These data support the likelihood that IL-6 is a 
physiologically important stimulator of innate IL-17A production. 
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Figure  34. Anti-IL-6 treatment reduced spontaneous IL-17A production in TRUC mice.  IL-
17A production (measured by ELISA) by A cultured unfractionated splenocytes (2x10
6
 
cells/mL), B Colon explant culture and C unfractionated mLN cells (1x10
5
 cells/mL) of 
TRUC mice following treatment with an anti-IL-6 mAb or control (isotype) antibody. 
This data are from the experiment described in 4.11. Each dot represents an individual 
mouse. Line depicts median of variable defined by the y-axis. 
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4.12 IL-6 blockade did not reduce CD69 expression by ILCs from 
TRUC mice 
In other immune cell populations, expression of the cell surface marker CD69 is 
associated with cellular activation. Therefore, the hypothesis that IL-6 blockade 
would reduce ILC activation, as measured by CD69 expression, was tested. Although 
CD69 was highly expressed by intestinal ILCs in TRUC mice (Figure 35A), 
consistent with an increased activation status of these cells, there was no statistically 
significant difference between the MFI of CD69 expression in anti-IL-6 or control 











A Representative flow cytometry histogram showing CD69 expression (or control isotype 




) from the cLP of TRUC mice following in 
vivo treatment with anti-IL-6 or control mAb. B Median Fluorescence Index (MFI) of 
flow histograms comparing CD69 expression in ILCs. Lines depict mean and error bars 













4.13 TL1A mRNA expression was increased in the distal colon of 
TRUC mice 
The possibility that TL1A might also impact innate IL-17A responses was 
considered. The expression of mRNA encoding Tl1a in the colon of TRUC and 
control Rag2
-/-
 mice was investigated by qPCR. Colon segments were harvested into 
Trizol reagent, pending RNA extraction, cDNA synthesis and subsequent qPCR with 
Tl1a–specific primers. mRNA encoding Tl1a was significantly increased in the colon 
of TRUC mice in comparison with Rag2
-/-
 mice (P<0.033, Figure 36A). Notably, 
Tl1a mRNA expression was significantly increased in the distal colon of TRUC mice 
in comparison with the proximal colon (P<0.001, Figure 36B), which correlates with 
the most significant site of inflammation histologically in TRUC mice. 
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Figure 36. mRNA encoding Tl1a was increased in the distal colon of TRUC mice.  A Relative 




(n=3) mice measured by qPCR. ND= not detected. B  Relative abundance of 
mRNA encoding Tl1a in the distal (0.5cm segment within 0.5cm of the anal verge) and 
proximal colon (0.5cm segment within 1cm of the caecum) of TRUC mice (n=10) 
measured by qPCR. ND= not detected. In both graphs bars represent mean relative 
abundance of cytokine transcript and error bars denote SEM. These data are from a single 
experiment and no additional experiments were performed.  
TRUC vs Rag2-/- colon




4.14 ILCs and macrophages from TRUC mice express the TL1A 
receptor, DR3 
To determine which innate immune cells would be capable of responding to TL1A 
stimulation in the gut, the expression of the TL1A receptor DR3 was investigated in 






 cells), NK cells (NKp46
+





from the mLN of TRUC mice by flow cytometry. Although there was little or no 
detectable DR3 staining in DCs or NK cells, there was positive staining of ILCs and 








Figure 37. ILCs and macrophages from in the mLN of TRUC mice expressed the TL1A 
receptor DR3.  Flow cytometry histograms showing DR3 staining (red histogram) in 
comparison with isotype control antibody (black histogram), in NK cells (gated on 
NKp46
+











) in the mLN of TRUC mice. These data are representative of 4 biological replicates in 







4.15 TL1A augmented IL-23 induced IL-17A production by ILCs 
Since mLN ILCs expressed the TL1A receptor, the possibility that these cells may 
also respond to TL1A stimulation was investigated. Unfractionated mLN cells (1x10
5
 
cells/mL) were cultured in the presence/absence of recombinant murine TL1A and/or 
IL-23. TL1A induced a significant and dose-dependent increase in the concentration 
of IL-17A in these cultures (Figure 38A). Most notably, TL1A in combination with 
IL-23, was the most potent stimulus for innate IL-17A production identified (Figure 
39A). 
The role of TL1A in triggering IL-17A production by ILCs in TRUC mice was also 
examined by flow cytometry. Unfractionated mLN cells were stimulated with 
recombinant TLA1 and/or IL-23. Cells were harvested, stained with surface 
antibodies (CD90 and NKp46) and then fixed in PFA before being permeabilised and 
stained with an anti-IL-17A mAb. Unstimulated cells had little or no intracellular IL-
17A staining (Figure 38B). However, there was only minor IL-17A production 
induced by recombinant TL1A by itself (Figure 38B). In contrast, IL-23 induced 
appreciable intracellular IL-17A production, and most notably the combination of 
TL1A and IL-23 was highly effective at inducing IL-17A (Figure 38B). 
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Figure 38. TL1A augmented IL-23 induced IL-17A production by ILCs from TRUC mice.  A 
IL-17A concentration in culture supernatants of unfractionated mLN cells from TRUC 
mice (n=4) in the presence or absence of combinations of IL-23 and TL1A. Cells were 
cultured for 24 hours. IL-17A concentration in culture supernatants was measured by 
ELISA. Bars denote mean IL-17A concentration and error bars denote SEM.  *P<0.05 v 
unstimulated cells. These data are from a single experiment, which was not repeated. B 





 cells) in mLN of TRUC mice following stimulation with IL-23(20ng/mL) and/or 
TL1A (50ng/mL). Cells were stimulated for 4 hours. Monensin (+M) was added for the 
final 2 hours of the stimulation. Unstimulated cells were also cultured in the presence of 
monensin for the final 2 hours of the experiment. These data are representative 5 
biological replicates.   
TL1A (50ng/mL) - + - - +
TL1A (100ng/mL) - - + - -
IL-23 (20ng/mL) - - - + +
+M  TL1A +M 
IL-23 +M TL1A+IL-23 +M 
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4.16 TL1A blockade failed to attenuate TRUC colitis 
Since TL1A mRNA was increased in the colon of TRUC mice, and TL1A was 
observed to stimulate ILCs, the hypothesis that TL1A was functionally important in 
TRUC disease was tested. Neutralising anti-TL1A mAbs were kindly provided by 
Professor Al-Shamkani (Southampton University). 
Five hundred µg of anti-TL1A (n=7) or rat IgG2a control antibody (n=9) was 
administered i.p. to 12-14 week old TRUC mice. Antibodies were administered on 
days 0, 4, 8 and 14. Mice were culled and organs harvested on day 16. At the end of 
the experiment there was no significant difference in colitis score in the distal colon 
between mice treated with anti-TL1A or control antibody (Figure 39A). Similarly, 
there was no significant difference in colon weight of TRUC mice treated with anti-
TL1A or control isotype (Figure 39B). Since colitis in TRUC mice tends to be most 
severe in the distal colon, the weight of the distal 3cm of colon was also measured. 
However, there was also no significant difference in the mass of the distal colon 
between anti-TL1A or control isotype treated TRUC mice (Figure 39C). Likewise 
there was no significant change in weight loss (as a % of initial body mass) between 
anti-TL1A or control isotype treated TRUC mice (Figure 39D). There was also no 
significant difference in spleen weight between anti-TL1A or control isotype treated 
TRUC mice (Figure 39E). 
The proportion of different immune cell populations in the colon of TRUC mice 
following treatment with an anti-TL1A mAb or control isotype was determined by 
flow cytometry. Colonic LPLs were stained with CD45, viability stain, F4/80 
(macrophages), Gr-1 (granulocytes) and CD90 (ILCs). Although there was a 
tendency for a reduced proportion of granulocytes (median = 4.8%, IQR 1.5-10.0% 
vs. 10.4%, IQR 3.95%-14.5%, P<0.094) and ILCs (median 10.4%, IQR 9.6-14.3% 
vs. 16.9%, IQR 12.35%-20.93%, P<0.073) in the colon of anti-TL1A treated TRUC 
mice as compared to control antibody treated mice, this did not achieve statistical 
significance. Taken together these data fail to support the hypothesis that TL1A is 
functionally important in TRUC disease. 
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Figure 39. TL1A blockade failed to attenuate colitis in TRUC mice.  A Colitis histology scores, 
B colon mass, C distal 3cm colon mass, D weight loss (as a % of initial body mass) and E 
spleen mass of 12-14 week old TRUC mice following in vivo treatment with anti-TL1A 
or control isotype antibody. This experiment was conducted on one occasion and was not 
repeated. In Figures B, C, E each dot represents an individual mouse. Lines depicts 
median of the variable defined in the y-axis. In Figure A bars represent median colitis 
score and error bars denote SEM. In Figure D dots denote median body weight (as a % of 
initial body weight) in control mAb (isotype) or anti-TL1A treated mice. Error bars 




In this chapter some of the proximal cytokine signals responsible for driving ILC 
activation and chronic colitis have been established. It is shown that IL-23, IL-6 and 
TL1A triggered IL-17A production by ILCs from TRUC mice.  
There is growing evidence implicating IL-23 as an important cytokine in IBD. It has 
previously been shown that IL-23 is important in driving innate immune mediated 
colitis caused by  Helicobacter hepaticus infection in Rag1
-/- 
mice (Buonocore et al., 
2010), therefore  the data presented in this thesis support this notion, since IL-23 was 
also capable of triggering IL-17A production by ILCs in TRUC disease. In this study 
specific antagonism of IL-23 (rather than IL-12) was therapeutic, which further 
supports other observations indicating that IL-23 seems to play an important role in 
colonic rather than systemic inflammation. Indeed, the Powrie group performed an 
elegant series of experiments to differentiate the relative contribution of IL-12 and 
IL-23 in gut and systemic inflammation caused by administration of agonistic anti-
CD40 mAbs (Uhlig et al., 2006). In these experiments Rag1
-/-
 mice were crossed 
with Il12p40
-/-
 mice (lacking both IL-12 and IL-23, since the IL-12p40 subunit is 
shared between these cytokines), Il12p35
-/-
 mice (lacking IL-12 but not IL-23, since 
the IL-12p35 subunit is only a component of IL-12) and Il23p19
-/-
 mice (this 




 double knockout 





 double knockout mice were resistant to systemic disease, 
but remained sensitive to colitis induction. Consistent with these observations Rag1
-/- 
mice lacking the IL-12p40 subunit common to both IL-12 and IL-23 were resistant to 
both colonic and systemic disease. The effectiveness of IL-23 blockade in preventing 
colonic disease in TRUC mice is consistent with these reports and persuasively 
supports the employment of strategies targeting IL-23 in IBD patients. To date only 
anti-IL-12p40 therapies have been evaluated in CD (Mannon et al., 2004). The 
potential advantage of blocking IL-23 alone (rather than dual blockade of IL-23 and 
IL-12 which occurs with anti-IL-12p40 therapy) is that only colonic inflammation is 
likely to be targeted and systemic immunity, which might be required for resistance 
to systemic infections, is left unhindered. Biological therapies targeting IL-23p19 
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have yet to be reported in IBD, but are due to be published in the near future in 
clinical trials of patients with other immune mediated diseases, such as psoriasis 
(unpublished communications with MERCK). 
For the first time it was also shown that IL-17A production by ILCs is also triggered 
by IL-6.  ILCs expressed the IL-6R receptors, thus enabling them to respond to 
excess IL-6 in TRUC disease. The functional importance of IL-6 in TRUC disease 
was demonstrated by neutralizing this cytokine in vivo. Biological neutralization of 
IL-6 reduced innate IL-17A production in the colon and spleen of treated TRUC 
mice and reduced colitis score (in the distal colon). Curiously colitis cores in the 
proximal colon were not significantly affected by IL-6 neutralization. This raised the 
intriguing possibility that some cytokines (and immune cells) might be differentially 
regulated regionally along the length of the colon. Alternatively, these observations 
may speak to the possible temporal differences in the role of different cytokines in 
the evolution of colitis in TRUC mice over time. In TRUC disease distal colitis 
scores are consistently higher (indicating more severe disease) in comparison with 
proximal colitis scores, which are more variable and develop later in the disease 
process. Interestingly, in TRUC mice the distal colon is most commonly affected by 
inflammation-associated colorectal cancer (Garrett et al., 2007, Garrett et al., 2009), 
a process in which IL-6 has also previously been implicated in the context of 
microbiota-dependent colitis (Hu et al., 2013). The possibility that particular 
inflammatory cytokines may play a different role in different anatomical sites of the 
GI tract is hypothetically attractive in view of the characteristic differences observed 
in the anatomical distribution the different forms of IBD. In UC most patients tend to 
have distal or left sided disease (distal to the splenic flexure) at presentation, 
although many of these will progress to more extensive disease over a 10 year period 
(Solberg et al., 2009). Likewise, the distribution of disease is completely different 
between patients with CD and UC. Notably, in IBD patients and non-inflammatory 
controls there is a gradient of gene expression, including inflammatory cytokines 
across the distribution of the colon (Noble et al., 2008), consistent with the 
possibility that the molecular drivers of disease may be anatomically separable. 
Further studies will focus on molecular and cellular differences between the proximal 
and distal colon in early and late TRUC disease to try and tease out the basis for 
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some of the interesting differences in disease evolution and response to IL-6 
neutralization.       
It is also shown for the first time that IL-6 likely triggers pSTAT3 activation in ILCs 
and that inhibition of STAT3 reduces innate IL-17A production, including IL-6 
induced IL-17A production in disease relevant tissue in TRUC mice. However, it 
should also be acknowledged that IL-23 also acts via the STAT3 pathway (at least in 
T-cells) (Parham et al., 2002), therefore, some of the inhibition of spontaneous innate 
IL-17A seen in explant organ culture experiments could also be due to limitation of 
IL-23 induced STAT3 phosphorylation. These interesting novel data potentially 
afford new insights into some of the lessons learned from genetic studies. It is 
possible that polymorphisms at the STAT3 locus identified as IBD risk conferring 
mutations could potentially impact IL-6 mediated innate IL-17A production in IBD 
(Jostins et al., 2012). Indeed, the IL6ST gene, which encodes the key IL-6R signal 
transducing protein is also associated with altered IBD risk (Jostins et al., 2012). 
These data also support the notion that the role of IL-6 in supporting adaptive IL-
17A responses is conserved in the primitive innate immune system. Just as 
monoclonal antibodies targeting IL-12p40 are emerging in to clinical practice for 
IBD patients (Mannon et al., 2004), these data support the rationale for IL-6 
neutralization as a tractable therapeutic option in some IBD patients. It is tempting to 
speculate that in the future it will be possible to stratify IBD patients according to 
their predominant effector cytokine pathway. Fewer than 50% of patients with IBD 
achieve robust remission (mucosal healing) with anti-TNFα therapies (Colombel et 
al., 2010), indicating that most patients have TNFα-independent mucosal lesions that 
are presumably driven by other inflammatory cytokines, such as IL-6 or IL-1. 
Accurate ways of stratifying patients according to their prevailing cytokine response, 
perhaps by explant organ culture or mucosal gene expression profiling may herald a 
new way of identifying which patients are likely to benefit from which biological 
therapies targeting a particular cytokine.          
Just like IL-6 and IL-23 cytokine pathways there are also polymorphisms at the 
TL1A locus which confer altered risk of IBD (Jostins et al., 2012). In the present 
study it is shown that ILCs express the TL1A receptor DR3  in TRUC mice and 
accordingly these cells are potential responders to the increased expression of TL1A 
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observed in the colon of TRUC mice. Notably, Rag2
-/-
 mice with non-inflamed 
colons have undetectable Tl1a mRNA, whereas this cytokine is enriched in the colon 
of TRUC mice. Similarly, Tl1a is also upregulated in the distal colon of TRUC mice 
in comparison with the proximal colon, correlating with the site of more severe 
inflammation in TRUC mice. These data mirror the situation in human disease. 
mRNA encoding TL1A is enriched in inflamed sigmoid colon biopsies in 
comparison with non-inflamed sigmoid colon biopsies from UC patients (Noble et 
al., 2008).    
Although only a weak inducer of IL-17A by itself TL1A synergized with IL-23 to 
potently induce IL-17A production by ILCs in TRUC mice. It should be noted that 
experimental blockade of TL1A in TRUC mice was potentially suboptimal in this 
series of experiments due to limited availability of neutralizing antibody (which was 
a kind gift, but in short supply). For example, in contrast to blockade of IL-17A, in 
which treated mice received 7 doses of antibody over the treatment regime, TRUC 
mice treated with anti-TL1A only received 4 doses. Therefore, it is not possible to be 
certain that TL1A was effectively blocked in vivo, and consequently the in vivo 
functional relevance of TL1A in driving innate IL-17A responses cannot be reliably 
or conclusively defined by this set of experiments. Further work and additional in 





will be needed to definitely answer this question. Additional experiments might also 
investigate how TL1A enhances IL-23 mediated IL-17A production by ILCs. 
Possible mechanisms of TL1A-augmented IL-23-induced IL-17A production by 
ILCs might include upregulation of the IL-23R on ILCs (thereby increasing IL-23 
mediated cell activation) or upregulation of other signalling components downstream 
of the IL-23 receptor (e.g. STAT3, JAK2, TYK2). Indeed, TL1A-triggered DR3 
signalling has been shown to induce other cytokine receptors, such as the IL-2 
receptor components CD25 and CD122 in T-cells, which results in increased 
sensitivity of T-cells to IL-2 (Meylan et al., 2011). Therefore, the possibility that 
TL1A might increase the expression of other cytokine receptors, such as IL-23R (and 
hence responsiveness to IL-23) is biologically plausible.              
In conclusion, the functionally important proximal signals responsible for ILC 
activation in TRUC disease are IL-23 and IL-6. It is interesting that these cytokines 
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are implicated in promoting the differentiation of Th17 cells, indicating that these 
cytokines play an evolutionary conserved role in driving both adaptive and innate IL-
17A responses. Therapies aimed at blocking these cytokines in vivo have shown 
promise in clinical trials in IBD patients (Ito et al., 2004; Mannon et al., 2004). It is 
possible that some of the clinical efficacy observed with these agents in IBD might 
correspond to the limitation of ILC activation. Currently, there are no data available 
regarding TL1A blocking drugs in IBD or indeed other autoimmune diseases. One 
might argue that irrespective of its function on ILCs, antagonism of the TL1A/DR3 
interaction remains an attractive therapeutic target, since TL1A is an important driver 
of pathogenic T-cell responses (Bamias et al., 2003), which also undoubtedly play an 
important role in IBD. It is arguable that targeting cytokine networks which act on 
both innate (ILC) and adaptive (T-cell) immune cells might be an especially 
advantageous strategy to prevent redundancy, where one arm of the immune system 
emerges as an effector pathway when the other is therapeutically antagonised. With 
this notion in mind, blockade of IL-6 or IL-23, which can now be acknowledged as 
cytokines which potently drive both innate and adaptive immune responses, are  
potentially attractive therapeutic targets in IBD. 
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CHAPTER 5 
Results: Defining the microbial triggers responsible for 
driving IBD in TRUC mice 
The intestinal microbiota is strongly implicated in IBD. No definite causative 
organisms have been identified in IBD, although important overall changes in the gut 
microbiota community composition include reduced biodiversity and probable 
expansion of usually low abundance phyla, such as Proteobacteria and even 
Actinobacteria (Frank et al., 2007; Lepage et al., 2011). In TRUC mice, colitis is 
dependent on the microbiota, since modulation of the microbiota with antibiotics 





 mice are reared in germ free conditions they do not get disease 
(Garrett et al., 2010). In view of the central importance of the intestinal microbiota in 
TRUC disease, and indeed in IBD, the work in this chapter endeavoured to determine 
whether there were any specific components of the intestinal microbiota of TRUC 
mice that were responsible for driving disease. 
5.1 Newly derived Tbx21-/- x Rag2-/- mice did not develop 
spontaneous colitis 














 colony was maintained in specific pathogen free 
(SPF) isolators, and unexpectedly mice from this new colony failed to develop 
disease. Histological assessment of the distal colon following H&E staining of mice 
from this new colony failed to show any evidence of colitis (Figure 40A). The 
macroscopic appearance of the colon of mice from the new colony was also 
markedly different from that of TRUC mice, with a lack of colonic thickening, 





 mice from their isogenic TRUC counterparts we 




 non-ulcerative colitis) mice. In 
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keeping with an absence of disease the colon weight of TRnUC mice was 
significantly less than that of age matched TRUC mice (P<0.0001, Figure 40C). In 
contrast, there was no significant difference in the colon weight of TRnUC mice in 
comparison with Rag2
-/-
 mice (Figure 40C). Similarly, spleen weight of TRUC mice 
was significantly greater than age matched TRnUC mice (Figure 40D). 
This new colony of disease free mice demonstrated that T-bet deficiency in the 
innate immune compartment (in the absence of adaptive immunity) by itself is 





 colonies with different phenotypes provided an opportunity to define the 










mice failed to develop spontaneous colitis.  A 









and WT mice. Photographs are all taken at the same 
magnification (approximately x40).  B Macroscopic appearance of the colon of TRUC 
and TRnUC mice. C Colon and D spleen mass of age matched TRUC, TRnUC and Rag2
-
/- 
mice. *P<0.0001). Each dot represents an individual mouse. Lines depicts median of the 










5.2 16S ribosomal RNA gene sequencing of the intestinal 
microbiota showed differences between the colonic bacterial 
community profiles of TRUC and TRnUC mice 
Since antibiotics and probiotics are therapeutic in TRUC colitis (Garrett et al., 2010; 
Garrett et al., 2007; Veiga et al., 2010), and intestinal inflammation is communicable 
(Garrett et al., 2007), the most likely colitogenic stimulus in TRUC disease was an 
intestinal microbe. Therefore the intestinal microbiota of isogenic TRUC and 
TRnUC mice was compared by performing 454 pyrosequencing of the V3-V5 
regions of bacterial 16S rRNA genes in faecal samples from TRUC and TRnUC 
colony members. 
Fresh stool samples were harvested from TRUC and TRnUC colony members and 
immediately frozen pending transportation on dry ice to the Sanger Institute in 
Cambridge, where Dr Alan Walker and Professor Julian Parkhill sequenced and 
profiled the bacterial 16S ribosomal RNA genes present in these samples. Bacterial 
DNA was extracted and PCR-amplicons were generated for 454 sequencing using 
barcoded primers targeting the V3-V5 regions of the 16S rRNA gene. PCR products 
were then quantified using a Qubit® 2.0 Fluorometer (Invitrogen). After processing, 
and subsequent manual removal of suspect or chimeric operational taxonomic units 
(OTUs), 33528 sequences remained, which were split into 256 OTUs overall. The 
median number of sequences per sample was 2817 (range 1781-3884). OTUs that 
were significantly differentially abundant between the TRUC and two TRnUC 
mouse cohorts were identified using the Metastats program (Schloss et al., 2009; 
White et al., 2009), allowing differences in the community structures of the different 
colonies to be identified at the level of both phylum and species. 
Stool samples from TRUC mice (n=4) and from 4 mice each from 2 colonies of 
TRnUC mice were analysed (8 in total). One of the disease free TRnUC colonies was 
housed at the biological services unit at King’s College London (KCL) and the 
second disease free colony of TRnUC mice was housed at a geographically separate 
isolator at Charles River laboratories (CRL). This second colony of TRnUC mice 
was derived from the initial founder TRnUC colony at KCL, but was relocated to 
CRL to preserve the non-colitis phenotype. 
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Individual samples shared broad similarities in community structure with other 
members of the same colony but were distinct from mice in the other colony (Figure 
41). As expected, all samples were dominated at the phylum level by Firmicutes, 
Bacteroidetes, Proteobacteria, Actinobacteria and Deferribacteres (Figure 42A). 
However, the proportional abundance of sequences from the Proteobacteria phylum 
was significantly increased in TRUC mice (Figure 42B), and the ratio of Firmicutes 












mice was different in 
mouse colonies with and without colitis.  Cluster dendogram showing relative 
family/species level composition of TRUC mice with colitis (TRUC 1-4) and TRnUC 
mice without colitis from KCL (TRnUC 1-4) and CRL (TRnUC 5-8). These data were 
generated by Alan Walker and Julian Parkhill. Adapted from Powell et al., 2012. 
     
179 
 
Figure 42. Phylum/family level differences in the intestinal microbiota of TRUC and TRnUC 
mice.  A-C Mean phylum level differences in the intestinal microbiota from TRUC (n=4) 
and TRnUC (n=8) mice by sequencing bacterial 16S rRNA genes. Error bars indicate 
SEM. Mice were aged 6-8 weeks old. Mice from the 2 separate TRnUC colonies (one at 
KCL and one at Charles River UK) had been separated for 14 months. In this experiment 
TRnUC mice from the 2 colonies were combined to generate sufficient statistical power 
to compare with individual Phyla frequencies from TRUC mice. D Proportion of 
family/species-level sequences in the different genotypes, including an analysis of the 2 
different TRnUC colonies (n=4 in each group). Bars show mean % sequences and error 
bars show SEM. SFB= Segmented filamentous bacteria. Adapted from Powell et al., 
2012. 
    
 
   
A B C 
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5.3 Species level differences in TRUC and TRnUC mice 
Analysis of the family level differences in the relative frequency (% of sequences) of 
selective families failed to demonstrate any significant differences between the 
TRUC colony and the 2 TRnUC colonies (Figure 42D). However, it should be noted 
that with only 4 mice in each group statistically significant differences might be 
potentially difficult to detect. However, in an alternative approach the experiment 
was analysed by trying to determine species-level differences between the colonies to 
see if any particular species were always present in mice with disease (e.g. TRUC 
mice), but consistently absent from disease-free TRnUC mice from either colon. In 
this experiment the faecal microbiota from the 2 colonies TRnUC mice were grouped 
together as they shared a disease-free phenotype. Analysis of species-level OTUs 
demonstrated that there were a total of 256 OTUs detected across the intestinal 
microbiota of all of the TRUC and TRnUC colony members. However, just 12 
species-level OTUs were consistently present in all TRUC mice and always absent 
from TRnUC mice (Figure 43A). 
Interestingly, one of the TRUC-specific OTUs matched with 100% identity to the 
proteobacterial species Helicobacter typhlonius. Notably, a number of different 
Helicobacter species have previously been linked to colitis development in research 
mice (Fox et al., 2011). To confirm that H. typhlonius was present in TRUC colony 
members and absent from TRnUC mice, H. typhlonius-specific PCR (Feng et al., 
2005) was performed on bacterial DNA isolated from faeces. PCR using H. 
typhlonius-specific primers confirmed the presence of this bacterium in all TRUC 





Figure 43. Bacterial species present in the colon of TRUC mice and consistently absent from 
non-colitic TRnUC mice.  A Species level (OTU) bacteria present in TRUC, but absent 
from TRnUC mice following 434 sequencing of bacterial rRNA genes. TRnUC mice 
from both colonies were included in this analysis – since both colonies were disease-free 
and therefore, served as appropriate controls for mice with a colitis phenotype. Phylum 
Key: P = Proteobacteria, B = Bacteroidetes, F = Firmicutes. Phylum, Family and Genus 
classifications were generated using the RDP Classifier tool (Cole et al., 2009). B 2% 
Agarose gel electrophoresis of PCR products following Helicobacter typhlonius specific 
PCR performed on bacterial DNA isolated from fresh faecal samples from TRUC and 
TRnUC mice (from the Charles River colony). These data are representative of similar 
experiments with TRnUC mice from the KCL colony which were also negative for H. 
typhlonius by PCR. The Helicobacter typhlonius specific PCR product is 122bp. Adapted 







NCBI BLAST ID Phylum Family Genus p value
Helicobacter typhlonius P Helicobacteraceae Helicobacter <2x10-9
Parasutterella
excrementihominis
P Alcaligenaceae Parasutterella <1x10-10
Parabacteroides 
distasonis
B Porphyromonadaceae Parabacteroides <1x10-10
Bacteroides 
splanchnicus
B Porphyromonadaceae Odoribacter 0.012
Alistipes shahii B Rikenellaceae Alistipes <1x10-10
Rikenella microfusus B unclassified unclassified <1x10-10
Anaerotruncus 
colihominis
F Ruminococcaceae Acetanaerobacterium <5x10-10
Coprobacillus 
cateniformis
F Erysipelotrichaceae Coprobacillus 7x10-5
Eubacterium 
plexicaudatum













Clostridium piliforme F unclassified unclassified <1x10-10
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5.4 There were no other recognised pathogens present in the 
intestinal microbiota of TRUC mice 
In an alternative approach, a high sensitivity PCR-based screening test was used to 
evaluate for the presence of other recognized pathogens in faecal samples acquired 
from TRUC and TRnUC. This commercially available assay (Prevalent Rodent 
Infectious Agent, or PRIA panel, Charles River Laboratories, UK) was conducted by 
an outside vendor (CRL), blinded to the earlier 16S rRNA gene sequencing results. 
The panel screens for important intestinal pathogens, and utilizes genus-generic 
primer sets for Helicobacter, Salmonella and Campylobacter, species-specific 
primers for Helicobacter hepaticus, Helicobacter bilis, Citrobacter rodentium, 
murine norovirus and rotavirus, and numerous additional well-recognized murine 
pathogens (Figure 44). No pathogens were identified in faecal samples from TRnUC 
colony members. In contrast, the Helicobacter genus-generic primers confirmed the 
presence of a Helicobacter species in the faecal samples from TRUC mice. However, 
species-specific PCR for Helicobacter hepaticus and Helicobacter bilis were 
negative, indicating that the Helicobacter species present was neither of these 
recognised pathogens. To confirm the identity of the Helicobacter present in TRUC 
faeces, a second Helicobacter genus generic PCR was performed. The PCR was 
performed together with a positive control (Helicobacter hepaticus DNA). The 
Helicobacter genus generic primers amplified a 374bp 16S rRNA gene PCR product 
(Figure 45A), which was subsequently excised from the agarose gel for DNA 
sequencing (performed by an outside vendor – CRL). The sequence generated is 
shown in Figure 45B. The sequence was compared with archived sequences in the 
NCBI GenBank database and with the amplicons generated using the universal 
bacterial primer sets for 454 sequencing. This analysis confirmed that the 
Helicobacter present in the faeces of TRUC mice shared >99% 16S rRNA gene 
sequence similarity with H. typhlonius. 
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Figure 45. The DNA sequence of the Helicobacter species present in the faeces of TRUC mice 
matched the sequence of H. typhlonius.  A 2% Agarose gel electrophoresis of a 
Helicobacter genus-generic PCR performed on a fresh faecal sample from 12 week old 
TRUC mouse. The band was excised and DNA sequenced. Positive +and negative -
controls are illustrated. The sequence of the PCR product (black sequence) was compared 
with archived DNA sequences in the NCBI GenBank database and with the amplicons 
generated using the universal bacterial primer sets for 454 sequencing (green sequence), 
which confirmed that the Helicobacter present in the faeces of TRUC mice shared >99% 


















Genus generic Primers 144 (black)
Universal 16S rRNA gene Primers 143 (green)
B
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5.5 Intestinal colonization with H. typhlonius transmitted colitis to 
TRnUC mice 
Since H. typhlonius (HT) was present in all diseased mice and absent from healthy 
mice, the hypothesis that HT might transmit colitis to TRnUC mice was tested. Pure 
lyophilized cultures of HT (CCUG 48335 T) were acquired from the Culture 
Collection of the University of Gothenburg (Franklin et al., 2001). Bacteria were 
grown on horse blood agar or Columbia agar and growth occurred under 
microaerophilic or anaerobic conditions, generating small translucent colonies. One-
5 x10
7 
organisms were gavaged in to TRnUC mice. As a control, some mice were 
gavaged with broth alone without the addition of HT. A faecal sample was acquired 
from test mice at baseline (time 0, prior to gavage) and at 1 week post gavage, 2 
weeks post gavage and 3 weeks post gavage. Total bacterial DNA was extracted 
from faecal pellets and HT-specific PCR performed to determine whether HT was 
present or not. As a positive control DNA was also extracted from a faecal pellet 
harvested from a TRUC mouse. PCR products were detected on 2% agarose gel 
electrophoresis. Although undetectable at baseline in TRnUC mice HT DNA was 
detectable at the earliest time point tested (1 week) and was detectable throughout the 
experiment, until week 3 (Figure 46A). In contrast, HT was undetectable in mice 
gavaged with broth alone. These data demonstrate that following gavage with HT 
there was successful transmission and maintenance of gastrointestinal colonization 
with HT in TRnUC mice (Figure 46A). 
Histological assessment of the colons of TRnUC mice newly colonized with HT 
demonstrated that colitis could also be transmitted following GI colonization with 
HT. In contrast to TRnUC mice gavaged with broth alone, TRnUC mice gavaged 
with HT developed severe colitis that was histologcially indistinguishable from 




Figure 46. H.typhlonius gavage to TRnUC mice resulted in colonization and colitis 
transmission.  A 2% Agarose gel electrophoresis of HT-specific PCR on bacterial DNA 
extracted from faecal pellets from TRnUC gavaged with HT or broth alone, at weeks 0 
(baseline), and then 1-3 weeks post-gavage. B Histology (H&E) of the distal colon of 
TRnUC mice following gavage with HT or broth alone. Magnification is the same in both 
panels (approximately x40). Mice were analysed 3-4 weeks post inoculation. These data 
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5.6 H. typhlonius was transmissible to TRnUC or Rag2-/- mice co-
housed with TRUC mice 
Since the initial report describing TRUC mice reported that colitis was transmissible 
to other non-TRUC genotypes after co-housing (or cross-fostering) mice with TRUC 
mice, experiments were conducted to determine whether HT could be transmitted to 
otherwise disease-free mice by co-housing with TRUC mice. TRnUC and Rag2
-/-
 
mice were co-housed with TRUC mice (ratio 2:1). Faecal pellets were collected 
directly from the co-housed mice and bacterial DNA extracted before HT-specific 
PCR was performed. Intestinal colonization with HT was clearly demonstrable in 
TRnUC and Rag2
-/-
 mice within the first week of co-housing and was also detectable 
6 weeks later (Figure 47A). 
Following co-housing, TRnUC mice also developed colitis that was histologically 
indistinguishable from TRUC colitis (Figure 47B). TRnUC mice co-housed with 
TRUC mice also developed increased colonic weight, as observed in TRUC mice, 
consistent with the development of colonic disease (Figure 47C). In contrast, Rag2
-/-
 
mice co-housed with TRUC mice developed only modestly enlarged colons and mild 
histological changes in the distal colon (Figure 47B and 47C). These data 
demonstrated that T-bet deficiency in the innate immune system is a critical 
determinant of full disease penetrance in HT associated colitis. 
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Figure 47. H. typhlonius was transmissible to TRnUC and Rag2
-/-
 
mice by co-housing with 
TRUC mice.  A 2% Agarose gel electrophoresis of HT-specific PCR on bacterial DNA 
extracted from faecal pellets from TRnUC or Rag2
-/-
 
mice co-housed with TRUC mice. 
Stool samples were taken at week 0 (baseline), week 1 and at 6 weeks. B Distal colon 
histology (H&E staining) of TRnUC and Rag2
-/-
 
mice co-housed with TRUC mice. 




mice co-housed (+) or not (-) with TRUC mice. Colon histology and disease 
features were analysed 6-8 weeks after co-housing was started. Each dot represents an 
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5.7 H. typhlonius colonization induced increased TNFα 
transcription in the colon of TRnUC mice 
Next we evaluated whether de novo colonization with H. typhlonius was capable of 
activating the immune pathways observed in TRUC mice. Colitis in TRUC mice is 
characterized by deregulated transcription of TNFα by colonic DCs (Garrett et al., 
2007; Garrett et al., 2009). Therefore, TRnUC and mice were gavaged with pure 
cultures of HT. Following HT gavage (4-6 weeks), distal colon samples were 
harvested from study animals to quantify colonic transcription of Tnfa by qPCR. 
HT inoculation to TRnUC mice resulted in a significant increase in Tnfa transcripts 
to levels seen in TRUC mice (Figure 48). Despite colonic Tnfa transcripts being 
markedly less abundant in uninfected TRnUC colons, it was noteworthy that they 
were significantly more abundant than in uninfected Rag2
-/-
 colons. Together these 
data suggest that de-repression of the Tnfa locus occurs in T-bet deficient DCs 
independently of colitis, but by itself is insufficient to induce disease. Furthermore, 
HT appears to markedly augment colonic Tnfa transcription in the colon, particularly 









Figure 48. H. typhlonius induced increased transcription of Tnfa in TRnUC mice. qPCR for 
Tnfa in the colon of TRnUC following GI colonization with HT (+HT) or not. Tnfa 
transcripts were also quantified in the colon of Rag2
-/-
 
and TRUC mice. In this 
experiment Tnfa transcripts were quantified in the distal colon (0.5cm segment within 
0.5cm of the anal verge) in 6x Rag2
-/-
, 9x TRnUC, 4x TRnUC (post-colonization with 
H.T.) and 14 TRUC mice. Bars denote mean relative abundance of Tnfa transcripts and 
error bars denote SEM. These data are from a single experiment and was not repeated. 




5.8 The major colonic DC subsets were the same in TRnUC and 
Rag2
-/-
 mice following HT colonization 
Dysregulated TNFα production by colonic CD11c+ DCs is a hallmark feature of 
TRUC IBD (Garrett et al., 2007; Garrett et al., 2009). CD11c
high
 MHC class II
+
 
intestinal DCs can be divided into subsets based on surface expression of CD103
 
and 
CD11b (Varol et al., 2009), with different functional properties. CD11b
+ 
intestinal 
DCs (often co-expressing CX3CR1) are believed to play an important inflammatory 
role in intestinal inflammation through production of cytokines such as TNFα (Varol 
et al., 2009). In contrast, CD103
+
 DCs imprint gut homing properties to circulating 
lymphocytes, and are thought to be involved in regulatory processes, including 
promoting FoxP3
+
 T-reg differentiation (Coombes et al., 2007). CD103
+
 DCs are 
less effective producers of inflammatory cytokines, such as TNFα, IL-6, IL-12p40 
and IL-23p19 (Coombes et al., 2007). 
One possibility for the exaggerated TNFα response observed in T-bet deficient hosts 
is that T-bet might alter the profiles of the different DC subsets. Indeed an imbalance 
in the composition of gut DC subsets, such as an inappropriate expansion of CD11b
+
 
DCs, could potentially account for enhanced production of TNFα in TRUC mice. 
Therefore, it was determined whether the profile of intestinal DCs was altered in 
mice lacking T-bet in the innate immune compartment. 
In the cLP of TRnUC and Rag2
-/-






























 cells were the most common subset in the colon, accounting 
for approximately 75-80% of DCs (Figure 49A and 49B). The frequency of each 
colonic DC subset was the same in Rag2
-/-
 and TRnUC mice. 
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Figure 49. Colonic DC subsets in TRnUC and Rag2
-/- 






DCs (and subsets) according to CD11b and 
CD103 expression in TRnUC and Rag2
-/-
 
mice following inoculation with HT. B 
Quantification of DC subsets present in the colon of TRnUC and Rag2
-/- 
mice 4-6 weeks 





of each subset. Error bars denote SEM. The relative proportion of DC subsets were 
defined in 5x Rag2
-/- 
and 5x TRnUC mice. These experiments were repeated on a further 
2 occasions. Adapted from Powell et al., 2012. 
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5.9 CD11b+ CD103- colonic DCs were responsible for enhanced 
production of TNFα in the absence of T-bet 
Since the profile of colonic DC subsets was not altered in TRnUC and Rag2
-/-
 mice, 
experiments were conducted to determine which DC subsets were responsible for 





 DCs were the principal subset responsible for TNFα 
production in TRnUC and Rag2
-/-
 mice (Figure 50A). However, there was a 2-3 fold 
increase in the percentage of TNFα producing cells in the CD11b+ CD103- DC subset 
in TRnUC mice in comparison to Rag2
-/-
 mice (Figure 50B). 




 DCs are the principle subset 
responsible for excess TNFα production in the colon of HT infected mice, and that in 













 DCs were the principle source of TNFα in TRnUC mice  A Flow 
cytometry plots demonstrating the percentage of cells expressing intracellular TNFα 





DC subsets in the colon of TRnUC and Rag2
-/- 
mice following inoculation with HT, and B statistical analysis (n=5 mice in each group). 
In this experiment unfractionated cLPLs were incubated at 37
o
C for 4 hours in the 
presence of monensin without any additional exogenous stimulus. Gates were defined by 
incubating control cells on ice without monensin. DC subsets were defined as in Figure 
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5.10 TNFα potentiated IL-23 induced innate IL-17A expression in 
TRUC disease 
Since chronic TRUC disease is dependent on ILCs, the hypothesis that TNFα 




 DCs might impact on ILC activation in TRUC IBD 
was tested. To determine whether TNFα might influence innate IL-17A production, 
unfractionated mLN cells were incubated in the presence or absence of recombinant 
TNFα. Although on its own, recombinant TNFα was unable to induce significant 
innate IL-17A production, it did potentiate IL-23 induced IL-17A production (Figure 
51). Indeed, the combination of TNFα and IL-23 potently and significantly increased 
IL-17A production in comparison with unstimulated cells or cells stimulated with IL-








Figure 51. TNF augmented IL-23 induced IL-17A production by ILCs from TRUC mice. 
 Unfractionated mLN cells (1x10
5
 cells/mL) from TRUC mice (n=5) were cultured with 
specified cytokines or left unstimulated (-) for 24 hours.  IL-17A secreted into culture 
supernatants was measured by ELISA. IL-23 was used at a final concentration of 
20ng/mL and TNFα was used at a concentration of 20ng/mL. Bars represent mean IL-
17A concentration in culture supernatant and error bars denote SEM. These data are from 




































5.11 TNFα blockade attenuated H. typhlonius induced colitis 
The functional importance of TNFα in HT induced colitis in TRnUC mice was also 
evaluated and its potential impact on ILC- derived IL-17A production. 
Two weeks following inoculation with HT, TRnUC mice were treated with an i.p. 
injection (500µg) of an anti-TNFα mAb (clone XT3.11) or control isotype antibody. 
Mice were treated on days 0, 3, 6, 9, 12, 15 and 18, culled on day 21 and organs 
harvested. Anti-TNFα treatment significantly attenuated HT induced colitis in 
TRnUC mice with improved histological appearances (Figure 52A) and reduced 
colitis scores (Figure 52B). 
Notably, TNFα blockade substantially reduced colonic Il17a transcripts, consistent 
with the possibility that TNFα augmented IL-17A production is physiologically 
relevant in HT associated ILC mediated colitis (Figure 52C). 
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Figure 52. TNFα blockade attenuated HT associated colitis in TRnUC mice.  A Distal colon 
histology (H&E staining) and colitis scores. Magnification is the same in both panels 
(approximately x40).  B from TRnUC mice inoculated with HT following treatment with 
anti-TNFα or control isotype antibody. Bars show mean colitis score and error bars 
denote SEM. C qPCR of Il17a mRNA in the colon of TRnUC mice given HT and treated 
with anti-TNFα or control isotype antibody. Six mice received isotype control antibody 
and 5 mice received anti-TNFα antibody. Each dot represents an individual mouse. Lines 
depict median relative abundance of Il17a transcripts. Like other in vivo blockade 
experiments these data are from a single experiment which was not repeated. Adapted 










Interactions between the host immune system and the intestinal microbiota are key 
determinants in maintaining intestinal homeostasis. For the host, an intact innate 
immune system is needed to sense luminal microbes and their products, and engage 
in critical decisions to generate protective, tolerogenic or inflammatory responses. In 
this thesis the way in which mice lacking T-bet and an adaptive immune system 
interact with the intestinal microbiota has been examined. In contrast to previous 
work this study shows that T-bet deficiency is necessary but not sufficient for the 





 mice did not develop spontaneous colitis without an additional environmental 
stimulus. H. typhlonius is now identified as the microbial constituent present in the 
microbiota of TRUC mice that can serve as an environmental trigger responsible for 
instigating colitis, particularly in Tbx21 deficient hosts. In many ways the TRUC 
model of IBD can therefore be considered a useful paradigm of human IBD where 
the genetic architecture of the host is only really a risk factor for IBD development 
rather than guarantee. Indeed, in the absence of appropriate environmental cues even 
individuals with a “high risk” genetic background do not necessarily develop IBD. 
This point is exemplified by the lack of full concordance seen in IBD development in 
monozygotic twins (Tysk et al., 1988). In agreement with this there are many more 
healthy individuals with polymorphisms at IBD susceptibility loci than there are IBD 
patients. 
In this study identification of H. typhlonius as the key pathobiont responsible for 
driving colitis in TRUC mice is novel and redefines the paradigm of this model of 
disease. It is noteworthy that the initial paper reporting the TRUC model of disease 
did identify Helicobacter present in the faeces of TRUC mice using genus generic 
primers (personal communication Professor Lord), however, Helicobacter hepaticus 
and Helicobacter bilis infection were excluded by specific PCR tests. Importantly, 
however, these initial analyses did not rule out the presence of H. typhlonius. Garrett 
et al., also recently performed 16S rRNA gene sequencing comparing Rag2
-/-
 and 
TRUC mice (Garrett et al., 2010). In the supplemental materials provided online in this 
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paper a Helicobacter species was detected in the intestinal microbiota of their 
conventionally housed SPF mice (by 16S rRNA gene sequencing and qPCR). They 
state that the Helicobacter identified was the closely related species Helicobacter 
ganmani, but unfortunately the 16S rRNA gene DNA sequence is not provided, nor 
are the primer sequences for PCR amplification, therefore, it is not possible to 
determine whether this OTU was misclassified. Also, the Rag2
-/-
 mice used for 
comparison/controls in the Garrett study are arguably not the optimal control group 
to employ for such analyses. It is likely that the causative bacterium in TRUC colitis 
was also present in the Rag2
-/-
 controls (and therefore not seen as a unique organism 
to the TRUC colony), especially as these Rag2
-/-
 controls would have been direct 
descendants of the same Rag2
-/-
 colony that founded the original TRUC colony. 
Unfortunately the original raw sequence data from this study is not available for 
analysis to check for the presence of H. typhlonius as this dataset has not been 
deposited in a central sequence repository such as the NCBI Short Read Archive. In 
addition, these previous data only provided species-level bacterial phylotypes that 
were significantly different between Rag2
-/-
 and TRUC mice (Table S1 supplemental 
data, Garrett et al., 2010). The bacteria common to both Rag2
-/-
 and TRUC mice are 
not available to evaluate. It is therefore unfortunately not possible to determine 
whether H. typhlonius was present in the intestinal microbiota of TRUC and Rag2
-/-
 





without colitis are a more appropriate control group. By analysing isogenic mice in 
the presence and absence of disease, this approach is likely to be more sensitive to 
define any changes in microbial composition associated with disease (and not due to 
alterations in host genotype). There are also technical differences in methodology 
that may be particularly relevant between the two studies. Garrett et al. used V2 
region primers for amplification, whereas in this study Professor Parkhill and Dr 
Alan Walker used a longer stretch of the 16S rRNA gene, covering the V3-V5 
regions. This may be a critically important distinction since H. typhlonius appears to 
include a rather large sequence insertion in the V2 region (Franklin et al., 2001). In 
this manuscript the authors that first described H. typhlonius state that "A 166-bp 
intervening sequence (IVS) was identified following position 198 in all [H. 
typhlonius] isolates. This IVS occupies the area normally occupied by a seven-base 
stem-loop centred on position 210 in several other species of Helicobacter."). 
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Therefore, at the V2 region of the 16S rRNA gene that was looked at by Garrett et al. 
it is possible that any H. typhlonius sequences present in their dataset would either 
not have aligned properly or would have been filtered out during processing as they 
would have falsely looked like chimeras, relative to the other sequences in their 
database. In contrast, since there are no insertions over the V3-V5 area of the 16S 
rRNA gene, it is likely that the primers used in our study would be able to detect H. 
typhlonius effectively. Indeed, in this study, the species of Helicobacter present was 
identified independently by 2 separate platforms, including DNA sequencing of the 
PCR product generated by Helicobacter genus generic primers. 
H. typhlonius is a Gram negative, microaerophilic, unease negative, spiral rod-
shaped bacterium. Amongst the growing number of Helicobacter species known to 
colonize laboratory mice, it is most closely related to H. hepaticus, with whom it 
shares 97.6% sequence similarity at the 16S rRNA gene locus (Franklin et al., 2001). 
In contrast to other Helicobacter species, including H. hepaticus, H. bilis and H. 
rodentium it does not induce hepatitis or billiard disease (Franklin et al., 1999), 
consistent with the phenotype of TRUC mice, which do not develop liver pathology 
(data not shown). In common with other Helicobacter species, H. typhlonius has 
been shown to induce colitis in mice, particularly in the context of immunodeficiency 
(Fox et al., 1999; Franklin et al., 1999). H. typhlonius is killed by desiccation, and is 
difficult to culture using conventional techniques. 
In the study reported by Garrett it was also suggested that Klebsiella pneumoniae and 
Proteus mirablis may be important in colitis development following culture of these 
bacteria from TRUC faeces (Garrett et al., 2010). However, these organisms by 
themselves or in combination were unable able to induce colitis in germ free mice. In 
our study Klebsiella pneumonia was not detected in the faeces of TRUC mice by 
either PRIA panel testing or 454 sequencing, suggesting that this bacterium must be 
of very low abundance or not present at all in our TRUC colony, which would argue 
against a significant role for this bacterium in this model of colitis.       
Identification of H. typhlonius as the key driver of colitis  also allowed some of the 
immune mechanisms of TRUC disease to be interrogated. Although increased Tnfa 
transcription was observed in the absence of colitis in TRnUC mice, intestinal 
colonization with H. typhlonius was required for maximal Tnfa transcription and 
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indeed for disease induction. The disease phenotype of otherwise healthy TRnUC 
mice following de novo infection with H. typhlonius was clinically, histologically 
and immunologically indistinguishable from chronic TRUC colitis. Analysis of the 
DC populations in TRUC and Rag2
-/-





were both the most frequent DC subset in the colon of these mice as well of the being 
the subset with the greatest proportion of cells which stained positive for intracellular 
TNFα. Notably, the proportion of TNFα CD11b+ CD103- DCs was significantly 
higher in TRnUC mice inoculated with H. typhlonius in comparison with Rag2
-/-
 
mice. It should be noted that the nomenclature, definitions and phenotypic markers 
associated with DCs often overlaps with that of other myeloid populations and in 
particular with tissue macrophages. In this study colonic DCs were defined in flow 




 cells. It is possible that some of these 
cells may include colonic macrophages and therefore in some ways it might be more 









cells. However, for consistency these cells will however be referred to as DCs, 
accepting the potential limitation of this definition. Irrespective of the definitions 
employed to define this particular population of cells in mice lacking T-bet there is 
dysregulated/increased expression of TNFα in comparison with the analogous 
population of cells in T-bet sufficient hosts. Additional support for the likelihood that 
this cell population is a DC population is that T-bet is expressed by DCs (Lighvani et 
al., 2001), but its expression has never been described in macrophages. These data 




 DCs (or myeloid 
cells) are primarily “inflammatory” in nature (Varol et al., 2009).  
In keeping with previous observations, colitis was also transmissible to T-bet 
sufficient Rag2
-/- 





 mice. These data highlight how host genotype profoundly 
influences the cross talk between the mucosal immune system and particular 
components of the intestinal microbiota. Despite the presence of a diverse 
community of microbes, the addition of a specific microbe, in this case H. typhlonius 
is required to exploit the colitogenic susceptibility of mice lacking T-bet in the innate 
immune system. Data are now beginning to emerge to suggest that particular 
intestinal microbes might also influence intestinal homeostasis in humans. Adherent 
invasive Escherichia coli has been implicated in the pathogenesis of Crohn’s disease 
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(Chassaing et al., 2011) and norovirus infection, an acute gastroenteritis in humans, 
has also recently been identified as a key disease trigger in a mouse model of 
Crohn’s disease (Cadwell et al., 2010), although notably, MNV was absent from 
TRUC and TRnUC colony members in this study (PRIA panel screening). 
Conversely, the presence of Faecalibacterium prausnitzii appears to be negatively 
correlated with IBD (Joossens et al., 2011; Sokol et al., 2008). These data suggest 
that under certain circumstances specific microbes may be capable of exploiting the 
genetic susceptibility of IBD prone individuals. 
In conclusion, T-bet deficiency is insufficient to cause colitis by itself, but additional 
environmental signals are required to trigger disease. It is now clear that particular 
intestinal microbes are necessary to exploit this susceptibility, and the proteobacterial 
species H. typhlonius has been identified as the key environmental stimulus 
responsible for precipitating IBD in TRUC mice. These findings in the mouse mirror 
some of the current thinking regarding the likely pathogenesis of human IBD, where 
it is now thought disease is probably due to exposure of a genetically susceptible 




Results: Defining the mechanisms whereby T-bet controls 
colitogenic immune pathways in TRUC mice 
T-bet was first described as the master transcription factor responsible for controlling 
the phenotype of CD4
+
 Th1 T-cells (Szabo et al., 2000). T-bet binds at the Ifng locus, 
where it transactivates the expression of this gene and is required for optimal 
production of IFN by Th1 cells (Szabo et al., 2000). CD4+ T-cells from Tbx21-/- 
mice not only have severely impaired IFN production, but also have a default gain 
of function with respect to their differentiation towards other effector lineages, such 
as Th17 cells (Lazarevic et al., 2011). In view of the dominant role played by T-bet 
in controlling the profile of cytokines produced by T-cells, the hypothesis that T-bet 
would also control the profile of cytokine produced by ILCs was also tested. In 
addition, existing data from the laboratory, including chromatin immunoprecipitation 
(ChIP) data from fellow students were analysed to determine whether other ILC-
related genes might be impacted by T-bet (or its genetic deficiency) in TRUC mice. 
6.1 T-bet deficient ILCs were relatively poor producers of IFN and 
instead preferentially expressed IL-17A in H. typhlonius 
associated colitis 
In the first results Chapter it was observed that ILCs from TRUC mice exhibit a 
highly polarized IL-17A response and lack significant IFNγ expression, suggestive of 
the possibility that T-bet is also required for optimal IFNγ production by innate 





 intestinal ILCs was compared in the context of de novo intestinal 
colonization with HT. 
TRnUC and Rag2
-/-
 mice were gavaged with HT. Mice were culled 6 weeks later. 
Colonic histology revealed that TRnUC mice developed severe colitis and Rag2
-/-
 
mice developed minor inflammatory changes, as reflected by the colitis scores 
(Figure 53A). There was also a tendency for increased colon mass (Figure 53B) and 
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spleen mass (Figure 53C) in TRnUC recipients of HT, although this did not achieve 
statistical significance. 
Cytokine production was studied in ex vivo colon explant cultures. Notably, there 
were significantly higher concentrations of IFNγ in culture supernatants from Rag2-/- 
mice in comparison with TRnUC mice (P<0.012, Figure 54A). Conversely, explant 
culture supernatants from TRnUC mice had significantly higher concentrations of 
IL-17A (P<0.012, Figure 54B). 
Cytokine production was also analysed in colonic ILCs from Rag2
-/-
 and TRnUC 
mice colonized with HT by flow cytometry following stimulation of unfractionated 
cLPLs with PMA and ionomycin. In contrast to CD90
high
 cLP cells from Rag2
-/-
 mice 
where there were very few IL-17A
+
 cells seen, CD90
high
 cLP cells from TRnUC mice 
were a rich source of IL-17A. In this experiment there was relatively few IFN+ ILCs 
seen in either genotype (Figure 54C). 
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Figure 53. HT inoculation resulted in more severe colitis in TRnUC mice in comparison with 
Rag2
-/-  
mice.  A Distal colitis histology scores, B colon mass and C spleen mass in Rag2
-
/- 
and TRnUC mice inoculated with HT. Five mice were used in each group. In panel A 
the bars represent mean colitis score and error bars denote SEM. These data are 
representative of an additional experiment which replicated these findings (although was 
performed in mice of different ages, therefore, data was not aggregated).  Mice were 
examined 6 weeks  post HT inoculation. In Figures B and C each dot represents an 





Figure 54. HT colonized mice lacking T-bet in the innate immune compartment were poor 
producers of IFN and instead preferentially produce IL-17A.  A IFN and B IL-17A 
concentrations in colon explant culture supernatants from TRnUC (n=5) and Rag2
-/-
 
(n=5) mice following colonization with HT (after 4-6 weeks), measured by ELISA. 
Explants were cultured for 24 hours. Bars represent mean cytokine concentration in 
culture supernatants and error bars denote SEM. C Flow cytometry plots showing 
intracellular cytokine expression in the colon of TRnUC and Rag2
-/-
 
mice (colonized with 
HT) following stimulation with PMA and ionomycin. Cells were stimulated for 4 hours 
with PMA and ionomycin and in the final 2 hours monensin was added. Data are 
representative of multiple (>3) biological replicates.  
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6.2 Establishment of an additional model of ILC activation in vivo 
ILCs can also be activated in vivo in lymphopaenic mice by administration of 
agonistic anti-CD40 mAbs (Buonocore et al., 2010). Therefore, an attempt was made 
to set up this model of ILC activation, in order to evaluate ILCs in TRnUC and Rag2
-
/- 
mice outside of the context of microbial-driven disease. This was considered 
necessary because some of differences observed in ILCs in the context of HT-
associated colitis might have been due to the disproportionately severe disease seen 
in TRnUC mice in comparison with Rag2
-/-
 mice. It has previously been shown that 
the anti-CD40 model of colitis occurs independently of the intestinal microbiota 
(Uhlig et al., 2006). Therefore, this model was used to further investigate the 
phenotype of ILCs in the presence or absence of T-bet.    
An agonistic anti-CD40 mAb (125µg, clone FGK4.5) or control isotype antibody (rat 
IgG2a, clone 2AE) was administered (i.p.) to Rag2
-/-
 mice. Mice receiving agonistic 
anti-CD40 mAbs rapidly started losing weight, which was statistically significant at 
just 1 day (P<0.007, Figure 55A). Mice were culled on either day 7 or 8. Abdominal 
dissection revealed splenomegaly, mesenteric lymphadenopathy and increased colon 
size (Figure 55B). Spleen weight was significantly higher in anti-CD40 treated mice 
in comparison with control mice (P<0.0001, Figure 55C). Likewise, liver weight was 
also significantly increased in anti-CD40 treated mice in comparison with control 
mice (P<0.0001, Figure 55D), demonstrating that in vivo activation of CD40 in 
lymphopaenic mice results in wasting and multi-system disease. Colitis changes were 
typically patchy, heterogeneous and very difficult to detect consistently in equivalent 
anatomical locations across groups of mice (data not shown). However, colon mass 
was reproducibly and significantly greater in anti-CD40 treated mice in comparison 
with isotype control treated mice (P<0.0001, Figure 56A). Furthermore, analysis of 
cLP cells demonstrated that there was marked expansion of Gr-1
high
 granulocytes in 
the colon of Rag2
-/-
 mice treated with anti-CD40 (Figure 56B), consistent with 
induction of acute colonic inflammation in these mice. 
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Figure 55 Agonistic anti-CD40 mAbs induced multisystem disease in Rag2
-/- 
mice.  A Body 
weight (as a % of initial body mass) in Rag2
-/-
 
mice treated with anti-CD40 mAb (n=7) or 
control isotype (n=6). *P<0.007, **P<0.002. B Abdominal dissection of Rag2
-/-
 mouse 
treated with anti-CD40 mAb. Data points represent median and error bars denote SEM. 
Other clinical features in Rag2
-/-
 mice treated with anti-CD40 mAb or control isotype, 
included changes in C spleen mass and D liver mass. In C and D each dot represents an 
individual mouse. Lines depicts median of the variable defined in the y-axis. Mice were 










Figure 56. Agonistic anti-CD40 mAbs induced increased colonic mass and infiltration of the 
colon with Gr-1
high
 neutrophils.  A Colon mass in Rag2
-/-
 
mice treated with anti-CD40 
mAb or control isotype. Each dot represents an individual mouse. Lines depict median 






mice treated with anti-CD40 mAb. These data are representative of 
multiple different biological replicates. These experiments were repeated multiple (>3) 
times with multiple biological replicates. Mice were examined on days 7 or 8 following 
anti-CD40 administration. Adapted from Powell et al., 2012. 
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6.3 CD90+ cells in Rag2-/- mice expressed T-bet 
If T-bet significantly impacts ILC effector function, showing that T-bet protein is 
expressed by gut ILCs would provide supportive evidence. Therefore, the expression 
of T-bet in ILCs was investigated in Rag2
-/-
 mice following induction of disease with 
anti-CD40. TRnUC mice were used as controls. 
Flow cytometry experiments were performed to assess T-bet and cytokine expression 
in intestinal ILCs from Rag2
-/-
 mice following innate immune activation with anti-
CD40. Unfractionated cLP cells were stimulated with PMA and ionomycin. There 
was an appreciable IFNγ response detected in these mice, predominantly from 
CD90
+
 cells, although there was little IL-17A production (Figure 57A). 
T-bet expression was also determined in CD90
high
 cells from Rag2
-/-
 mice (and in 
TRnUC mice as controls) following activation of the innate immune system with 
anti-CD40. Importantly, there was clear intracellular expression of T-bet in CD90
high
 
ILCs from the mLN of Rag2
-/-
 mice. As expected there was no detectable T-bet 
found in ILCs from TRnUC mice (Figure 57B). These data show for the first time 




Figure 57. Cytokine and T-bet expression in the colon of Rag2
-/- 
mice treated with agonistic 
anti-CD40 mAbs.  A Flow cytometry plot showing CD90, IFN and IL-17A expression 
in unfractionated cLPLs from Rag2
-/-
 
mice following in vivo administration of anti-CD40 
(cells were activated with PMA and ionomycin). B Flow cytometry histogram showing 
T-bet expression in CD90
high
 cells in the mLN of Rag2
-/-
 
mice following anti-CD40 
administration. Anti-CD40 treated TRnUC mice were used as controls to accurately 
define the negative T-bet gate. These data are representative of multiple biological 
replicates. Experiments were also repeated on at least 3 separate occasions.  Mice were 
examined on days 7 or 8 following anti-CD40 administration. 
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6.4 T-bet expression correlated with the expression of interferon-γ 
and was negatively correlated with IL-17A expression by 
intestinal ILCs in anti-CD40 induced disease 
To determine how T-bet relates to cytokine expression in ILCs, the innate immune 
system of Rag2
-/-
 and TRnUC mice was activated by administering anti-CD40 mAbs. 
Cytokine production and T-bet expression in ILCs in this disease setting was then 
determined by flow cytometry. mLNs were harvested from Rag2
-/-
 and TRnUC mice 
following induction of disease. Unfractionated mLN cells were stimulated with PMA 
and ionomycin. ILCs were identified by gating live, CD90
high
 cells. 
ILCs isolated from the mLN of Rag2
-/-
 mice expressed T-bet, which positively 
correlated with IFNγ expression, but was inversely correlated with IL-17A 
expression. Conversely, IFNγ expression was markedly diminished in ILCs from 
TRnUC mice and instead these cells predominantly produced IL-17A (Figure 58A). 
The proportion of IL-17A and IFNγ positive CD90+ cells in the cLP was also 
calculated. ILCs from Rag2
-/-
 mice were significantly more likely to be positive for 
IFNγ (P<0.03) in comparison with ILCs from TRnUC mice, whereas ILCs from 
TRnUC mice were significantly more likely to be positive for IL-17A (P<0.002) in 
comparison with ILCs from Rag2
-/-




Figure 58. T-bet correlated with IFNγ and is inversely correlated with IL-17A in ILCs.  A Flow 
cytometry plot showing intracellular cytokine and T-bet expression in ILCs (CD90
+
) cells 
from mLN of Rag2
-/-
 
and TRnUC mice following administration of agonistic anti-CD40. 
These data are representative of multiple experiments (>10 individual mice). B % 
cytokine positive CD90
high 
cells in the cLP of Rag2
-/-
 
(n=8) and TRnUC (n=7)mice 
following administration of agonistic anti-CD40. Mice were examined on days 7 or 8 
following anti-CD40 administration. Individual dots represent individual mice and the 
lines depict median % of cytokine positive cells. Adapted from Powell et al., 2012. 
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6.5 Delayed wasting disease in T-bet deficient hosts 
Following induction of disease with anti-CD40 mAbs, there were also differences in 
the disease phenotype of Rag2
-/-
 and TRnUC mice. Rag2
-/- 
mice lost weight 
significantly faster than TRnUC mice (expressed as a % of initial body weight). As 
early as 1 day following administration of anti-CD40, Rag2
-/- 
mice had lost 
significantly more weight than TRnUC mice (P<0.0005, Figure 59A). In contrast, 
administration of anti-CD40 antibody induced a significant increase in colon weight 
in both of Rag2
-/-
 and TRnUC mice, which did not differ significantly between the 
genotypes (Figure 59B). Colon histology was not available for this experiment, since 
in our hands histological changes were very patchy in this model and if anatomically 
consistent sections of colon (e.g. distal 0.5cm) were taken, some clearly diseased 
animals (i.e. with evidence of increased colon mass, weight loss and Gr-1
high
 
neutrophilic infiltration of colon as assessed by flow cytometry) might have absence 
of clear inflammation in particular segments.   
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Figure 59. Distinct disease phenotypes in TRnUC and Rag2
-/-
 
mice following administration of 




and TRnUC mice following administration of agonistic anti-CD40. *P<0.0005, 
**P<0.01. ***P<0.001. These data are a composite of 2 separate experiments. These 
experiments have been additionally repeated on at least 4 occasions with comparable 
results. Mice were examined on days 7 or 8 following anti-CD40 administration.  Note – 
control antibody treated mice did not lose/gain weight in this short time span experiment 
(7 days). Therefore, data regarding control m ice weights are not shown to avoid 
overloading the graphical representation with data. In A dots represent mean weight loss 
and error bars represent SEM. In B each dot represents an individual mouse. Lines depict 




6.6 T-bet bound at the Il7r locus in CD4+ T-cells 
In Th1 cells T-bet binds at the loci encoding multiple different Th1 related 
molecules, to ensure that a co-ordinated, appropriately polarised response ensues. 
Therefore, in addition to altering the profile of cytokines produced by ILCs, it was 
postulated that T-bet might regulate other genes involved in ILC biology. The 
majority of ILCs in TRUC colitis and other ILC associated diseases (Buonocore et 
al., 2010; Sonnenberg et al., 2011) express IL-7R. Signalling through IL-7R has been 
shown to play an important role in the homeostasis of several immune cell 
populations (Crellin et al., 2010; Satoh-Takayama et al., 2010; Schmutz et al., 2009). 
Although ILCs are too infrequent to perform chromatin immunoprecipitation 
sequencing (ChIP-seq) to identify which genes are bound by T-bet, there was already 
data available in the laboratory regarding which genes that T-bet binds at in CD4
+
 T-
cells (Dr Refik Gokmen PhD thesis 2012, King’s College London). ChIP-seq data 
generated by Dr Gokmen was examined to determine whether T-bet is likely to bind 
to the Il7r locus. The methodology for this experiment has subsequently been 









T-cells were sorted from unfractionated splenocytes from WT and Tbx21
-/-
 Balb/C 
mice and differentiated in vitro with skewing cytokines (IL-2, IL-12 and anti-IL-4) 
into Th1 cells. Proteins were cross-linked to DNA and then immunoprecipitated with 
a T-bet specific antibody. DNA sequences associated with T-bet were then 
sequenced. T-bet binding was enriched at Il7ra gene locus. Importantly, binding was 
found at the transcriptional start site of the gene in a region highly conserved in 
mammals (Figure 60), consistent with the likelihood that this observation was 
biologically relevant. The negative control cell population used in this experiment 
were Th1 cells from Tbx21
-/-
 mice, in which there was no binding of T-bet detected 
at the Il7r locus, as expected, indicating that the signals observed in T-bet sufficient 
Th1 cells was specific binding (Figure 60). To serve as positive control for T-bet 
binding the Ifng locus was also analysed, which also showed T-bet binding at the 
transcriptional start site of this gene (Figure 60). No binding was seen in Tbx21
-/-
 Th1 
cells. Comparison of T-bet binding at the Ifng and Il7r loci shows stronger binding of 
T-bet at the Ifng locus, albeit it with comparable orders of magnitude. Using model 
based analysis of ChIP-seq (MACS) (Zhang et al., 2008) the binding of T-bet at the 
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Il7r locus was identified as statistically significant binding (P<1.0 x10
-6
), consistent 















Figure 60. T-bet bound at the promoter of the Il7r locus in CD4
+
 Th1 T-cells.  UCSC genome 
browser image is shown for T-bet binding at the il7ra locus in Tbx21
+/+




 Th1 cells (upper panel) following stimulation with PMA and ionomycin for 4 
hours. The lower panel shows T-bet binding at the Ifng locus, which serves as a positive 
control. Chromatin was immunoprecipitated, cross-lined and prepared as in Jenner et al., 
2009. Samples were sequenced using an Illumina Genome Analyzer II-x. The vertical 
axis depicts the number of tags per million total sequences, with the genomic location 
running along the horizontal axis. The direction of transcription is indicated by arrows. 
Three T-bet binding sites are illustrated (red arrows). Whole genome data were generated 














6.7 T-bet was a transcriptional repressor of Il7r 
To determine whether T-bet was likely to be a transcriptional repressor of Il7ra in 
ILCs, these cells were purified from the mLN of TRnUC and Rag2
-/-
 mice following 
in vivo activation of these cells with anti-CD40. Unfractionated mLN cells were 







 cells were then FACs sorted and snap frozen in Trizol reagent pending 
cDNA synthesis and qPCR to quantify Il7ra mRNA. Notably, Il7ra mRNA was 
more abundant in Tbx21
-/-





 mice (Figure 61A), consistent with the possibility that T-bet is a 
transcriptional repressor of the Il7ra locus and when absent there is de-
regulated/increased expression of Il7ra. However, these data should be regarded with 
some caution as the qPCR data corresponded to a single experiment of flow 
cytometry sorted ILCs from TRnUC and Rag2
-/-
 mice and the data presented in 
Figure 62 correspond to technical replicates rather than biological replicates and 
therefore these data should be considered preliminary and in need of replication.   
IL-7R expression was also determined at the protein level in ILCs by flow 
cytometry. Unfractionated splenocytes and cLP cells were labelled with monoclonal 
antibodies specific for CD90, NKp46 and IL-7R. The expression of IL-7R was 




 population of cells in these organs. In these 





 ILCs in either the spleen or colon of Rag2
-/-





Figure 61. T-bet was a transcriptional repressor of Il7r.  A qPCR data showing relative 
expression if Il7ra in ILCs from Rag2
-/-
 
and TRnUC mice following in vivo activation 
with anti-CD40 mAbs. These data represent 2 technical replicates. Bars represent mean 
relative abundance of Il7ra mRNA and error bars denote SEM. Since this graph only 
represents technical replicates (2 separate analyses) of single ILC populations statistical 
analysis was inappropriate.  In this experiment ILCs were purified by FACS as described 
in the methods. Cells purity was >95%. B Flow cytometry plot showing the expression of 
IL-7R in ILCs from the spleen and colon of Rag2-/-
 
and TRnUC mice. These flow 
cytometry plots are representative of 4 additional biological replicates. This experiment 

















6.8 Chronic TRUC IBD was dependent on the common γ chain 
cytokine receptor 
IL-7R protein expression was not different in ILCs from Rag2-/- and TRnUC mice 
at the time points analysed in these experiments, but it is also possible that T-bet 
mediated regulation of the Il7ra locus operates at different times during ILC 
ontogeny or under different physiological circumstances. Although additional 
experiments will endeavour to demonstrate when and under what circumstances T-
bet regulates IL-7R protein expression in ILCs, it is also important to demonstrate 
whether this pathway is relevant in the context of colitis. 
The functional IL-7R complex comprises IL-7R associated with the common γ-
chain cytokine receptor
 
(IL-2R, also known as CD132). In order to determine the 
functional significance of IL-2R in TRUC disease Tbx21-/- Rag2-/- Il2rg-/- triple 
knockout mice were generated. It has previously been reported that common γ-chain 
cytokine receptor deficient mice have >90% reduction in the number of ILCs in 
secondary lymphoid organs (Kim et al., 2005a). The possibility that intestinal ILCs 
in TRUC disease would also be dependent on this receptor was considered. LP cells 






 triple knockout 







 knockout mice had significantly diminished 
percentages of CD90
+
 cells in the colon compared to TRUC mice (Figure 62A and 
62B). As mentioned previously these data should be interpreted with some caution 
since comparing the relative proportions of particular cell types can sometimes be 
misleading as the proportion of an undefined cells type varying between the two 
genotypes might account for relative shifts in the proportion of other cells. In this 






 triple knockout mice were barely 
detectable at all and were diminished 20-fold in comparison with TRUC mice, 
therefore it is unlikely that the changes observed in ILC proportions were art factual. 
Indeed, additional subsequent experiments looked at absolute cell numbers (e.g. 
Figure 62) in a similar context, which gives further support to these observations.       















 triple knockout mice failed to develop colitis, 
and had normal (=0) colitis scores (Figure 63A). Similarly, there was no evidence of 







 triple knockout mice. In additional to the lack of disease features, the 














 triple knockout mice had undetectable levels of mRNA 















mice.  A Flow cytometry histogram showing the % of CD90
high
 ILCs (as a proportion of 
live, CD45
+








mice, and B statistical 
analysis of age matched biological replicates (n=5 in each group). Each dot represents an 
individual mouse. The lines depict the median % ILCs among CD45
+ 
cells in the cLP. 




Figure 63. TRUC mice lacking the common  chain cytokine receptor did not develop colitis.  A 













mice (n=5). *P<0.001. This experiment was repeated on 2 further occasions with 
comparable results, but with fewer mice and of different age groups. B  Spleen mass and 







mice.  In A-C each dot represents 
an individual mouse. The lines depict the median of the variable defined by the y-axis). 
These data are representative data of 2 additional experiments. D Real time PCR of 








Bars represent mean relative abundance of Il17a transcripts and error bars represent 
SEM. This experiment was a single experiment and no additional experiments have been 
performed. Adapted from Powell et al., 2012. 
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6.9 Tbx21-/- Rag2-/- Il2rg-/- triple knockout mice gavaged with faeces 
from TRUC mice failed to develop colitis 
Since the microbiota plays such a critical role in TRUC disease, an additional 






 triple knockout mice 
were fully exposed to the colitogenic microbiota present in TRUC mice in order to 
show that the phenotypic differences were due to changes in ILC numbers rather than 







 triple knockout mice were gavaged with a homogenised 
suspension of faecal bacteria harvested from TRUC mice. 
Even following gavage of the colitogenic flora from TRUC mice, CD90
+
 ILCs were 







knockout mice (Figure 64A and 64B). Similarly, in contrast to TRnUC mice which 







 triple knockout mice failed to develop colitis (Figure 64C). 
Notably, inspection of the distal colon of naïve TRnUC mice commonly revealed the 
presence of lymphoid aggregates within the lamina propria, whereas these aggregates 






 triple knockout 
mice (Figure 65). Taken together these data are consistent with a non-redundant role 











mice gavaged with faeces from TRUC mice were resistant 












mice following gavage with faeces from TRUC 





cell count. Each dot represents an individual mouse. 








mice following gavage with faeces from TRUC mice. Mice 
were examined 3-4 weeks post-gavage. *P<0.01. Bars denote mean colitis score in the 
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mice lacked lymphoid aggregates in the colon.  Colon 








mice. Aggregates of lymphoid cells were commonly seen, even in naïve TRnUC mice, 









depicted). Magnification is the same in both panels (approximately x100). These data are 










6.10 TRUC disease was dependent on IL-7 signalling 
Although the common γ chain cytokine receptor is essential for IL-7R signalling, it is 
also a critical component of the receptor complex for other cytokines, including IL-2, 
IL-4, IL-9, IL-15 and IL-21. Therefore, to dissect the role of IL-7R in TRUC disease 
antibody mediated blockade of the IL-7R was performed in vivo. 
Twelve week old TRUC mice were treated with 1mg of anti-IL-7R mAb (n=5, clone 
A7R34) or control isotype antibody (n=4) administered i.p. on days 0, 3, 6, 9, 12, 15 
and 18. Mice were culled on day 21 and organs harvested for analysis. 
The number of CD90
+
 ILCs in the spleen and colon of TRUC mice following 
treatment with anti-IL-7R mAb or control antibody was investigated by flow 




 ILC numbers 3-4 




 ILC were also 
significantly diminished in the spleen of anti-IL-7R treated TRUC mice (Figure 66C 
and 66D). However, unlike the colon, ILCs were almost completely eliminated from 
the spleen of anti-IL-7R treated TRUC mice. As discussed previously there is a 
theoretical risk that using the same depleting mAb as the staining antibody used to 
identify/show depletion in subsequent flow cytometry experiments might result in 
lack of detection due to the epitope already being occupied by the depleting mAb 
which had been administered in vivo. In this experiment the same clone was used to 
block and stain for IL7R (clone A7R34). However, since an additional ILC marker 
was employed in the staining protocol in this experiment the loss of ILCs was readily 
apparent not just by loss of cells bearing IL-7R, but by the lack of CD90 cells. In 
other words if the cells were not being detected because the in vivo administered 
mAb was preventing binding of the staining mAb used in flow experiments then it 




cells in the mice treated with A7R34. However, it is clear from the experiment that 
CD90 cells are also lost (Figure 66C), thus confirming that blockade of Il-7R results 
in loss of IL-7R bearing ILCs rather than resulting in an inability to detect them. 
IL-7R blockade significantly improved disease parameters in TRUC mice, including 
a significant reduction in colitis scores (Figure 67A), spleen weight (Figure 67B) and 
colon weight (Figure 67C), demonstrating that IL-7R signalling plays a functionally 
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Figure 66. IL-7R blockade reduced the number of ILCs in the colon and spleen of TRUC mice.  




 cells and B absolute number of CD90
high
 
ILCs in the colon of TRUC mice treated with anti-IL-7R mAb or control (isotype) 




 cells and D absolute number of 
CD90
high
 ILCs in the colon of TRUC mice treated with anti-IL-7R mAb or control 
(isotype) antibody. The flow data illustrated are representative of 4 biological replicates 
in each group. Insufficient cells were available for analysis from 2 mice (one in each 
group). This in vivo blocking experiment was only performed once. In Figures B and D 
each dot represents an individual mouse. Lines depict median of parameter defined by the 
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Figure 67. IL-7R blockade attenuated TRUC disease.  A Colitis histology scores, B spleen mass 
and C colon mass of TRUC mice treated with anti-IL-7R mAb or control (isotype) 
antibody. There were 5 mice in each group. In panel A the bar represents the median  
histology score in the study group and the error bars represent SEM. This in vivo 
blocking experiment was only performed once. In panel B and C each dot represents an 
individual mouse and the lines represent the median (of the parameter defined by the y-
axis). Adapted from Powell et al., 2012. 
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6.11 Discussion 
Some of the specific molecular mechanisms that impact on colitis development as a 
consequence of T-bet deficiency have been defined. TRUC mice are prolific 
producers of cytokines, such as IL-17A and IL-22, yet are relatively poor producers 
of IFNγ. Indeed, in microbiota-dependent (HT-induced) or microbiota-independent 
(agonistic anti-CD40 induced) models of intestinal inflammation, intestinal ILCs 
from T-bet sufficient Rag2
-/-
 mice predominantly produce IFNγ, whereas T-bet 
deficient ILCs from TRnUC mice predominantly produce IL-17A, with relatively 
few IFNγ producing cells. These data indicate that T-bet is necessary for optimal 
IFNγ expression by intestinal ILCs. These data are consistent with studies in T-cells 
in which T-bet is required for transactivation of the Ifng locus (Szabo et al., 2000). It 
therefore seems most likely that T-bet is also required for optimal transcription of the 
Ifng gene in ILCs as well as in T-cells. Although, T-bet has been shown to bind at the 
Ifng locus in CD4
+
 T-cells, these experiments are technically challenging with ILCs 
since many millions of cells are needed to perform ChIP experiments and it is very 
difficult to isolate this many ILCs from the colon of TRUC mice, even if cells are 
pooled from different donors. Loss of IFN production and paradoxical augmentation 
of IL-17A production by T-bet deficient ILCs mirrors observations in T-bet deficient 
CD4
+
 T-cells in which T-bet also appears to be a repressor of IL-17 production 
(Durrant et al., 2009; Harrington et al., 2005; Park et al., 2005; Gokmen et al., 
2012). Given the enhanced IL-17A production in the absence of T-bet in t-cells and 
ILCs it is possible that the molecular mechanisms responsible for this phenotype are 
conserved across these particular lymphoid lineages. Possible mechanisms include 
loss of T-bet mediated suppression of IL-23R expression (Harrington et al., 2005), 
loss of T-bet mediated limitation of Runx1 transactivation of Rorgt (Lazarevic et al., 
2011), or loss of T-bet mediated repression of IRF4 (Gokmen et al., 2012). 
Diminished innate production of IFNγ observed in T-bet deficient hosts likely 
accounts for the delayed wasting disease observed in anti-CD40 induced disease, 
consistent with previous reports showing that systemic disease in this model is 
mediated by the IL-12/IFNγ pathway (Uhlig et al., 2006). These data also imply that 
T-bet impacts on innate immunity in a tissue specific manner, and that intestinal 
rather than systemic disease is favoured in its absence. In contrast to other studies 
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showing that ILC-mediated intestinal pathology requires dual blockade of IL-17 and 
IFNγ to abrogate disease (Buonocore et al., 2010), in TRUC IBD, IL-17A blockade 
alone was sufficient to reverse disease. It is possible that IL-17A blockade alone 
would not fully prevent ILC mediated pathology in T-bet sufficient hosts because 
unlike TRUC mice these animals can still mount effective IFNγ responses. These 
data are also consistent with recent hypotheses suggesting that ILCs form distinct 
functional lineages, similar to effector T-cell populations. T-bet appears to be an 
important molecule responsible for regulating the profile of cytokines produced by 
ILCs. In the absence of T-bet these cells fail to mount a significant IFNγ response, 
and instead preferentially produce IL-17A. 
In this study signalling through the common -chain cytokine receptor (Il2rg) was 







 triple deficient mice were resistant to colitis 
development even following exposure to the colitogenic flora present in TRUC mice. 
The common -chain cytokine receptor is a component of multiple different cytokine 
receptors including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 (Yamane and Paul, 
2012), and therefore deficiency of this receptor could potentially impact numerous 
cell types, including macrophages, dendritic cells , NK cells as well as ILCs. It might 






 triple deficient mice might 
account for the impaired inflammatory response observed in the colon of these mice, 
since NK cell development is totally dependent on IL-15 signalling, and its receptor 
belongs to the common -chain cytokine receptor family (Vosshenrich et al., 2005). 
However, other evidence makes this unlikely. Firstly, T-bet plays an important role 
in NK cell ontogeny/maturation and consequently mice lacking T-bet have markedly 
diminished numbers of NK cells (Townsend et al., 2004; Soderquest et al,. 2011). 
Therefore, it seems improbable that NK cells are playing a significant pathological 
role in TRUC disease as these cells are markedly diminished in these mice by virtue 
of their T-bet deficiency. Furthermore, in other models of colitis NK cells appear to 
play a protective or regulatory role rather than an inflammatory role. For instance, 
depletion of NK cells in Il10
-/-
 mice, which develop spontaneous colitis, results in 
even more severe disease (Fort et al., 1998). Therefore, it seems unlikely that loss of 
NK cells due to loss of IL-15 signalling would confer resistance to TRUC colitis as 
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 mice. In this study it was shown that the 
cytokines IL-4 and IL-21 are unlikely to play a significant role in TRUC disease 
since these cytokines are either undetectable or at low levels comparable to disease 
free Rag2
-/-
 mice, therefore, it is unlikely that these common -chain cytokine 






 mice to colitis induction. IL-9 is predominantly expressed by T-cells and 
plays an important role in allergic responses (Stassen et al., 2012), and its expression 
in the colon of TRUC mice was not specifically analysed in this study. Although in 
this study it was clearly demonstrated that ILC numbers are reduced in the context of 
common -chain cytokine receptor deficiency, it would be beneficial to determine the 
impact of losing this receptor on other key innate immune cells in the colon of TRUC 
mice. 
However, evidence for an important role for another common -chain cytokine 
receptor, IL7R, was seen in further in vivo blockade experiments in TRUC mice. 
Blockade of the IL-7R with specific mAbs resulted in a significant reduction in ILC 
numbers (particularly in the spleen and to a lesser, but significant degree in the 
colon) in TRUC mice. This was associated with reduced innate IL-17A expression 
and significantly attenuated disease in TRUC mice. Interestingly, unlike splenic ILCs 
that were almost completely eliminated, colonic ILCs were less prone to depletion by 
IL-7R blockade, indicating that additional IL-7 independent ILC survival signals 
may exist in the colon or in inflamed tissue.   
Further evidence for an important role for IL-7R in TRUC disease (as a consequence 
of T-bet deficiency) came from molecular studies. Crucially, T-bet binds at the Il7ra 
locus (at least in CD4 T-cells), consistent with the likelihood that T-bet 
transcriptionally regulates IL-7R expression and thereby may control ILC 
homeostasis. Indeed, T-bet deficient ILCs had increased expression of mRNA 
encoding Il7ra, indicating that T-bet is a transcriptional repressor of this locus in 
ILCs. However, it should be noted that these experiments should be considered 
preliminary, as the data presented in this thesis are from a single experiment (with 
technical replicates). Although the data support the hypothesis that T-bet is a 
transcriptional repressor of the Il7ra locus these data will need replicating in future 
work. The importance of IL-7R signalling in human IBD is also implied by recent 
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data identifying single nucleotide polymorphisms at the IL7R locus in patients with 
UC (Anderson et al., 2011). 
In conclusion, potential molecular mechanisms whereby T-bet controls ILC 
phenotype in TRUC disease include regulation of cytokine production (IL-17A 




7.1 Updating the TRUC paradigm of intestinal inflammation 
The data presented in this study along with prior work allows the TRUC paradigm of 
colitis to be expanded (Figure 68) and also allows further parallels with human IBD 
to be drawn. The earliest abnormality present in TRUC mice is increased mucosal 
TNFα-induced colonic epithelial apoptosis which subsequently results in impaired 
intestinal barrier function (Garrett et al., 2007). The data presented in this thesis data 
corroborate these observations and confirm that TNFα expression is constitutively 
increased in T-bet deficient DCs, which is even further enhanced following exposure 
to “colitogenic” microbes, such as Helicobacter typhlonius. Data in this thesis show 




 are both the most populous and chief source of 
TNFα in the colon of TRUC mice. These data are consistent with reports from other 
groups suggesting that DCs characterized by expression of CD11b and CX3CR1, but 
lacking CD103 are the major inflammatory subset of gut dwelling DCs in mice in the 
context of intestinal inflammation (Varol et al., 2009). 
Excess TNFα production in TRUC disease is responsible for driving increased 
colonic epithelial apoptosis and impaired barrier function, the earliest lesions 
observed in TRUC mice, predating overt colitis (Garrett et al., 2007). Impaired 
epithelial barrier function is also implicated in human inflammatory bowel disease. 
Polymorphisms at loci encoding genes involved in maintaining the intestinal barrier, 
such as ECM1, CDH1, HNF4a and laminin B1 have been identified as susceptibility 
loci in UC (Thompson and Lees, 2011). Increased intestinal permeability has also 
been observed in subgroups of healthy first degree relatives of IBD patients (Hilsden 
et al., 1996; Peeters et al., 1997), suggesting that epithelial abnormalities may be 
associated with IBD risk, but by themselves are insufficient to instigate disease 
without an additional environmental cue. 
Chronic TRUC disease was dependent on IL-17A secreting CD90
+
 ILCs. As well as 
attenuating disease, blockade of IL-17A, the chief effector cytokine produced by 
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ILCs in TRUC mice, markedly reduced colonic neutrophil recruitment, which is a 
key feature of chronic TRUC disease. The absence of T-bet in TRUC mice resulted 
in preferential production of IL-17A at the expense of IFNγ. In T-bet sufficient Rag2-
/-
 mice, ILCs expressed T-bet which correlated with IFNγ production. However, T-
bet deficient ILCs were poor producers of IFNγ, and instead preferentially produced 
IL-17A, resembling the phenotype of Tbx21
-/-
 T-cells (Lazarevic et al., 2011). 
In this thesis is has been shown that key cytokine signals responsible for driving ILC 
activation are IL-23 and IL-6. Furthermore, TNFα was observed to synergise with 
IL-23 to stimulate IL-17A. The TNF superfamily member TL1A was also found to 
be increased in TRUC disease, and was observed to weakly promote IL-17A 
production as well. TL1A also seemed to synergise with IL-23 to promote IL-17A 
production in TRUC mice. However, unlike IL-23 and IL-6, which were shown to be 
functionally important activators of innate immunity in the gut, since blockade of 
these cytokines attenuated TRUC disease, neutralization of TL1A failed to control 
TRUC disease. However, it was discussed that these blocking experiments were 
likely suboptimal therefore the functional role of TL1A in TRUC should be 
considered yet to be conclusively defined and a clear role for TL1A in driving innate 
immune mediated colitis  remains to be demonstrated. 
TRUC disease is characterised by chronic, progressive colitis with the severity of 
disease increasing with time (Garrett et al., 2007; Garrett et al., 2009; Powell et al., 
2012). Accordingly, additional studies will focus on the contribution of different 
immune cells over time. Since early TNFα production triggers epithelial apoptosis in 
the colon of TRUC mice as young as 2-4 weeks old (Garrett et al., 2007) the cellular 
sources of this cytokine should probably be considered the most proximal cellular 
mediators of disease. In the initial studies TNFα production predominantly mapped 
to CD11c DCs, although a contribution from macrophages cannot easily be 
discounted in view of some shared cell surface phenotypic markers between these 
related myeloid cells. It is likely that DC derived TNFα is very important in these 
early events, which rapidly leads to early loss of epithelial integrity. Indeed,  early 
rather than late blockade of this cytokine is therapeutically beneficial in TRUC mice 
and TNFα blockade in TRUC mice aged >12 weeks old lacks efficacy, indicating 
that other cytokine networks and alternative cells emerge as important mediators. It 
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is tempting to speculate that ILCs (perhaps driven by IL-23, IL-6 or TL1A) are 
responsible for chronic TRUC disease, especially once the effectiveness of the 
colonic epithelial barrier has been compromised and inflammatory cascades are 
initiated by the innate immune compartment. However, mice lacking ILCs from birth 
(e.g. TRUC x Il2rg
-/-
 mice) are totally resistant to colitis, consistent with the 
possibility that ILCs are also involved in early disease. However, given the 
widespread expression of the common –chain receptor across many immune cells it 
is difficult to discount a contribution from other cells types in these early phases of 
disease as well. Undoubtedly ILCs play an important in the chronic phase of disease, 
since depletion of these cells, even in late disease (mice >12 weeks old) is curative. 
Future experiments will focus specifically on the role of ILCs in early TRUC disease 
versus late TRUC disease. The role of macrophages and NK cells in early and late 
disease in TRUC mice also merits research attention in the future.   
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Figure 68. The updated TRUC paradigm of IBD.  Particular constituents of the intestinal 
microbiota (such as HT) drive excess TNFα production by colonic CD11b+ CD103-
 
DCs, 
leading to epithelial apoptosis and loss of epithelial barrier function. This triggers 






 ILCs, which in turn leads to neutrophil recruitment and propagation of 
chronic intestinal inflammation, with further epithelial damage from neutrophil products, 
such as reactive oxygen intermediates (ROI) and elastase.  
1. Disrupted epithelial barrier function
TNFαCD11b+ CD103- DCs
Gr-1high neutrophils












7.2 Translating lessons from new insights into TRUC disease in to 
clinical practice 
The TRUC model of IBD provides some interesting insights into current, 
experimental and future therapies in IBD. IBD therapies are unsatisfactory. For 
instance, after one year of treatment with azathioprine, the first line treatment for 
CD, only about a quarter of patients will still be in remission (Colombel et al., 2010). 
This has prompted pharmaceutical companies to search for newer “biological” 
targets. The first of these to emerge was infliximab, a humanised mouse mAb that 
specifically targets TNFα. Infliximab and newer, fully humanised mAbs targeting 
TNFα are now commonly used to treat both CD and UC. However, infliximab 
monotherapy will only keep a third of CD patients in remission after 1 year of 
treatment (Colombel et al., 2010), and even optimal therapy with a combination of 
infliximab and azathioprine manages to maintain remission in less than half of CD 
patients after 1 year of treatment (Colombel et al., 2010). It is notable that anti-TNFα 
therapies are also effective in early TRUC disease. TNFα synergised with IL-23 to 
augment IL-17A production by ILCs which could be significantly attenuated by 
TNFα blockade, highlighting a previously unrecognised potential therapeutic action 
of anti-TNFα antibodies. It is interesting that TNFα blockade is most effective in 
early TRUC disease (Garrett et al., 2007; Garrett et al., 2009), and although many 
factors are likely involved, in human IBD the clinical response to anti-TNFα agents 
are also greatest in patients treated early in their disease course, and are less effective 
in patients with firmly established disease (Schreiber et al., 2010). 
Similarly, IL-23 is identified as a key driver of ILC effector function in TRUC 
disease and for the first time it is shown that antibody mediated blockade of IL-
23p19 attenuated chronic TRUC colitis and limited innate IL-17A production. These 
data are consistent with the possibility that blockade of IL-23 mediated ILC 
activation maybe one of the therapeutic mechanisms of action of anti-IL-12p40 
mAbs that have shown some promise in IBD (Mannon et al., 2004). These data also 
lend credence to the development of specific anti-IL-23p19 therapies as possible 
future therapies for IBD. 
In this work it was shown that IL-6 is elevated in TRUC disease and when blocked in 
vivo results in reduced innate production of IL-17A and attenuated TRUC disease. 
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Biological therapies targeting IL-6 or its receptor, such as tocilizumab, are 
efficacious in the treatment of other inflammatory diseases, including arthritis 
(Smolen et al., 2008; Yokota et al., 2008) and lupus (Illei et al., 2010). A pilot study 
of anti-IL-6R therapy in Crohn’s disease had promising initial results (Ito et al., 
2004), and awaits validation in a large, randomised placebo-controlled trial. 
Currently, there are no data on blocking the IL-6 pathway in UC. 
This thesis also potentially provides some novel insights in to therapies blocking IL-
17A and IFNγ. In contrast to other studies showing that ILC mediated intestinal 
pathology requires dual blockade of IL-17 and IFNγ to abrogate disease (Buonocore 
et al., 2010), in TRUC IBD IL-17A blockade alone reversed disease. It is possible that 
IL-17A blockade alone would not fully prevent ILC mediated pathology in T-bet 
sufficient hosts because unlike TRUC mice these animals can still mount effective 
IFNγ responses. In other words, since ILCs from T-bet deficient hosts are unable to 
mount an effective IFNγ response, then blockade of IL-17A alone was sufficient to 
cure chronic IBD in TRUC mice. These observations offer potentially relevant 
insights into clinical trials evaluating blockade of these cytokines in human IBD. 
Antibody blockade of IFNγ is largely disappointing in Crohn’s disease (Reinisch et 
al., 2010) and recently a placebo controlled trial of an anti-IL-17A mAb 
(secukinumab) showed that blockade of this cytokine therapy lacked efficacy, or even 
exacerbated moderate to severe CD (Hueber et al., 2012). However, in both of these 
studies improvements were seen in certain patient sub-groups, including those with 
raised inflammatory markers (anti-IFNγ) or in patients with particular genetic 
polymorphisms (risk variant alleles at the TL1A locus in anti-IL-17A treated patients). 
Redundancy and plasticity of IL-17A and IFNγ responses also potentially accounts for 
the lack of efficacy observed following monotherapy with either anti-IL-17 or anti-
IFNγ. Trials evaluating dual blockade of these cytokines, and thereby limiting 
plasticity/redundancy might prove to be useful in these difficult diseases. Alternatively, 
blockade of IL-12p40, which is required for biological activity of both IL-12 and IL-
23, and hence is a common upstream signal for both IL-17A and IFNγ production, is 
efficacious in CD (Mannon et al., 2004). In the future it is conceivable that IBD 
patients will be stratified according to their genetic profile or their mucosal immune 
response in order to better guide selective cytokine blockade in individual patients. 
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7.3 ILCs and the genetic risk of IBD 
The data presented in this thesis also potentially provide novel interpretations of 
current understanding of the genetic basis of IBD. At present there are 163 genes 
now associated with altered risk of developing IBD (Jostins et al., 2012). Most of 
these are common to both CD and UC. Although innate pathways, such as NOD2 
and autophagy are well recognised, particularly in CD, it has been assumed that a 
large number of risk variant alleles are implicated in altering the phenotype of 
adaptive immune cells, and in particular, effector T-cell lineages, such as Th1 and 
Th17 cells function (Jostins et al., 2012). However, one could also make the case that 
most of these risk alleles might equally impact ILC phenotype. Among these alleles 
include IL-23/IL-17 axis or the IL-12/IFNγ axis molecules, such as IL12A (IL-12p40 
subunit common to both IL-12 and IL-23), CCR6, IL23R, IFNG, RORC and STAT3, 
all of which are now known to be expressed by or are involved in the regulation of 
gut ILCs. Similarly, polymorphisms at loci encoding IL7R, TL1A, IL6ST and CD25 
are also associated with IBD (Jostins et al., 2012), and are likely involved in ILC 
biology as well as T-cell biology. Now that ILCs have been identified in 
inflammatory lesions of IBD patients, the impact of risk variant polymorphisms in 
ILC phenotype may yield new insights into these important diseases. 
7.4 Future work 
In addition to increased expression of IL-17A, it was also noteworthy that TRUC 
disease was also characterised by increased expression of IL-22. Further work will 
focus on the role of this important cytokine in TRUC disease. There is also a 
pressing need to translate these crucial pre-clinical findings to human disease. 
Indeed, preliminary studies show that ILCs are present in the colon of UC patients 
and that IL-23 and IL-6 are capable of stimulating these cells to produce IL-17A.  
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